



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) **Date de dépôt PCT/PCT Filing Date:** 2022/04/07
(87) **Date publication PCT/PCT Publication Date:** 2022/10/13
(85) **Entrée phase nationale/National Entry:** 2023/10/06
(86) **N° demande PCT/PCT Application No.:** CA 2022/050536
(87) **N° publication PCT/PCT Publication No.:** 2022/213204
(30) **Priorité/Priority:** 2021/04/07 (US63/171,955)


(51) **Cl.Int./Int.Cl.** **A61K 31/4985** (2006.01),
A61K 31/395 (2006.01), **A61K 31/437** (2006.01),
A61K 31/444 (2006.01), **A61K 31/497** (2006.01),
A61K 31/501 (2006.01), **A61K 31/506** (2006.01),
A61K 31/519 (2006.01), **A61K 31/5377** (2006.01),
A61K 31/5386 (2006.01), **A61P 35/00** (2006.01),
C07D 471/04 (2006.01), **C07D 487/04** (2006.01),
C07D 519/00 (2006.01)

(71) **Demandeurs/Applicants:**
REPAIRE THERAPEUTICS INC., CA;
SINAI HEALTH SYSTEM, CA

(72) **Inventeurs/Inventors:**
FOURTOUNIS, JIMMY, CA; ...

(54) **Titre :** POLYTHERAPIES COMPRENANT DES INHIBITEURS DE MYTL

(54) **Title:** CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER



(I)

(57) **Abrégé/Abstract:**

The use of inhibitors of tyrosine and threonine- specific cdc2-inhibitory kinase (Mytl) in the treatment of cancer is disclosed. In preferred embodiments, the Mytl inhibitor is a carboxamide pyrrolopyrazine or carboxamide pyrrolopyridine of Formula I. The Mytl inhibitors may be used in combination with a variety of other anti-cancer agents. Such agents include a WEE1 inhibitor, TOP1 or TOP2A inhibitor, RRM1 or RRM2 inhibitor, AURKA or AURKB inhibitor, ATR inhibitor, TTK inhibitor, SOD1 or SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analogs, and platinum-based DNA alkylating agents.



(72) **Inventeurs(suite)/Inventors(continued):** YOUNG, JORDAN, CA; BERNIER, CYNTHIA, CA; DUROCHER, DANIEL, CA;
HUSTEDT, NICOLE, CA

(74) **Agent:** BORDEN LADNER GERVAIS LLP

Date Submitted: 2023/10/06

CA App. No.: 3214900

Abstract:

The use of inhibitors of tyrosine and threonine- specific cdc2-inhibitory kinase (Mytl) in the treatment of cancer is disclosed. In preferred embodiments, the Mytl inhibitor is a carboxamide pyrrolopyrazine or carboxamide pyrrolopyridine of Formula I. The Mytl inhibitors may be used in combination with a variety of other anti-cancer agents. Such agents include a WEE1 inhibitor, TOP1 or TOP2A inhibitor, RRM1 or RRM2 inhibitor, AURKA or AURKB inhibitor, ATR inhibitor, TTK inhibitor, SOD1 or SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analogs, and platinum-based DNA alkylating agents.

CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER

FIELD OF THE INVENTION

The invention relates to methods utilizing inhibitors of a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1), e.g., in the treatment of a disease or condition, e.g., cancer, and, in particular, those diseases or conditions (e.g., cancers that harbor CCNE1 amplification/overexpression or FBXW7-mutated cancers) which depend on the activity of Myt1.

BACKGROUND

DNA is continuously subjected to both endogenous insults (e.g., stalled replication forks, reactive oxygen species) and exogenous insults (UV, ionizing radiation, chemical) that can lead to DNA damage. As a result, cells have established sophisticated mechanisms to counteract these deleterious events that would otherwise compromise genomic integrity and lead to genomic instability diseases such as cancer.

These mechanisms are collectively referred to as the DNA damage response (DDR). One component of the overall DDR is the activation of various checkpoint pathways that modulate specific DNA-repair mechanisms throughout the various phases of the cell cycle, which includes the G1, S, G2 and Mitosis checkpoints. A majority of cancer cells have lost their G1 checkpoint owing to p53 mutations and as such, rely on the G2 checkpoint to make the necessary DNA damage corrections prior to committing to enter mitosis and divide into 2 daughter cells.

There is a need for new anti-cancer therapeutic approaches, e.g., those utilizing small-molecules, especially therapies allowing for targeted cancer treatment.

SUMMARY OF THE INVENTION

In one aspect, the invention provides a method of inhibiting Myt1 in a cell expressing Myt1, the method including contacting the cell with the compound disclosed herein and a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof.

In some embodiments, the cell is overexpressing CCNE1. In some embodiments, the cell is in a subject.

In another aspect, the invention provides a method of treating a subject in need thereof including administering to the subject the compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, or the pharmaceutical composition disclosed herein.

In some embodiments, the subject is suffering from, and is in need of a treatment for, a disease or condition having the symptom of cell hyperproliferation. In some embodiments, the disease or condition is a cancer. In some embodiments, the cancer is a cancer overexpressing *CCNE1*.

In still another aspect, the invention provides a method of treating a cancer in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, where the cancer has been previously identified as a cancer overexpressing *CCNE1*.

In another aspect, the invention provides a method of treating a cancer in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, where the cancer is a cancer overexpressing *CCNE1*.

In yet another aspect, the invention provides a method of inducing cell death in a cancer cell overexpressing *CCNE1*, the method including contacting the cell with an effective amount of a Myt1 inhibitor.

In some embodiments of any of the above aspects, the cell is in a subject. In some embodiments, the Myt1 inhibitor is the compound disclosed herein or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer overexpressing *CCNE1* is uterine cancer, ovarian cancer, bladder cancer, pancreatic cancer, mesothelioma, kidney cancer, bladder cancer, gastric cancer, ovarian cancer, breast cancer, stomach cancer, esophageal cancer, lung cancer, or endometrial cancer.

In still another aspect, the invention provides a method of treating a cancer in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, where the cancer has been previously identified as a cancer having an inactivating mutation in the *FBXW7* gene.

In another aspect, the invention provides a method of treating a cancer in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor,

SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, where the cancer has an inactivating mutation in the *FBXW7* gene.

In yet another aspect, the invention provides a method of inducing cell death in an FBXW7-mutated cancer cell, the method including contacting the cell with an effective amount of a Myt1 inhibitor and an effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof.

In some embodiments, the cell is in a subject. In some embodiments, the cancer is uterine cancer, ovarian cancer, bladder cancer, pancreatic cancer, mesothelioma, kidney cancer, bladder cancer, gastric cancer, colorectal cancer, breast cancer, lung cancer, or esophageal cancer. Preferably, the cancer is uterine cancer, colorectal cancer, breast cancer, lung cancer, or esophageal cancer. In some embodiments, the Myt1 inhibitor is the compound disclosed herein, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the WEE1 inhibitor. In some embodiments, the WEE1 inhibitor is AZD1775, Debio-0123, ZN-c3, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the FEN1 inhibitor. In some embodiments, the FEN1 inhibitor is C8 (PMID: 32719125), SC13, FEN1-IN-3, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the TOP1 inhibitor. In some embodiments, the TOP1 inhibitor is irinotecan, topotecan, camptothecin, lamellarin D, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the RRM1 inhibitor.


In some embodiments, the method includes the step of administering the RRM2 inhibitor. In some embodiments, the RRM2 inhibitor is motexafin gadolinium, hydroxyurea, fludarabine, cladribine, tezacitabine, triapine, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the AURKB inhibitor. In some embodiments, the AURKB inhibitor is MK0547, AZD1152, PHA739358, AT9283, AMG900, SNS-314, TAK-901, CYC116, GSK1070916, PF03814735, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the TOP2A inhibitor. In some embodiments, the TOP2A inhibitor is etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticine, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering a nucleoside analog. In some embodiments, the nucleoside analog is cytarabine, gemcitabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nelarabine, or a pharmaceutically acceptable salt thereof or a combination thereof.

In some embodiments of any of the above aspects, the method includes the step of administering the ATR inhibitor. In some embodiments, the ATR inhibitor is a compound of formula (III):



5 or a pharmaceutically acceptable salt thereof,
where

===== is a double bond, and each Y is independently N or CR⁴; or ===== is a single bond, and each Y is independently NR^Y, carbonyl, or C(R^Y)₂; where each R^Y is independently H or optionally substituted C₁₋₆ alkyl;

10 R¹ is optionally substituted C₁₋₆ alkyl or H;

R² is optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, –N(R⁵)₂, –OR⁵, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or –Q–R^{5B};

15 R³ is optionally substituted C₁₋₉ heteroaryl or optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl;
each R⁴ is independently hydrogen, halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, or optionally substituted C₂₋₆ alkynyl;

each R⁵ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, or –SO₂R^{5A}; or both
20 R⁵, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

each R^{5A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;


R^{5B} is hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, –N(R⁵)₂, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or optionally substituted alkoxy;

each R⁶ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or both R⁶, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

30 Q is optionally substituted C₂₋₉ heterocyclylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₁₋₉ heteroarylene, or optionally substituted C₆₋₁₀ arylenes; and

X is hydrogen or halogen.

In some embodiments, the ATR inhibitor is a compound of formula (IV):





or a pharmaceutically acceptable salt thereof,

where

- 5 each Y is independently N or CR⁴;
 R¹ is optionally substituted C₁₋₆ alkyl or H;
 R² is optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, –
 10 N(R⁵)₂, –OR⁵, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or –Q–R^{5B};
 R³ is optionally substituted C₁₋₉ heteroaryl or optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl;
 each R⁴ is independently hydrogen, halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, or optionally substituted C₂₋₆ alkynyl;
 each R⁵ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, or –SO₂R^{5A}; or both
 15 R⁵, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;
 each R^{5A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;
 20 R^{5B} is hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, –N(R⁵)₂, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or optionally substituted alkoxy;
 each R⁶ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or both R⁶, together with the atom to
 25 which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;
 Q is optionally substituted C₂₋₉ heterocyclylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₁₋₉ heteroarylene, or optionally substituted C₆₋₁₀ arylenes; and
 X is hydrogen or halogen.


- In some embodiments, the ATR inhibitor is selected from the group consisting of compounds
 30 A43, A57, A62, A87, A93, A94, A95, A99, A100, A106, A107, A108, A109, A111, A112, A113, A114, A115, A116, A118, A119, A120, A121, A122, A123, A135, A147, A148, and pharmaceutically acceptable salts thereof. In some embodiments, the ATR inhibitor is compound A43 or a pharmaceutically acceptable salt thereof. In some embodiments, the ATR inhibitor is compound A121 or a pharmaceutically acceptable salt thereof. In some embodiments, the ATR inhibitor is compound A122 or
 35 a pharmaceutically acceptable salt thereof.

In some embodiments, the ATR inhibitor is



5 In some embodiments, the method includes the step of administering the TTK inhibitor. In some embodiments, the TTK inhibitor is BAY1217389 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the SOD1 inhibitor. In some embodiments, the SOD1 inhibitor is LCS1, ATN-224, Pyrimethamine, a compound of the following structure:



10 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the SOD2 inhibitor. In some embodiments, the SOD2 inhibitor is LCS1, ATN-224, Pyrimethamine, or a pharmaceutically acceptable salt thereof.

15 In some embodiments, the method includes the step of administering the BUB1 inhibitor. In some embodiments, the BUB1 inhibitor is BAY-320, BAY-419, BAY1816032, or a pharmaceutically acceptable salt thereof. In some embodiments, the method includes the step of administering the CDC7 inhibitor. In some embodiments, the CDC7 inhibitor is SRA141, TAK931, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the SAE1 inhibitor. In some embodiments, the SAE1 inhibitor is ML792 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the PLK1 inhibitor. In some embodiments, the PLK1 inhibitor is BI2536, BI6727, TAK960, NMSP937, GSK461364, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the UBA2 inhibitor. In some embodiments, the UBA2 inhibitor is TAK981 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the DUT inhibitor. In some embodiments, the DUT inhibitor is TAS114 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the HDAC3 inhibitor. In some embodiments, the HDAC3 inhibitor is RGFP966 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the CHEK1 inhibitor. In some embodiments, the CHEK1 inhibitor is SRA737 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the AURKA inhibitor. In some embodiments, the AURKA inhibitor is MLN8237, MK0547, MLN8054, PHA739358, AT9283, AMG900, MK5108, SNS314, TAK901, CYC116, ENMD2076, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the MEN1 inhibitor. In some embodiments, the MEN1 inhibitor is MI3454, SNDX5613, VTP50469, KO539, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the DOT1L inhibitor. In some embodiments, the DOT1L inhibitor is EPZ5676 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the CREBBP inhibitor. In some embodiments, the CREBBP inhibitor is CPI4, CCS1477, E7386, NEO1132, NEO2734, PRI724, C82, BC001, C646, EML425, CBP30, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the EZH2 inhibitor. In some embodiments, the EZH2 inhibitor is EPZ-6438, GSK126, or a pharmaceutically acceptable salt thereof.


In some embodiments, the method includes the step of administering the PLK4 inhibitor. In some embodiments, the PLK4 inhibitor is centrinone, CFI-400945, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the HASPIN inhibitor. In some embodiments, the HASPIN inhibitor is SEL120 or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the METTL3 inhibitor. In some embodiments, the METTL3 inhibitor is UZH1a, sTC-15, or a pharmaceutically acceptable salt thereof.

In some embodiments, the method includes the step of administering the platinum-based DNA damaging agent. In some embodiments, the platinum-based DNA damaging agent is cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin. In some embodiments, the platinum-based DNA damaging agent is carboplatin.

In some embodiments, the Myt1 inhibitor is a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

where

5 each of X, Y, and Z is independently N or CR²;

R¹ and each R² are independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, cyano -N(R⁷)₂, -OR⁷, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or -Q-R^{7B}; or R¹ combines with one R² that is *vicinal* to R¹ to form an optionally substituted C₃₋₆ alkylene;

each of R³ and R⁴ is independently optionally substituted C₁₋₆ alkyl or halogen;

R⁵ is H or -N(R⁷)₂;

R⁶ is -C(O)NH(R⁸), -C(O)R^{7A}, or -SO₂R^{7A};

15 each R⁷ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, or -SO₂R^{7A}; or two R⁷ groups, together with the atom to which both are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;


20 each R^{7A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;

each R^{7B} is independently hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₉ heteroaryl, -N(R⁷)₂, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or optionally substituted alkoxy;

25 each R⁸ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or two R⁸, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;


30 Q is optionally substituted C₁₋₆ alkylene, optionally substituted C₂₋₆ alkenylene, optionally substituted C₂₋₆ alkynylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₃₋₈ cycloalkenylene optionally substituted C₆₋₁₀ arylene, optionally substituted C₂₋₉ heterocyclylene, or optionally substituted C₁₋₉ heteroarylene.

In some embodiments, the Myt1 inhibitor is enriched for the atropisomer of formula (IA):




(IA)

In some embodiments, X is CR². In some embodiments, the Myt1 inhibitor is a compound of formula (II):




(II)

In some embodiments, the compound is enriched for the atropisomer of formula (IIA):



(IIA)


In some embodiments, the Myt1 inhibitor is a compound of formula (III):



(III)

where R^{2A} is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, -N(R⁷)₂, -OR⁷, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or -Q-R^{7B}.

In some embodiments, the compound is enriched for the atropisomer of formula (IIIA):



In some embodiments, R^{2A} is hydrogen, optionally substituted C₁₋₆ alkyl, or halogen.

In some embodiments, R³ is optionally substituted C₁₋₆ alkyl. In some embodiments, R³ is halogen. In some embodiments, R⁴ is optionally substituted C₁₋₆ alkyl. In some embodiments, R⁴ is halogen (e.g., chlorine).

In some embodiments, R² is hydrogen. In some embodiments, R² is optionally substituted C₁₋₆ alkyl. In some embodiments, R² is optionally substituted methyl or optionally substituted isopropyl. R² is halogen.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is chlorine or bromine. In some embodiments, R¹ is optionally substituted C₁₋₆ alkyl. In some embodiments, R¹ is optionally substituted methyl, optionally substituted ethyl, optionally substituted isopropyl, or optionally substituted butyl. In some embodiments, R¹ is optionally substituted C₁₋₉ heteroaryl. In some embodiments, R¹ is 1,3-thiazolyl, 1,2-thiazolyl, 1,3-oxazolyl, benzo-1,3-thiazolyl, benzo-1,3-oxazolyl, indolyl, benzimidazolyl, pyridyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, or pyrazolyl, where R¹ is optionally substituted with substituents as defined for optionally substituted C₁₋₉ heteroaryl. In some embodiments, R¹ is optionally substituted C₃₋₈ cycloalkyl. In some embodiments, R¹ is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, where R¹ is optionally substituted with substituents as defined for optionally substituted C₃₋₈ cycloalkyl. In some embodiments, R¹ is optionally substituted C₂₋₉ heterocyclyl. In some embodiments, R¹ is 1,2,3,6-tetrahydropyridinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, oxa-aza-spiro[3.3]heptane, or oxa-aza-bicyclo[3.2.1]octane, where R¹ is optionally substituted with substituents as defined for optionally substituted C₂₋₉ heterocyclyl. In some embodiments, R¹ is optionally substituted C₃₋₈ cycloalkyl. In some embodiments, R¹ is optionally substituted cyclohexenyl or optionally substituted cyclopentenyl. In some embodiments, R¹ is optionally substituted C₆₋₁₀ aryl. In some embodiments, R¹ is optionally substituted phenyl.

In some embodiments, R¹ is -Q-R^{7B}. In some embodiments, Q is optionally substituted C₂₋₆ alkynylene. In some embodiments, Q is optionally substituted C₁₋₆ alkylene. In some embodiments, Q is optionally substituted C₆₋₁₀ arylene. In some embodiments, R^{7B} is optionally substituted C₂₋₉ heterocyclyl. In some embodiments, R^{7B} is optionally substituted C₆₋₁₀ aryl.

In some embodiments, R¹ is optionally substituted with one, two, or three groups independently selected from the group consisting of methyl, difluoromethyl, trifluoromethyl, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, -C(O)NH₂, -C(O)NH(Me), -C(O)N(Me)₂, -(CH₂)_n-C(O)OH, and -(CH₂)_n-C(O)Ot-Bu, where n is 0 or 1.

In some embodiments, R¹ is -N(R⁷)₂. In some embodiments, R¹ is diethylamino.

In some embodiments, R⁵ is hydrogen. In some embodiments, R⁵ is -N(R⁷)₂. In some embodiments, R⁵ is -NH₂. In some embodiments, R⁶ is -C(O)NH(R⁸). In some embodiments, R⁶ is -

C(O)NH₂. In some embodiments, R⁶ is -C(O)NH(Me). In some embodiments, R⁶ is -SO₂R^{7A}. In some embodiments, R⁶ is -SO₂Me.

In some embodiments, the Myt1 inhibitor is a compound selected from the group consisting of compounds 1-328 (e.g., compounds 1-288) and pharmaceutically acceptable salts thereof.

5 In some embodiments, the Myt1 inhibitor is administered as a pharmaceutical composition. In some embodiments, the pharmaceutical composition is isotopically enriched in deuterium.

ABBREVIATIONS

Abbreviations and terms that are commonly used in the fields of organic chemistry, medicinal
10 chemistry, pharmacology, and medicine and are well known to practitioners in these fields are used herein. Representative abbreviations and definitions are provided below:

Ac is acetyl [CH₃C(O)-], Ac₂O is acetic anhydride; AcOH is acetic acid; APC is antigen-presenting cell; aq. is aqueous; 9-BBN is 9-borabicyclo[3.3.1]nonane; BINAP is (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl); Bn is benzyl; BOC is tert Butyloxycarbonyl; CDI is carbonyldiimidazole; DCM is
15 dichloromethane; DIAD is diisopropylazodicarboxylate; DIBAL is diisobutylaluminum hydride; DIPEA is diisopropylethyl amine; DMA is dimethylacetamide; DMAP is 4-dimethylaminopyridine; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; dppe is 1,1'-bis(diphenylphosphino)ferrocene; EDAC (or EDC) is 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide HCl; ESI is electrospray ionization mass spectrometry; Et₂O is diethyl ether; Et₃N is triethylamine; Et is ethyl; EtOAc is ethyl acetate; EtOH is
20 ethanol; 3-F-Ph is 3-fluorophenyl; HATU is (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; HCl is hydrochloric acid; HOBt is 1-hydroxybenzotriazole; HPLC is high performance liquid chromatography; LCMS is HPLC with mass spectral detection; LiHMDS is lithium bis(trimethylsilyl)amide; LG is leaving group; M is molar; mCPBA is metachloroperbenzoic acid; mmol is millimole; Me is methyl; MeCN is acetonitrile; MeOH is methanol; Ms is methanesulfonyl; MS is
25 mass spectrometry; N is normal; NaHMDS is sodium hexamethyldisilazide; NaOAc is sodium acetate; NaOtBu is sodium tert-butoxide; NMO is N-methylmorpholine N-oxide; NMP is N-methyl pyrrolidinone; NMR is nuclear magnetic resonance spectroscopy; Pd₂(dba)₃ is tris(dibenzylideneacetone)dipalladium; PdCl₂(PPh₃)₂ is dichlorobis-(triphenylphosphine) palladium; PG Denotes an unspecified protecting group; Ph is phenyl; PhMe is toluene; PPh₃ is triphenylphosphine; PMB is para-methoxybenzyl; rt is room
30 temperature; RBF is round-bottom flask; RuPhos Pd G1 is chloro-(2-Dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II); SEM is [2-(trimethylsilyl)ethoxy]methyl; SFC is supercritical fluid chromatography; S_NAr is nucleophilic aromatic substitution; TBAB is tetrabutyl ammonium bromide; TBAF is tetrabutyl ammonium fluoride; TBS is tert-butyldimethylsilyl; tBu is tert-butyl; Tf is triflate; TFA is trifluoroacetic acid; THF is tetrahydrofuran; THP is tetrahydropyran; TLC is thin layer
35 chromatography; TMAD is tetramethylazodicarboxamide; TMS is trimethylsilyl; TPAP is tetrapropylammonium perruthenate; Ts is *p*-toluenesulfonyl; UPLC is ultra performance liquid chromatography.

DEFINITIONS

40 The term "aberrant," as used herein, refers to different from normal. When used to describe activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a

disease, where returning the aberrant activity to a normal or non-disease-associated amount (e.g. by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.

The term "acyl," as used herein, represents a group $-C(=O)-R$, where R is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocyclyl. Acyl may be optionally substituted as described herein for each respective R group.

The term "adenocarcinoma," as used herein, represents a malignancy of the arising from the glandular cells that line organs within an organism. Non-limiting examples of adenocarcinomas include non-small cell lung cancer, prostate cancer, pancreatic cancer, esophageal cancer, and colorectal cancer.

The term "alkanoyl," as used herein, represents a hydrogen or an alkyl group that is attached to the parent molecular group through a carbonyl group and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, propionyl, butyryl, and iso-butyryl. Unsubstituted alkanoyl groups contain from 1 to 7 carbons. The alkanoyl group may be unsubstituted or substituted (e.g., optionally substituted C1-7 alkanoyl) as described herein for alkyl group. The ending "-oyl" may be added to another group defined herein, e.g., aryl, cycloalkyl, and heterocyclyl, to define "aryloyl," "cycloalkanoyl," and "(heterocyclyl)oyl." These groups represent a carbonyl group substituted by aryl, cycloalkyl, or heterocyclyl, respectively. Each of "aryloyl," "cycloalkanoyl," and "(heterocyclyl)oyl" may be optionally substituted as defined for "aryl," "cycloalkyl," or "heterocyclyl," respectively.

The term "alkenyl," as used herein, represents acyclic monovalent straight or branched chain hydrocarbon groups of containing one, two, or three carbon-carbon double bonds. Non-limiting examples of the alkenyl groups include ethenyl, prop-1-enyl, prop-2-enyl, 1-methylethenyl, but-1-enyl, but-2-enyl, but-3-enyl, 1-methylprop-1-enyl, 2-methylprop-1-enyl, and 1-methylprop-2-enyl. Alkenyl groups may be optionally substituted as defined herein for alkyl.

The term "alkenylene," as used herein, refers to a divalent alkenyl group. An optionally substituted alkenylene is an alkenylene that is optionally substituted as described herein for alkenyl.

The term "alkoxy," as used herein, represents a chemical substituent of formula $-OR$, where R is a C₁₋₆ alkyl group, unless otherwise specified. In some embodiments, the alkyl group can be further substituted as defined herein. The term "alkoxy" can be combined with other terms defined herein, e.g., aryl, cycloalkyl, or heterocyclyl, to define an "aryl alkoxy," "cycloalkyl alkoxy," and "(heterocyclyl)alkoxy" groups. These groups represent an alkoxy that is substituted by aryl, cycloalkyl, or heterocyclyl, respectively. Each of "aryl alkoxy," "cycloalkyl alkoxy," and "(heterocyclyl)alkoxy" may optionally substituted as defined herein for each individual portion.

The term "alkoxyalkyl," as used herein, represents a chemical substituent of formula $-L-O-R$, where L is C₁₋₆ alkylene, and R is C₁₋₆ alkyl. An optionally substituted alkoxyalkyl is an alkoxyalkyl that is optionally substituted as described herein for alkyl.

The term "alkyl," as used herein, refers to an acyclic straight or branched chain saturated hydrocarbon group, which, when unsubstituted, has from 1 to 12 carbons, unless otherwise specified. In certain preferred embodiments, unsubstituted alkyl has from 1 to 6 carbons. Alkyl groups are exemplified by methyl; ethyl; n- and iso-propyl; n-, sec-, iso- and tert-butyl; neopentyl, and the like, and may be optionally substituted, valency permitting, with one, two, three, or, in the case of alkyl groups of two carbons or more, four or more substituents independently selected from the group consisting of: amino;

alkoxy; aryl; aryloxy; azido; cycloalkyl; cycloalkoxy; cycloalkenyl; cycloalkynyl; halo; heterocyclyl; (heterocyclyl)oxy; heteroaryl; hydroxy; nitro; thiol; silyl; cyano; alkylsulfonyl; alkylsulfinyl; alkylsulfenyl; =O; =S; -C(O)R or -SO₂R, where R is amino; and =NR', where R' is H, alkyl, aryl, or heterocyclyl. Each of the substituents may itself be unsubstituted or, valency permitting, substituted with unsubstituted

5 substituent(s) defined herein for each respective group.

The term "alkylene," as used herein, refers to a divalent alkyl group. An optionally substituted alkylene is an alkylene that is optionally substituted as described herein for alkyl.

The term "alkylamino," as used herein, refers to a group having the formula -N(R^{N1})₂ or -NHR^{N1}, in which R^{N1} is alkyl, as defined herein. The alkyl portion of alkylamino can be optionally substituted as

10 defined for alkyl. Each optional substituent on the substituted alkylamino may itself be unsubstituted or, valency permitting, substituted with unsubstituted substituent(s) defined herein for each respective group.

The term "alkylsulfenyl," as used herein, represents a group of formula -S-(alkyl). Alkylsulfenyl may be optionally substituted as defined for alkyl.

The term "alkylsulfinyl," as used herein, represents a group of formula -S(O)-(alkyl). Alkylsulfinyl

15 may be optionally substituted as defined for alkyl.

The term "alkylsulfonyl," as used herein, represents a group of formula -S(O)₂-(alkyl). Alkylsulfonyl may be optionally substituted as defined for alkyl.

The term "alkynyl," as used herein, represents monovalent straight or branched chain hydrocarbon groups of from two to six carbon atoms containing at least one carbon-carbon triple bond

20 and is exemplified by ethynyl, 1-propynyl, and the like. The alkynyl groups may be unsubstituted or substituted (e.g., optionally substituted alkynyl) as defined for alkyl.

The term "alkynylene," as used herein, refers to a divalent alkynyl group. An optionally substituted alkynylene is an alkynylene that is optionally substituted as described herein for alkynyl.

The term "amino," as used herein, represents -N(R^{N1})₂, where, if amino is unsubstituted, both R^{N1} are H; or, if amino is substituted, each R^{N1} is independently H, -OH, -NO₂, -N(R^{N2})₂, -SO₂OR^{N2}, -SO₂R^{N2}, -SOR^{N2}, -C(O)OR^{N2}, an N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, aryloxy, cycloalkyl, cycloalkenyl, heteroalkyl, or heterocyclyl, provided that at least one R^{N1} is not H, and where each R^{N2} is independently H, alkyl, or aryl. Each of the substituents may itself be unsubstituted or

25 substituted with unsubstituted substituent(s) defined herein for each respective group. In some embodiments, amino is unsubstituted amino (i.e., -NH₂) or substituted amino (e.g., -NHR^{N1}), where R^{N1} is independently -OH, SO₂OR^{N2}, -SO₂R^{N2}, -SOR^{N2}, -COOR^{N2}, optionally substituted alkyl, or optionally substituted aryl, and each R^{N2} can be optionally substituted alkyl or optionally substituted aryl. In some

30 embodiments, substituted amino may be alkylamino, in which the alkyl groups are optionally substituted as described herein for alkyl. In some embodiments, an amino group is -NHR^{N1}, in which R^{N1} is

35 optionally substituted alkyl.

The term "aryl," as used herein, represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings. Aryl group may include from 6 to 10 carbon atoms. All atoms within an unsubstituted carbocyclic aryl group are carbon atoms. Non-limiting examples of carbocyclic aryl groups include phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl,

40 indenyl, etc. The aryl group may be unsubstituted or substituted with one, two, three, four, or five substituents independently selected from the group consisting of: alkyl; alkenyl; alkynyl; alkoxy; alkylsulfinyl; alkylsulfenyl; alkylsulfonyl; amino; aryl; aryloxy; azido; cycloalkyl; cycloalkoxy; cycloalkenyl;

cycloalkynyl; halo; heteroalkyl; heterocyclyl; (heterocyclyl)oxy; hydroxy; nitro; thiol; silyl; $-(CH_2)_n-$ $C(O)OR^A$; $-C(O)R$; and $-SO_2R$, where R is amino or alkyl, R^A is H or alkyl, and n is 0 or 1. Each of the substituents may itself be unsubstituted or substituted with unsubstituted substituent(s) defined herein for each respective group.

5 The term "aryl alkyl," as used herein, represents an alkyl group substituted with an aryl group. The aryl and alkyl portions may be optionally substituted as the individual groups as described herein.

 The term "arylene," as used herein, refers to a divalent aryl group. An optionally substituted arylene is an arylene that is optionally substituted as described herein for aryl.

 The term "aryloxy," as used herein, represents a chemical substituent of formula $-OR$, where R is an aryl group, unless otherwise specified. In optionally substituted aryloxy, the aryl group is optionally substituted as described herein for aryl.

 The term "ATR," as used herein, refers to Ataxia-telangiectasia and RAD-3-related protein kinase. The protein is encoded by the ATR gene. This protein is a serine/threonine kinase and DNA damage sensor, believed to activate cell cycle checkpoint signaling upon DNA stress. This protein can phosphorylate and activate several proteins involved in the inhibition of DNA replication and mitosis, and can promote DNA repair, recombination, and apoptosis.

 The term "AURKB," as used herein, refers to aurora kinase B. This protein is encoded by the AURKB gene. This protein is a member of the aurora kinase subfamily of serine/threonine kinases. This kinase participates in the regulation of alignment and segregation of chromosomes during mitosis and meiosis through association with microtubules.

 The term "AURKA," as used herein, refers to aurora kinase A. This protein is encoded by the AURKA gene. This protein is a cell cycle-regulated kinase that appears to be involved in microtubule formation and/or stabilization at the spindle pole during chromosome segregation. The protein is found at the centrosome in interphase cells and at the spindle poles in mitosis.

25 The term "azido," as used herein, represents an $-N_3$ group.

 The term "BUB1," as used herein, refers to BUB1 mitotic checkpoint serine/threonine kinase B. This protein is encoded by the BUB1 gene.

 The term "cancer," as used herein, refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g., humans).

30 The term "carbocyclic," as used herein, represents an optionally substituted C3-16 monocyclic, bicyclic, or tricyclic structure in which the rings, which may be aromatic or non-aromatic, are formed by carbon atoms. Carbocyclic structures include cycloalkyl, cycloalkenyl, cycloalkynyl, and certain aryl groups.

 The term "carbonyl," as used herein, represents a $-C(O)-$ group.

35 The term "carcinoma," as used herein, refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.

 The term "cyano," as used herein, represents $-CN$ group.

 The terms "CCNE1" and "cyclin E1," as used interchangeably herein, refer to G1/S specific cyclin E1 (Gene name: *CCNE1*). A cell overexpressing CCNE1 is one that exhibits a higher activity of CCNE1 than a cell normally expressing CCNE1. For example, a CCNE1-overexpressing cell is a cell that exhibits a copy number of at least 3 compared to a diploid normal cell with 2 copies. Thus, a cell exhibiting a copy number greater than 3 of CCNE1 is a cell overexpressing CCNE1. The CCNE1 overexpression may be

measured by identifying the expression level of the gene product in a cell (e.g., CCNE1 mRNA transcript count or CCNE1 protein level).

5 The term "CDC7," as used herein, represents cell division cycle 7 protein. This protein is encoded by the CDC7 gene. This protein has kinase activity that is believed to be critical for the G1/S transition.

The term "CHEK1," as used herein, represents checkpoint kinase 1. This protein is encoded by the CHEK1 gene. It belongs to the Ser/Thr protein kinase family. It is required for checkpoint mediated cell cycle arrest in response to DNA damage or the presence of unreplicated DNA. This protein acts to integrate signals from ATM and ATR, two cell cycle proteins involved in DNA damage responses, that also associate with chromatin in meiotic prophase I.

10 The term "CREBBP," as used herein, represents CREB binding protein. This protein is encoded by the CREBBP gene. This protein is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this protein is now known for its roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. This protein has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins.

20 The term "cycloalkenyl," as used herein, refers to a non-aromatic carbocyclic group having at least one double bond in the ring and from three to ten carbons (e.g., a C₃₋₁₀ cycloalkenyl), unless otherwise specified. Non-limiting examples of cycloalkenyl include cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, norbornen-2-yl, norbornen-5-yl, and norbornen-7-yl. The cycloalkenyl group may be unsubstituted or substituted (e.g., optionally substituted cycloalkenyl) as described for cycloalkyl.

25 The term "cycloalkenyl alkyl," as used herein, represents an alkyl group substituted with a cycloalkenyl group, each as defined herein. The cycloalkenyl and alkyl portions may be substituted as the individual groups defined herein.

30 The term "cycloalkenylene," as used herein, represents a divalent cycloalkenyl group. An optionally substituted cycloalkenylene is a cycloalkenylene that is optionally substituted as described herein for cycloalkyl.

The term "cycloalkoxy," as used herein, represents a chemical substituent of formula -OR, where R is cycloalkyl group, unless otherwise specified. In some embodiments, the cycloalkyl group can be further substituted as defined herein.

35 The term "cycloalkyl," as used herein, refers to a cyclic alkyl group having from three to ten carbons (e.g., a C₃₋₁₀ cycloalkyl), unless otherwise specified. Cycloalkyl groups may be monocyclic or bicyclic. Bicyclic cycloalkyl groups may be of bicyclo[p.q.0]alkyl type, in which each of p and q is, independently, 1, 2, 3, 4, 5, 6, or 7, provided that the sum of p and q is 2, 3, 4, 5, 6, 7, or 8. Alternatively, bicyclic cycloalkyl groups may include bridged cycloalkyl structures, e.g., bicyclo[p.q.r]alkyl, in which r is 1, 2, or 3, each of p and q is, independently, 1, 2, 3, 4, 5, or 6, provided that the sum of p, q, and r is 3, 4, 5, 6, 7, or 8. The cycloalkyl group may be a spirocyclic group, e.g., spiro[p.q]alkyl, in which each of p and q is, independently, 2, 3, 4, 5, 6, or 7, provided that the sum of p and q is 4, 5, 6, 7, 8, or 9. Non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-

bicyclo[2.2.1]heptyl, 2-bicyclo[2.2.1]heptyl, 5-bicyclo[2.2.1]heptyl, 7-bicyclo[2.2.1]heptyl, and decalynyl. The cycloalkyl group may be unsubstituted or substituted (e.g., optionally substituted cycloalkyl) with one, two, three, four, or five substituents independently selected from the group consisting of: alkyl; alkenyl; alkynyl; alkoxy; alkylsulfinyl; alkylsulfenyl; alkylsulfonyl; amino; aryl; aryloxy; azido; cycloalkyl; cycloalkoxy; cycloalkenyl; cycloalkynyl; halo; heteroalkyl; heterocyclyl; (heterocyclyl)oxy; heteroaryl; hydroxy; nitro; thiol; silyl; cyano; =O; =S; -SO₂R, where R is optionally substituted amino; =NR', where R' is H, alkyl, aryl, or heterocyclyl; and -CON(R^A)₂, where each R^A is independently H or alkyl, or both R^A, together with the atom to which they are attached, combine to form heterocyclyl. Each of the substituents may itself be unsubstituted or substituted with unsubstituted substituent(s) defined herein for each respective group.

The term "cycloalkyl alkyl," as used herein, represents an alkyl group substituted with a cycloalkyl group, each as defined herein. The cycloalkyl and alkyl portions may be optionally substituted as the individual groups described herein.

The term "cycloalkylene," as used herein, represents a divalent cycloalkyl group. An optionally substituted cycloalkylene is a cycloalkylene that is optionally substituted as described herein for cycloalkyl.

The term "cycloalkynyl," as used herein, refers to a monovalent carbocyclic group having one or two carbon-carbon triple bonds and having from eight to twelve carbons, unless otherwise specified. Cycloalkynyl may include one transannular bond or bridge. Non-limiting examples of cycloalkynyl include cyclooctynyl, cyclononyl, cyclodecynyl, and cyclodecadiynyl. The cycloalkynyl group may be unsubstituted or substituted (e.g., optionally substituted cycloalkynyl) as defined for cycloalkyl.

"Disease" or "condition" refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein.

The term "DOT1L," as used herein, refers to DOT1-like histone lysine methyltransferase. This protein is encoded by the DOT1L gene. This protein is a histone methyltransferase that methylates lysine-79 of histone H3. It is inactive against free core histones but shows significant histone methyltransferase activity against nucleosomes.

The term "EZH2," as used herein, refers to enhancer of zeste 2 polycomb repressive complex 2 subunit. This protein is encoded by the EZH2 gene. This protein is a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein.

The term "DUT," as used herein, refers to deoxyuridine triphosphatase. This protein is encoded by the DUT gene. This protein forms a ubiquitous, homotetrameric enzyme that hydrolyzes dUTP to dUMP and pyrophosphate. This reaction is believed to serve two cellular purposes: providing a precursor (dUMP) for the synthesis of thymine nucleotides needed for DNA replication, and limiting intracellular pools of dUTP. Elevated levels of dUTP can lead to increased incorporation of uracil into DNA, which induces extensive excision repair mediated by uracil glycosylase. This repair process, resulting in the removal and reincorporation of dUTP, is self-defeating and leads to DNA fragmentation and cell death.

The term "FEN1," as used herein, refers to flap structure-specific endonuclease 1. This protein is encoded by the FEN1 gene. This protein removes 5' overhanging flaps in DNA repair and processes the

5' ends of Okazaki fragments in lagging strand DNA synthesis. Direct physical interaction between this protein and AP endonuclease 1 during long-patch base excision repair is believed to provide coordinated loading of the proteins onto the substrate, thus passing the substrate from one enzyme to another. The protein is a member of the XPG/RAD2 endonuclease family and is one of ten proteins believed to be essential for cell-free DNA replication.

The term "FBXW7," as used herein, refers to F-box/WD Repeat-Containing Protein 7 gene, transcript, or protein. An FBXW7-mutated gene, also described herein as an FBXW7 gene having an inactivating mutation, is one that fails to produce a functional FBXW7 protein or produces reduced quantities of FBXW7 protein in a cell.

The term "halo," as used herein, represents a halogen selected from bromine, chlorine, iodine, and fluorine.

The term "HASPIN," as used herein, refers to histone H3-associated protein kinase. This protein is encoded by the HASPIN gene.

The term "HDAC3," as used herein, refers to histone deacetylase 3. This protein is encoded by the HDAC3 gene. The protein has histone deacetylase activity and represses transcription when tethered to a promoter. It may participate in the regulation of transcription through its binding with the zinc-finger transcription factor YY1.

The term "heteroalkyl," as used herein refers to an alkyl, alkenyl, or alkynyl group interrupted once by one or two heteroatoms; twice, each time, independently, by one or two heteroatoms; three times, each time, independently, by one or two heteroatoms; or four times, each time, independently, by one or two heteroatoms. Each heteroatom is, independently, O, N, or S. In some embodiments, the heteroatom is O or N. None of the heteroalkyl groups includes two contiguous oxygen or sulfur atoms. The heteroalkyl group may be unsubstituted or substituted (e.g., optionally substituted heteroalkyl). When heteroalkyl is substituted and the substituent is bonded to the heteroatom, the substituent is selected according to the nature and valency of the heteroatom. Thus, the substituent bonded to the heteroatom, valency permitting, is selected from the group consisting of =O, -N(R^{N2})₂, -SO₂OR^{N3}, -SO₂R^{N2}, -SOR^{N3}, -COOR^{N3}, an N protecting group, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, or cyano, where each R^{N2} is independently H, alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, or heterocyclyl, and each R^{N3} is independently alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, or heterocyclyl. Each of these substituents may itself be unsubstituted or substituted with unsubstituted substituent(s) defined herein for each respective group. When heteroalkyl is substituted and the substituent is bonded to carbon, the substituent is selected from those described for alkyl, provided that the substituent on the carbon atom bonded to the heteroatom is not Cl, Br, or I. It is understood that carbon atoms are found at the termini of a heteroalkyl group.

The term "heteroaryl alkyl," as used herein, represents an alkyl group substituted with a heteroaryl group, each as defined herein. The heteroaryl and alkyl portions may be optionally substituted as the individual groups described herein.

The term "heteroarylene," as used herein, represents a divalent heteroaryl. An optionally substituted heteroarylene is a heteroarylene that is optionally substituted as described herein for heteroaryl.

The term "heteroaryloxy," as used herein, refers to a structure -OR, in which R is heteroaryl. Heteroaryloxy can be optionally substituted as defined for heterocyclyl.

The term "heterocyclyl," as used herein, represents a monocyclic, bicyclic, tricyclic, or tetracyclic ring system having fused, bridging, and/or spiro 3-, 4-, 5-, 6-, 7-, or 8-membered rings, unless otherwise specified, containing one, two, three, or four heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, "heterocyclyl" is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system having fused or bridging 5-, 6-, 7-, or 8-membered rings, unless otherwise specified, containing one, two, three, or four heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. Heterocyclyl can be aromatic or non-aromatic. Non-aromatic 5-membered heterocyclyl has zero or one double bonds, non-aromatic 6- and 7-membered heterocyclyl groups have zero to two double bonds, and non-aromatic 8-membered heterocyclyl groups have zero to two double bonds and/or zero or one carbon-carbon triple bond. Heterocyclyl groups include from 1 to 16 carbon atoms unless otherwise specified. Certain heterocyclyl groups may include up to 9 carbon atoms. Non-aromatic heterocyclyl groups include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, pyridazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, thiazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydroindolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, pyranyl, dihydropyranyl, dithiazolyl, etc. If the heterocyclic ring system has at least one aromatic resonance structure or at least one aromatic tautomer, such structure is an aromatic heterocyclyl (i.e., heteroaryl). Non-limiting examples of heteroaryl groups include benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, furyl, imidazolyl, indolyl, isoindazolyl, isoquinolinyl, isothiazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrrolyl, pyridinyl, pyrazinyl, pyrimidinyl, quinazolinyl, quinolinyl, thiadiazolyl (e.g., 1,3,4-thiadiazole), thiazolyl, thienyl, triazolyl, tetrazolyl, etc. The term "heterocyclyl" also represents a heterocyclic compound having a bridged multicyclic structure in which one or more carbons and/or heteroatoms bridges two non-adjacent members of a monocyclic ring, e.g., quinuclidine, tropanes, or diaza-bicyclo[2.2.2]octane. The term "heterocyclyl" includes bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one, two, or three carbocyclic rings, e.g., an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another monocyclic heterocyclic ring. Examples of fused heterocyclyls include 1,2,3,5,8a-hexahydroindolizine; 2,3-dihydrobenzofuran; 2,3-dihydroindole; and 2,3-dihydrobenzothiophene. The heterocyclyl group may be unsubstituted or substituted with one, two, three, four or five substituents independently selected from the group consisting of: alkyl; alkenyl; alkynyl; alkoxy; alkylsulfenyl; alkylsulfenyl; alkylsulfonyl; amino; aryl; aryloxy; azido; cycloalkyl; cycloalkoxy; cycloalkenyl; cycloalkynyl; halo; heteroalkyl; heterocyclyl; (heterocyclyl)oxy; hydroxy; nitro; thiol; silyl; cyano; -C(O)R or -SO₂R, where R is amino or alkyl; =O; =S; =NR', where R' is H, alkyl, aryl, or heterocyclyl. Each of the substituents may itself be unsubstituted or substituted with unsubstituted substituent(s) defined herein for each respective group.

The term "heterocyclyl alkyl," as used herein, represents an alkyl group substituted with a heterocyclyl group, each as defined herein. The heterocyclyl and alkyl portions may be optionally substituted as the individual groups described herein.

The term "heterocyclylene," as used herein, represents a divalent heterocyclyl. An optionally substituted heterocyclylene is a heterocyclylene that is optionally substituted as described herein for heterocyclyl.

The term “(heterocyclyl)oxy,” as used herein, represents a chemical substituent of formula –OR, where R is a heterocyclyl group, unless otherwise specified. (Heterocyclyl)oxy can be optionally substituted in a manner described for heterocyclyl.

The terms “hydroxyl” and “hydroxy,” as used interchangeably herein, represent an –OH group.

5 The term “isotopically enriched,” as used herein, refers to the pharmaceutically active agent with the isotopic content for one isotope at a predetermined position within a molecule that is at least 100 times greater than the natural abundance of this isotope. For example, a composition that is isotopically enriched for deuterium includes an active agent with at least one hydrogen atom position having at least 100 times greater abundance of deuterium than the natural abundance of deuterium. Preferably, an
10 isotopic enrichment for deuterium is at least 1000 times greater than the natural abundance of deuterium. More preferably, an isotopic enrichment for deuterium is at least 4000 times greater (e.g., at least 4750 times greater, e.g., up to 5000 times greater) than the natural abundance of deuterium.

The term “leukemia,” as used herein, refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of
15 leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease—acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood—leukemic or aleukemic (subleukemic).

The term “lymphoma,” as used herein, refers to a cancer arising from cells of immune origin.

20 The term “melanoma,” as used herein, is taken to mean a tumor arising from the melanocytic system of the skin and other organs.

The term “MEN1,” as used herein, refers to menin. This protein is encoded by the MEN1 gene. Menin is a scaffold protein that functions in histone modification and epigenetic gene regulation.

The term “METTL3,” as used herein, refers to methyltransferase like 3. This protein is encoded
25 by the METTL3 gene. This enzyme is 70 kDa subunit of MT-A which is part of N6-adenosine-methyltransferase. This enzyme is involved in the posttranscriptional methylation of internal adenosine residues in eukaryotic mRNAs, forming N6-methyladenosine.

The term “Myt1,” as used herein, refers to membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1).

30 The term “Myt1 inhibitor,” as used herein, represents a compound that upon contacting the enzyme Myt1, whether in vitro, in cell culture, or in an animal, reduces the activity of Myt1, such that the measured Myt1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain Myt1 inhibitors, the Myt1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 3 nM or less) and could be as low as 100 pM or 10 pM. Preferably, the Myt1 IC₅₀ is 1 nM to 1 μM (e.g., 1 nM to 750 nM, 1 nM to 500 nM, or 1 nM to 250
35 nM). Even more preferably, the Myt1 IC₅₀ is less than 20 nM (e.g., 1 nM to 20 nM).

The term “nitro,” as used herein, represents an –NO₂ group.

The term “oxo,” as used herein, represents a divalent oxygen atom (e.g., the structure of oxo may be shown as =O).

The term “Ph,” as used herein, represents phenyl.

40 The term “pharmaceutical composition,” as used herein, represents a composition containing a compound described herein, formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the

treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein.

The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier," as used interchangeably herein, refers to any ingredient other than the compounds described herein (e.g., a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluent), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

The term "pharmaceutically acceptable salt," as use herein, represents those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., *J. Pharmaceutical Sciences* 66:1-19, 1977 and in *Pharmaceutical Salts: Properties, Selection, and Use*, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

The term "PLK1," as used herein, represents polo like kinase 1. This protein is encoded by the PLK1 gene. This protein is a Ser/Thr protein kinase belonging to the CDC5/Polo subfamily.

The term "PLK4," as used herein, represents polo like kinase 4. This protein is encoded by the PLK4 gene. This protein is a Ser/Thr protein kinase. The protein localizes to centrioles, complex microtubule-based structures found in centrosomes, and regulates centriole duplication during the cell cycle.

5 The term "pre-malignant" or "pre-cancerous," as used herein, refers to a condition that is not malignant but is poised to become malignant.

The term "protecting group," as used herein, represents a group intended to protect a hydroxy, an amino, or a carbonyl from participating in one or more undesirable reactions during chemical synthesis. The term "O-protecting group," as used herein, represents a group intended to protect a hydroxy or
10 carbonyl group from participating in one or more undesirable reactions during chemical synthesis. The term "N-protecting group," as used herein, represents a group intended to protect a nitrogen containing (e.g., an amino, amido, heterocyclic N-H, or hydrazine) group from participating in one or more undesirable reactions during chemical synthesis. Commonly used O- and N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New
15 York, 1999), which is incorporated herein by reference. Exemplary O- and N-protecting groups include alkanoyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxycetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, t-butyltrimethylsilyl, tri-iso-propylsilyloxymethyl, 4,4'-dimethoxytrityl, isobutyryl, phenoxyacetyl, 4-isopropylphenoxycetyl, dimethylformamidino, and 4-
20 nitrobenzoyl.

Exemplary O-protecting groups for protecting carbonyl containing groups include, but are not limited to: acetals, acylals, 1,3-dithianes, 1,3-dioxanes, 1,3-dioxolanes, and 1,3-dithiolanes.

Other O-protecting groups include, but are not limited to: substituted alkyl, aryl, and aryl-alkyl ethers (e.g., trityl; methylthiomethyl; methoxymethyl; benzyloxymethyl; siloxymethyl; 2,2,2,-
25 trichloroethoxymethyl; tetrahydropyranyl; tetrahydrofuranyl; ethoxyethyl; 1-[2-(trimethylsilyl)ethoxy]ethyl; 2-trimethylsilylethyl; t-butyl ether; p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, benzyl, p-methoxybenzyl, and nitrobenzyl); silyl ethers (e.g., trimethylsilyl; triethylsilyl; triisopropylsilyl; dimethylisopropylsilyl; t-butyltrimethylsilyl; t-butyl diphenylsilyl; tribenzylsilyl; triphenylsilyl; and diphenylmethylsilyl); carbonates (e.g., methyl, methoxymethyl, 9-fluorenylmethyl; ethyl; 2,2,2-
30 trichloroethyl; 2-(trimethylsilyl)ethyl; vinyl, allyl, nitrophenyl; benzyl; methoxybenzyl; 3,4-dimethoxybenzyl; and nitrobenzyl).

Other N-protecting groups include, but are not limited to, chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, phenylalanine, and the like; sulfonyl-containing groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups
35 such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5 dimethoxybenzyl oxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5 trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5 dimethoxybenzyloxycarbonyl, benzhydryloxy
40 carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl,

cyclohexyloxycarbonyl, phenylthiocarbonyl, and the like, aryl-alkyl groups such as benzyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, triphenylmethyl, benzyloxymethyl, and the like, silylalkylacetal groups such as [2-(trimethylsilyl)ethoxy]methyl and silyl groups such as trimethylsilyl, and the like. Useful N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, dimethoxybenzyl, [2-(trimethylsilyl)ethoxy]methyl (SEM), tetrahydropyranyl (THP), t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

The term "RRM1," as used herein, refers to ribonucleotide reductase catalytic subunit M1. This protein is encoded by the RRM1 gene.

The term "RRM2," as used herein, refers to ribonucleotide reductase regulatory subunit M2. This protein is encoded by the RRM2 gene. This gene encodes one of two non-identical subunits for ribonucleotide reductase. This reductase catalyzes the formation of deoxyribonucleotides from ribonucleotides. Synthesis of the encoded protein (M2) is regulated in a cell-cycle dependent fashion. Transcription from this gene can initiate from alternative promoters, which results in two isoforms that differ in the lengths of their N-termini.

The term "sarcoma" generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.

The term "SAE1," as used herein refers to SUMO1 activating enzyme subunit 1. This protein is encoded by the SAE1 gene. SAE1 and UBA2 form a heterodimer that is believed to function as a SUMO-activating enzyme for the sumoylation of proteins.

The term "subject," as used herein, represents a human or non-human animal (e.g., a mammal) that is suffering from, or is at risk of, disease or condition, as determined by a qualified professional (e.g., a doctor or a nurse practitioner) with or without known in the art laboratory test(s) of sample(s) from the subject. Preferably, the subject is a human. Non-limiting examples of diseases and conditions include diseases having the symptom of cell hyperproliferation, e.g., a cancer.

The term "SOD1," as used herein, refers to superoxide dismutase 1. This protein is encoded by the SOD1 gene. This protein binds copper and zinc ions and is one of two isozymes responsible for destroying free superoxide radicals in the body. This isozyme is a soluble cytoplasmic protein, acting as a homodimer to convert superoxide radicals to molecular oxygen and hydrogen peroxide.

The term "SOD2," as used herein, refers to superoxide dismutase 2. This protein is encoded by the SOD2 gene. This protein is a member of the iron/manganese superoxide dismutase family. It is a mitochondrial protein that forms a homotetramer and binds one manganese ion per subunit. This protein binds to the superoxide byproducts of oxidative phosphorylation and converts them to hydrogen peroxide and diatomic oxygen.

The term "tautomer" refers to structural isomers that readily interconvert, often by relocation of a proton. Tautomers are distinct chemical species that can be identified by differing spectroscopic characteristics, but generally cannot be isolated individually. Non-limiting examples of tautomers include ketone - enol, enamine - imine, amide - imidic acid, nitroso - oxime, ketene - ymol, and amino acid - ammonium carboxylate.

The term "TOP1," as used herein, refers to DNA topoisomerase I. This protein is encoded by the TOP1 gene. TOP1 is believed to control and alter the topologic states of DNA during transcription. This enzyme catalyzes the transient breaking and rejoining of a single strand of DNA which allows the strands

to pass through one another, thus altering the topology of DNA. This gene is localized to chromosome 20 and has pseudogenes which reside on chromosomes 1 and 22.

The term "TOP2A," as used herein, refers to DNA topoisomerase II alpha. This protein is encoded by the TOP1 gene. This enzyme is believed to control and alter the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA.

The term "UBA2," as used herein, refers to ubiquitin like modifier activating enzyme 2. This protein is encoded by the UBA2 gene. SAE1 and UBA2 form a heterodimer that is believed to function as a SUMO-activating enzyme for the sumoylation of proteins.

"Treatment" and "treating," as used herein, refer to the medical management of a subject with the intent to improve, ameliorate, stabilize, prevent or cure a disease or condition. This term includes active treatment (treatment directed to improve the disease or condition); causal treatment (treatment directed to the cause of the associated disease or condition); palliative treatment (treatment designed for the relief of symptoms of the disease or condition); preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease or condition); and supportive treatment (treatment employed to supplement another therapy).

The term "TTK," as used herein, refers to TTK protein kinase. This protein is encoded by the TTK gene. This protein is a dual specificity protein kinase with the ability to phosphorylate tyrosine, serine and threonine.

The term "WEE1," as used herein, refers to a nuclear kinase that is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. This protein is encoded by the WEE1 gene. This protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a bar graph showing the CCNE1 amplification/overexpression across tumors sequenced from TCGA PanCancer Atlas.

FIG. 1B is a scatter plot showing the CCNE1 gene expression data from TCGA PanCancer Atlas.

FIG. 2A is a bar graph showing the FBXW7 mutations across tumors sequenced from TCGA PanCancer Atlas.

FIG. 2B is a lollipop graph showing the frequency of FBXW7 mutations across the gene. This graph highlights three common arginine hotspot mutations (R465, R479, and R505) within the third and fourth WD40 repeats that disrupt recognition of the Cyclin E1 substrate and are classified as deleterious.

FIG. 3A is a bar graph showing the results of a proliferation assay using RPE1-hTERT Cas9 TP53^{-/-} and CCNE1-overexpressing clones treated with different doses of compound 133.

FIG. 3B is a series of images depicting the results of a clonogenic survival assay using RPE1-hTERT Cas9 TP53^{-/-} and CCNE1-overexpressing clones transduced with PKMYT1 sgRNAs. Infected cells were plated at low density to measure their ability to form colonies of >50 cells. After 10 days of growth, the colonies were stained, imaged, and quantified. The results are normalized to the survival of

RPE1-hTERT Cas9 TP53^{-/-} parental and CCNE1-overexpressing clones transduced with a non-targeting LacZ control sgRNA.

FIG. 3C is a line graph showing the results of a proliferation assay using RPE1-hTERT Cas9 TP54^{-/-} and CCNE1-overexpressing clones treated with different doses of compound 133.

5 FIG. 4A is a bar graph showing the results of a clonogenic survival assay using FT282-hTERT TP53^{R175H} and CCNE1-overexpressing cells transduced with PKMYT1 sgRNAs. Infected cells were plated at low density to measure their ability to form colonies of >50 cells. After 10 days of growth, the colonies were stained, imaged, and quantified. The results are normalized to the survival of FT282-hTERT TP53^{R175H} and CCNE1-overexpressing cells transduced with an AAVS1 control sgRNA.

10 FIG. 4B is a series of images showing of stained colonies described in FIG. 4A.

FIG. 4C is a line graph showing the results of a proliferation assay using FT282-hTERT TP53^{R175H} and CCNE1-overexpressing clones treated with different doses of compound 133.

FIGS. 5A, 5B, and 5C show the results of clonogenic survival assays for stable RPE1-hTERT Cas9 TP53^{-/-} parental and CCNE1-overexpressing clones expressing either a wild type or catalytic-dead
15 FLAG-tagged PKMYT1 sgRNA-resistant ORF. These stable cell lines were transduced with either a LacZ non-targeting sgRNA or PKMYT1 sgRNA #4 and plated at low density to measure their ability to form colonies of >50 cells. After 10 days of growth, the colonies were stained, imaged, and quantified. The results are normalized to the survival of RPE1-hTERT Cas9 TP53^{-/-} CCNE1-overexpressing clones transduced with a non-targeting LacZ control sgRNA and represented as a bar graph in FIG. 5C. Both
20 clones 2 and 21 behave similarly in this study.

FIG. 6 is a chart showing the results of proliferation assays for a panel of CCNE1 wild type and CCNE1-amplified/overexpressing cancer cell lines treated with different doses of compound 28. The IC₅₀ values are plotted for each cell line and demonstrate that CCNE1-overexpressing cell lines show enhanced sensitivity to a Myt1 inhibitor compared to CCNE1 WT cell lines.

25 FIG. 7 is a chart showing the results of proliferation assays for a panel of FBXW7 wild type and FBXW7-mutated cancer cell lines treated with different doses of compound 95. The IC₅₀ values are plotted for each cell line and demonstrate that FBXW7- mutated cell lines show enhanced sensitivity to a Myt1 inhibitor compared to FBXW7 WT cell lines.

FIG. 8A is a chart showing the cell viability for HCC1569 cells overexpressing cyclin E1 after the exposure to negative control (DMSO), Myt1 inhibitor (compound 182; 6.2 nM), gemcitabine (0.8 nM), or a combination of compound 182 and gemcitabine.

FIG. 8B is a chart showing the cell viability for HCC1569 cells overexpressing cyclin E1 after the exposure to negative control (DMSO), Myt1 inhibitor (compound 182; 18.5 nM), irinotecan (247 nM), or a combination of compound 182 and irinotecan.

35 FIG. 8C is a chart showing the cell viability for HCC1569 cells overexpressing cyclin E1 after the exposure to negative control (DMSO), Myt1 inhibitor (compound 182; 6.2 nM), ATR inhibitor (compound A121; 12.5 nM), or a combination of compound 182 and compound A121.

FIG. 8D is a scatter plot showing the effect of a vehicle, Myt1 inhibitor (compound 182; 10 mg/kg BID×21 PO), gemcitabine (20 mg/kg QW×4 IP), or a combination of Myt1 inhibitor (compound 182; 10
40 mg/kg) and gemcitabine (20 mg/kg) on the tumor volume in an OVCAR3 xenograft model.

FIG. 8E is a scatter plot showing the effect of a vehicle, Myt1 inhibitor (compound 182; 10 mg/kg BID×21 PO), irinotecan (15 mg/kg BIW×3 IP), or a combination of Myt1 inhibitor (compound 182; 10 mg/kg) and irinotecan (15 mg/kg) on the tumor volume in an OVCAR3 xenograft model.

FIG. 8F is a scatter plot showing the effect of a vehicle, Myt1 inhibitor (compound 182; 10 mg/kg BID×21 PO), ATR inhibitor (compound A121; 5 mg/kg QD PO), or a combination of Myt1 inhibitor (compound 182; 5 mg/kg) and ATR inhibitor (compound A121; 5 mg/kg) on the tumor volume in an OVCAR3 xenograft model.

FIG. 8G is a scatter plot showing the effect of a vehicle, Myt1 inhibitor (compound 182; 10 mg/kg BID×21 PO), carboplatin (20 mg/kg QW×3 IP), or a combination of Myt1 inhibitor (compound 182; 10 mg/kg) and carboplatin (20 mg/kg QW×3 IP), on the tumor volume in an OVCAR3 xenograft model.

DETAILED DESCRIPTION

In general, the invention provides methods of using Myt1 inhibitors in combination with a second therapeutic. The second therapeutic may be a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof. Advantageously, the combination of an Myt1 inhibitor and the second therapeutic may act synergistically in treating cancer or inducing cell death.

Myt1 inhibitors may be used to inhibit Myt1 in a cell, e.g., a cell in a subject (e.g., a cell overexpressing *CCNE1* or having an inactivating mutation in the *FBXW7* gene). The subject may be in need of a treatment for a disease or condition, e.g., a disease or condition having a symptom of cell hyperproliferation, e.g., a cancer. The Myt1 inhibitory activity is useful for treating a subject in need of a treatment for cancer.

Myt1 is a cell cycle regulating kinase localized predominantly in the endoplasmic reticulum and golgi complex. It is part of the Wee family of kinases that includes Wee1 and Wee1b. It is involved in the negative regulation of the CDK1-Cyclin B complex which promotes the progression of cells from G2-phase into the mitotic phase (M-phase) of the cell cycle. During DNA damage, Myt1 drives the phosphorylation on CDK1 (both Tyr15 and Thr14 of CDK1) which maintains the kinase complex in an inactive state in G2 as part of the G2 checkpoint response along with Wee1 (which mediates only Tyr15 phosphorylation) and prevents entry into mitosis until the damage has been repaired. Additionally, it has been proposed that Myt1 directly interacts with CDK1 complexes in the cytoplasm and prevents their nuclear translocation thus inhibiting cell cycle progression.

Myt1 has been implicated as a potentially important cancer target as it is essential in many cancer cells. Overexpression of Myt1 has been observed in various cancers including hepatocellular carcinoma as well as clear-cell renal-cell carcinoma. Myt1 downregulation has a minor role in unperturbed cells but has a more prominent role in cells exposed to DNA damage. Additionally, cells that exhibit high levels of replication stress in addition to defective G1 checkpoint regulation may be particularly sensitive to loss of Myt1 function, as these cells will be prone to entering mitosis prematurely with compromised genomic material leading to mitotic catastrophe.

Inhibitors of Myt1, a regulator of G2-M transition, may be particularly useful in the treatment of tumors harboring *CCNE1*-amplification or *FBXW7* loss-of-function mutations using a synthetic lethal therapeutic strategy.


Cyclin E1 (encoded by the *CCNE1* gene) is involved in the G1 to S phase cell cycle transition. In late G1 phase of the cell cycle, it complexes with cyclin-dependent kinase 2 (CDK2) to promote E2F transcription factor activation and entry into S-phase. Cyclin E1 levels are tightly regulated during normal cell cycles, accumulating at the G1/S transition and being completely degraded by the end of S phase. The cell cycle-dependent proteasomal degradation of Cyclin E1 is mediated by the SCF^{FBW7} ubiquitin ligase complex. Once activated in late G1, the Cyclin E1/CDK2 complex promotes the transition into S phase through phosphorylation and inactivation of RB1 and subsequent release of E2F transcription factors. S phase is promoted by E2F-mediated transcription of numerous genes involved in DNA replication including the pre-replication complex subunits ORC1, CDC6, CDT1, and the MCM helicase factors.

CCNE1 is frequently amplified and/or over-expressed in human cancers (FIG. 1). *CCNE1* amplification has been reported in several cancer types including endometrial, ovarian, breast and gastric, ranging in frequency from 5-40%. Importantly, numerous studies have confirmed Cyclin E1 as a driver of tumorigenesis in these indications and *CCNE1* amplification is observed in the more aggressive subtypes including uterine carcinosarcoma (UCS; ~40%), uterine serous carcinoma (USC; ~25%), high-grade serous ovarian carcinoma (HGSOC; ~25%), and triple-negative breast cancer (TNBC; ~8%). Patients with evidence of Cyclin E1 over-expression in tumor biopsies by immunohistochemistry and/or genomic copy number analysis have a lower overall survival compared to patients with normal Cyclin E1 levels. HGSOC patients with Cyclin E1 over-expression have a lower response rate to cisplatin, the current standard of care.

Defective cell cycle-regulated proteolysis of Cyclin E1 by the SCF^{FBW7} ubiquitin ligase complex is another mechanism of *CCNE1* over-expression observed in tumors. The F-box protein gene, *FBXW7*, is frequently mutated in several cancer types including endometrial, colorectal, and gastric, ranging in frequency from 5-35% (FIG. 2). Like *CCNE1*, *FBXW7* driver mutations are observed in the more aggressive subtypes of endometrial cancer including UCS (~35%) and USC (~25%). *FBXW7* has a diverse spectrum of loss-of-function mutations in cancer including truncating mutations peppered across the gene and missense mutations within the Cyclin E1 recognizing WD40 repeats. *FBW7* functions as a homodimer within the SCF complex and many deleterious missense mutations within the WD40 repeats are mostly heterozygous and dominant negative. Remarkably, several recurring hotspot missense mutations are found in the WD40 repeats including R465, R479, and R505 – all of which disrupt Cyclin E1 binding and ubiquitylation.

Cyclin E1 over-expression and/or *FBXW7* loss-of-function is thought to drive tumorigenesis by inducing genome instability (e.g., increased origin firing, defective nucleotide pools, transcription-replication conflicts, and/or fork instability). Over-expression of Cyclin E1 has been shown to induce replication stress characterized by slowed or stalled replication forks and loss-of-heterozygosity at fragile sites. The primary mechanism by which Cyclin E1 over-expression causes replication stress is increased origin firing in early S-phase followed by depletion of replication factors including nucleotide pools. The decrease in overall replication proteins and nucleotides decreases fork progression and causes stalling and subsequent collapse or reversal.

The compound used in the methods of the invention may be, e.g., a compound of formula (I):



or a pharmaceutically acceptable salt thereof,

5 where

each of X, Y, and Z is independently N or CR²;

R¹ and each R² are independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, cyano, -N(R⁷)₂, -OR⁷, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or -Q-R^{7B}; or R¹ combines with one R² that is *vicinal* to R¹ to form an optionally substituted C₃₋₆ alkylene;

each of R³ and R⁴ is independently optionally substituted C₁₋₆ alkyl or halogen;

R⁵ is H or -N(R⁷)₂;

15 R⁶ is -C(O)NH(R⁸), -C(O)R^{7A}, or -SO₂R^{7A};

each R⁷ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, or -SO₂R^{7A}; or two R⁷ groups, together with the atom to which both are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;


20 each R^{7A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;

each R^{7B} is independently hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₉ heteroaryl, -N(R⁷)₂, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or optionally substituted alkoxy;

25 each R⁸ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or two R⁸, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl; and

30 Q is optionally substituted C₁₋₆ alkylene, optionally substituted C₂₋₆ alkenylene, optionally substituted C₂₋₆ alkynylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₃₋₈ cycloalkenylene optionally substituted C₆₋₁₀ arylene, optionally substituted C₂₋₉ heterocyclylene, or optionally substituted C₁₋₉ heteroarylene.


Preferably, the compound of formula (I) is enriched for the atropisomer of formula (IA):



(IA)

where all variables are as described herein.


The compound used in the methods of the invention may be, e.g., a compound of formula (II):



(II)

where all variables are as described herein.


Preferably, the compound of formula (II) is enriched for the atropisomer of of formula (IIA):



(IIA)

where all variables are as described herein.


The compound used in the methods of the invention may be, e.g., a compound of formula (III):



(III)

where R^{2A} is hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted C_{3-8} cycloalkyl, optionally substituted C_{3-8} cycloalkenyl, optionally substituted C_{2-9} heterocyclyl, optionally substituted C_{2-9} heterocyclyl C_{1-6} alkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{1-9} heteroaryl, optionally substituted C_{1-9} heteroaryl C_{1-6} alkyl, halogen, $-N(R^7)_2$, $-OR^7$, $-C(O)N(R^8)_2$, $-SO_2N(R^8)_2$, $-SO_2R^{7A}$, or $-Q-R^{7B}$.


Preferably, the compound of formula (III) is enriched for the atropisomer of formula (IIIA):





The compound used in the methods of the invention may be, e.g., a compound listed in Table 1
 5 below or a pharmaceutically acceptable salt thereof.


Table 1


1	2	3
4	5	6
7	8	9






























































199 	200 	201 
202 	203 	204 
205 	206 	208 
209 	212 	213 
214 	215 	216 














































238 	239 	240 
241 	242 	243 
244 	245 	246 




259 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C=C</chem>	260 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	261 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>
262 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	263 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	264 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>
265 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	266 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	267 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>
268 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	269 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	270 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>
271 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	272 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>	273 <chem>Nc1nc2c(ncn2C(=O)N)C(=O)N1c3cc(O)c(C)cc3C4=CC=CC=C4O</chem>

274 	275 	276 
	278 	279 
280 	281 	282 
283 	284 	285 

286 	287 	288 
289 	290 	291 
292 	293 	294 
295 	296 	297 
298 	299 	300 

301 	302 	303 
304 	305 	306 
307 	308 	309 
310 	311 	312 
313 	314 	315 



The methods of the invention include (where possible) individual diastereomers, enantiomers, epimers, and atropisomers of the compounds disclosed herein, and mixtures of diastereomers and/or enantiomers thereof including racemic mixtures. Although the specific stereochemistries disclosed herein are preferred, other stereoisomers, including diastereomers, enantiomers, epimers, atropisomers, and mixtures of these may also have utility in treating Myt1-mediated diseases. Inactive or less active

diastereoisomers and enantiomers may be useful, e.g., for scientific studies relating to the receptor and the mechanism of activation.

It is understood that certain molecules can exist in multiple tautomeric forms. This invention includes all tautomers even though only one tautomer may be indicated in the examples.

5 The invention also includes pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier. The compounds are especially useful, e.g., in certain kinds of cancer and for slowing the progression of cancer once it has developed in a patient.

10 The compounds disclosed herein may be used in pharmaceutical compositions comprising (a) the compound(s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier. The compounds may be used in pharmaceutical compositions that include one or more other active pharmaceutical ingredients. The compounds may also be used in pharmaceutical compositions in which the compound disclosed herein or a pharmaceutically acceptable salt thereof is the only active ingredient.

15

Optical Isomers - Diastereomers - Geometric Isomers - Tautomers

Compounds disclosed herein may contain, e.g., one or more stereogenic centers and can occur as racemates, racemic mixtures, single enantiomers, individual diastereomers, and mixtures of diastereomers and/or enantiomers. The invention includes all such isomeric forms of the compounds disclosed herein. It is intended that all possible stereoisomers (e.g., enantiomers and/or diastereomers) in mixtures and as pure or partially purified compounds are included within the scope of this invention (i.e., all possible combinations of the stereogenic centers as pure compounds or in mixtures).

20 Some of the compounds described herein may contain bonds with hindered rotation such that two separate rotomers, or atropisomers, may be separated and found to have different biological activity which may be advantageous. It is intended that all of the possible atropisomers are included within the scope of this invention.

Some of the compounds described herein may contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

30 Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. An example is a ketone and its enol form, known as keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed by the invention.

Compounds disclosed herein having one or more asymmetric centers may be separated into diastereoisomers, enantiomers, and the like by methods well known in the art.

35 Alternatively, enantiomers and other compounds with chiral centers may be synthesized by stereospecific synthesis using optically pure starting materials and/or reagents of known configuration.

Metabolites – Prodrugs

40 The invention includes therapeutically active metabolites, where the metabolites themselves fall within the scope of the claims. The invention also includes prodrugs, which are compounds that are converted to the claimed compounds as they are being administered to a patient or after they have been administered to a patient. The claimed chemical structures of this application in some cases may themselves be prodrugs.

Isotopically Enriched Derivatives

The invention includes molecules which have been isotopically enriched at one or more position within the molecule. Thus, compounds enriched for deuterium fall within the scope of the claims.

5

Methods of Preparing Compounds

Compounds used in the methods of the invention may be prepared using reactions and techniques known in the art and those described herein. One of skill in the art will appreciate that methods of preparing compounds of the invention described herein are non-limiting and that steps within the methods may be interchangeable without affecting the structure of the end product.

10

Method A


Compounds of the present invention may be prepared as shown in Scheme A and described herein. The amino group of the commercially available 5-bromo-6-chloropyrazin-2-amine can be converted to a hydroxyl that can be benzylated with benzyl bromide in presence of a base to generate key **Intermediate B**. The bromo may be substituted by an aromatic amine under metal-mediated conditions. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The chloro may be substituted by malononitrile under metal-mediated conditions to afford the aminopyrrole **Intermediate C**. The nitrile may be hydrolyzed to the carboxamide upon treatment with an acid with concomitant cleavage of the benzyl group. The resulting hydroxyl may be converted to the triflate to generate the triflate key **Intermediate D** that can be derivatized in a number of different ways to provide compounds of the present invention. For example, a metal-mediated coupling or S_NAr displacement may be used to install a group at R^1 . Depending on the nature of the R^1 group, a protecting group may be required to be in place prior to the triflate derivatization reaction. In the case where the R^1 group bears an unsaturation, a hydrogenation reaction may be required to give compound of the present invention. In the case where the arylamine and/or the R^1 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention. For example, key **intermediate D** may be purified by chiral chromatography to provide an atropisomerically pure intermediate that may be manipulated similarly to **intermediate D** described above to provide compounds of the present invention.

15

20

25


30



Method B


- Compounds of the present invention may be prepared as shown in Scheme B and described herein. The chloro of **Intermediate B** can be displaced by an aromatic amine under S_NAr conditions. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The bromo may then be substituted by malononitrile under metal-mediated conditions to afford an aminopyrrole. The OBn may be hydrogenolyzed to afford the key **Intermediate E** that may be derivatized in a number of different ways to give compounds of the present invention following nitrile hydrolysis. For example, Mitsunobu or alkylation conditions may be used to install a group at R^2 . Alternatively, **Intermediate E** may be converted to the triflate key **Intermediate F** that may be derivatized in a number of different ways to give compounds of the present invention following nitrile hydrolysis. For example, a metal-mediated coupling may be used to install a group at R^2 . Depending on the nature of the R^2 group, a protecting group may be required to be in place prior to the hydroxyl or triflate derivatization reaction. In the case where the R^2 group bears an unsaturation, a hydrogenation reaction may be required to give compound of the present invention. In the case where the arylamine and/or the R^2 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

Scheme B



5 Method C


Compounds of the present invention may be prepared as shown in Scheme C and described herein. The 2-chloro of the commercially available 3-bromo-2,6-dichloropyridine can be substituted by malononitrile under $\text{S}_{\text{N}}\text{Ar}$ conditions with a base. The bromo may be substituted by an aromatic amine under metal-mediated conditions to afford an aminoazaindole. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. Protecting group(s) may be removed before the nitrile may be hydrolyzed to the carboxamide upon treatment with an acid to yield **Intermediate G**. The remaining chloro can be derivatized in a number of different ways to provide compounds of the present invention. For example, a metal-mediated coupling may be used to install a group at R^1 . Depending on the nature of the R^1 group, a protecting group may be required to be in place prior to the chloro derivatization reaction. In the case where the R^1 group bears an unsaturation, a hydrogenation reaction may be required to give a compound of the present invention. In the case where the arylamine and/or the R^1 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.



Method D


- 5 Compounds of the present invention may be prepared as shown in Scheme D and described herein. The halogen at position 2 of an adequately substituted 5-nitropyridine may be substituted with an aromatic amine under S_NAr conditions or a metal-mediated C-N coupling conditions. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The 3-bromo may be substituted by malononitrile under palladium-mediated conditions to afford an
- 10 aminoazaindole. The resulting amino group can be protected with a suitable protecting group, e.g. BOC. The nitro can be reduced and the resulting amino can be converted to a halogen under Sandmeyer conditions yielding halogenated derivatives. The aminopyrrole N-protecting group may be cleaved and the nitrile can be hydrolyzed to the carboxamide to yield **Intermediate I** that can be derivatized in a number of different ways to provide compounds of the present invention. For example, a metal-mediated
- 15 coupling may be used to install a group at R^1 . In the case where the R^1 group bears an unsaturation, a hydrogenation reaction may be required to give a compound of the present invention. Depending on the nature of the R^1 group, a protecting group may be required to be in place prior to the halogen derivatization reaction. In the case where the arylamine and/or the R^1 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present
- 20 invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

Scheme D

**Method E**


- 5 Compounds of the present invention may be prepared as shown in Scheme E and described herein. One chloro of commercially available 2,3-dichloro-pyrazine can be substituted by malononitrile under S_NAr or palladium-mediated conditions. The remaining chloro can be substituted with an aromatic amine under S_NAr or palladium-mediated conditions to afford an aminopyrrole. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. Hydrolysis of the
- 10 nitrile can be done under acidic or basic conditions to give compounds of the present invention. In the case where the arylamine group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically
- 15 pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

Scheme E

**Method F**


- 5 Compounds of the present invention may be prepared as shown in Scheme F and described herein. One chloro of commercially available 2,3-dichloropyrazine can be substituted by malononitrile under S_NAr or palladium-mediated conditions. The other chloro can be substituted with an aromatic amine under S_NAr or palladium-mediated conditions to afford an aminopyrrole. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The pyrazine ring can
- 10 be brominated using a suitable bromination reagent such as NBS. Hydrolysis of the nitrile can be done under acidic or basic conditions and protecting group may be cleaved to give key **Intermediate H** that may be derivatized in a number of different ways to give compounds of the present invention. For example, a metal-mediated coupling may be used to install a group at R^2 . Depending on the nature of the R^2 group, a protecting group may be required to be in place prior to the bromo derivatization reaction. In
- 15 the case where the R^2 group bears an unsaturation, a hydrogenation reaction may be required to give compound of the present invention. In the case where the arylamine and/or the R^2 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give
- 20 compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

Scheme F

**Method G**


- 5 Compounds of the present invention may be prepared as shown in Scheme G and described herein. The chloro of commercially available 2-chloro-3-bromopyridines can be substituted by malononitrile under S_NAr conditions. The bromo can be substituted with an aromatic amine under S_NAr or palladium-mediated conditions to afford an aminopyrrole. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. Hydrolysis of the nitrile can be done
- 10 under acidic or basic conditions to give compounds of the present invention. For an arylamine group bearing a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated
- 15 and may be derivatized further to give compounds of the present invention.

Scheme G

**Method H**


- 20 Compounds of the present invention may be prepared as shown in Scheme H and described herein. Key **Intermediate C** may be brominated using a suitable bromination reagent such as NBS. The

nitrile may be hydrolyzed to the carboxamide upon treatment with an acid with concomitant cleavage of the benzyl group. The resulting hydroxyl may be converted to the triflate. The bromo and the triflate may be derivatized sequentially with different groups or, alternatively the bromo and the triflate may be derivatized simultaneously with the same groups. The bromo and triflate may be derivatized in a number of different ways to give compounds of the present invention. For example, metal-mediated couplings may be used to install a group at R¹ and/or R² sequentially or simultaneously. Depending on the nature of the R¹ and/or R² group, a protecting group may be required to be in place prior to the bromo or triflate derivatization reaction. In the case where the arylamine, the R¹ and/or the R² group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine used to prepare **intermediate C**, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.



Method I


Compounds of the present invention may be prepared as shown in Scheme I and described herein. The chloro of commercially available 3-bromo-2-chloro-5-(trifluoromethyl)pyridine can be substituted with an aromatic amine under S_NAr or palladium-mediated conditions. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The bromo can be substituted with malononitrile under palladium-mediated conditions to afford an aminopyrrole. Hydrolysis of the nitrile can be done under acidic or basic conditions to give compounds of the present invention. In the case where the arylamine group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.



Method J


Compounds of the present invention may be prepared as shown in Scheme J and described herein. Key **Intermediate C** may be halogenated using a suitable halogenating reagent such as NBS or NIS. The halogen can be derivatized in a number of different ways. For example, a metal-mediated coupling may be used to install a group at R^2 . The nitrile may be hydrolyzed to the carboxamide upon treatment with an acid with concomitant cleavage of the benzyl group. The resulting hydroxyl may be converted to the triflate. The triflate may be derivatized in a number of different ways to give compounds of the present invention. For example, a metal-mediated coupling may be used to install a group at R^1 . Depending on the nature of the R^1 and/or R^2 group, a protecting group may be required to be in place prior to the halogen and/or triflate derivatization reaction. In the case where the arylamine, the R^1 and/or the R^2 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine used to prepared **intermediate C**, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

Scheme J

**Method K**

Compounds of the present invention may be prepared as shown in Scheme K and described herein. The fluoro of a 3-bromo-2-fluoro-pyridine can be substituted with an aromatic amine under S_NAr conditions. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The bromo can be substituted with malononitrile under palladium-mediated conditions to afford an aminoazaindole. Hydrolysis of the nitrile can be done under acidic or basic conditions to give compounds of the present invention. In the case where the arylamine or R^1 group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

Scheme K


**Method L**

Compounds of the present invention may be prepared as shown in Scheme L and described herein. The triflate of key **Intermediate D** may be derivatized in a number of different ways to give compounds of the present invention. For example, a metal-mediated coupling may be used to install a group at R^1 . the pyrazine may be brominated using a suitable bromination reagent such as NBS. The bromo may be derivatized in a number of different ways to give compounds of the present invention. For

example, a metal-mediated coupling may be used to install a group at R². Depending on the nature of the R¹ and/or R² group, a protecting group may be required to be in place prior to the triflate and/or bromo derivatization reaction. In the case where the arylamine, the R¹ and/or the R² group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine used to prepare **intermediate D**, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.


10

Scheme L




Method M

Compounds of the present invention may be prepared as shown in Scheme M and described herein. The nitrile of key **Intermediate C** can yield a ketone upon treatment with a Grignard reagent. The benzyl group can be cleaved under acidic conditions. The resulting hydroxyl may be converted to the triflate to generate the triflate that can be derivatized in a number of different ways to provide compounds of the present invention. For example, a metal-mediated coupling may be used to install a group at R¹. Depending on the nature of the R¹ group, a protecting group may be required to be in place prior to the triflate derivatization reaction. In the case where the R¹ group bears an unsaturation, a hydrogenation reaction may be required to give compound of the present invention. In the case where the arylamine and/or the R¹ group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine used to prepare **intermediate C**, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.



Method N

Compounds of the present invention may be prepared as shown in Scheme N and described herein. The amino of an aminopyrrole described herein can be substituted by a proton under diazotization conditions. The nitrile can be hydrolyzed to the carboxamide under acidic or basic conditions to give compound of the present invention. In the case where the arylamine, the R¹ and/or the R² group bear a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the N-aryl group, an atropisomeric mixture may be obtained. In such cases it may be necessary to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.




Method O

Compounds of the present invention may be prepared as shown in Scheme O and described herein. The 2-aminopyridine can be converted to the 2-hydroxypyridine which can be converted to the 2-bromopyridine. The 2-bromo can be substituted with an aromatic amine under palladium-mediated conditions. Depending on the nature of the arylamine, a protecting group may be required to be in place prior to this reaction. The 3-bromo can be substituted with malononitrile under palladium-mediated conditions to afford an aminopyrrole. Hydrolysis of the nitrile can be done under acidic or basic conditions to give compounds of the present invention. In the case where the arylamine group bears a protecting group, a deprotection step(s) may be required using acid, base and/or fluoride to give compounds of the present invention. Depending on the nature of the arylamine, an atropisomeric mixture may be obtained.

In such cases it may be necessary to perform chiral chromatography to isolate the atropisomer of interest to give compounds of the present invention. Alternatively, an atropisomerically pure intermediate can be isolated and may be derivatized further to give compounds of the present invention.

5

Scheme O



Methods of Treatment

Methods disclosed herein may be used for the treatment of a disease or condition (e.g., a cancer overexpressing CCNE1 or having an inactivating mutation in the *FBXW7* gene) which depend on the activity of membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1). Methods disclosed herein may include the step of administering to the subject in need thereof a therapeutically effective amount of a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) inhibitor and a therapeutically effective amount of a second therapeutic. The second therapeutic may be, e.g., WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof.

The disease or condition may have the symptom of cell hyperproliferation. For example, the disease or condition may be a cancer (e.g., a cancer overexpressing CCNE1 or having an inactivating mutation in the *FBXW7* gene).

Cancers which have a high incidence of CCNE1 overexpression include e.g., uterine cancer, ovarian cancer, bladder cancer, pancreatic cancer, mesothelioma, kidney cancer, bladder cancer, gastric cancer, ovarian cancer, breast cancer, stomach cancer, esophageal cancer, lung cancer, and endometrial cancer. Preferably, the cancer is uterine cancer, colorectal cancer, breast cancer, lung cancer, or esophageal cancer.

Cancers which have a deficiency in FBXW7 include, e.g., uterine cancer, ovarian cancer, bladder cancer, pancreatic cancer, mesothelioma, kidney cancer, bladder cancer, gastric cancer, colorectal cancer, breast cancer, lung cancer, and esophageal cancer. Preferably, the cancer is uterine cancer, colorectal cancer, breast cancer, lung cancer, or esophageal cancer.

Compounds disclosed herein may be administered by a route selected from the group consisting of oral, sublingual, buccal, transdermal, intradermal, intramuscular, parenteral, intravenous, intra-arterial,



intracranial, subcutaneous, intraorbital, intraventricular, intraspinal, intraperitoneal, intranasal, inhalation, intratumoral, and topical administration.

In some embodiments, the Myt1 inhibitor is administered before the second agent (e.g., within 1 week, within 6 days, within 5 days, within 4 days, within 3 days, within 2 days, within 1 day, or within 12 hours). In some embodiments, the Myt1 inhibitor is administered after the second agent (e.g., within 1 week, within 6 days, within 5 days, within 4 days, within 3 days, within 2 days, within 1 day, or within 12 hours). In some embodiments, the Myt1 inhibitor is co-administered with the second agent. In some embodiments, the Myt1 inhibitor is administered intermittently (e.g., 1 day/week, 2 days/week, or 3 days/week). In some embodiments, the second agent is administered on a continuous daily basis.

ATR Inhibitors

ATR inhibitors a compound that upon contacting the enzyme ATR kinase, whether in vitro, in cell culture, or in an animal, reduces the activity of ATR kinase, such that the measured ATR kinase IC_{50} is 10 μ M or less (e.g., 5 μ M or less or 1 μ M or less). For certain ATR inhibitors, the ATR kinase IC_{50} may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, the ATR kinase IC_{50} is 0.1 nM to 1 μ M (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM).

Examples of ATR inhibitors are:




M4344 (VX-803)

, and pharmaceutically acceptable salts thereof.

Non-limiting examples of ATR inhibitors include, e.g., those described in, e.g., International Application Publication Nos. WO 2020087170, WO 2018218197, WO 2020259601, WO 2019036641, WO 2020049017, WO2019154365, WO 2020103897, WO2021233376, WO2022028598, WO2022012484, WO2022002245, and WO2022002243, each of which is incorporated by reference
 5 herein; U.S. Patent Nos. 11,028,076, 10,745,420, 10,301,324, 10,196,405, 9,663,535, 9,549,932, 8,552,004, and 8,841,308, each of which is incorporated by reference herein; and U.S. Patent Application Publication Nos. 2019/0055240 and 2019/0300547, each of which is incorporated by reference herein.

In one embodiment, an ATR inhibitor is a compound of formula (III):



or a pharmaceutically acceptable salt thereof,
 where

===== is a double bond, and each Y is independently N or CR⁴; or ===== is a single bond, and each Y is independently NR^Y, carbonyl, or C(R^Y)₂; where each R^Y is independently H or optionally substituted C₁₋₆ alkyl;

R¹ is optionally substituted C₁₋₆ alkyl or H;

R² is optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, —N(R⁵)₂, —OR⁵, —CON(R⁶)₂, —SO₂N(R⁶)₂, —SO₂R^{5A}, or —Q—R^{5B};

R³ is optionally substituted C₁₋₉ heteroaryl or optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl;

each R⁴ is independently hydrogen, halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, or optionally substituted C₂₋₆ alkynyl;

each R⁵ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, or —SO₂R^{5A}; or both R⁵, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

each R^{5A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;


R^{5B} is hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, —N(R⁶)₂, —CON(R⁶)₂, —SO₂N(R⁶)₂, —SO₂R^{5A}, or optionally substituted alkoxy;

each R⁶ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or both R⁶, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

Q is optionally substituted C₂₋₉ heterocyclylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₁₋₉ heteroarylene, or optionally substituted C₆₋₁₀ arylene; and

X is hydrogen or halogen.

The ATR inhibitor may be, e.g., a compound of formula (IV):



or a pharmaceutically acceptable salt thereof,

where

each Y is independently N or CR⁴;

10 R¹ is optionally substituted C₁₋₆ alkyl or H;

R² is optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, –N(R⁵)₂, –OR⁵, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or –Q–R^{5B};

15 R³ is optionally substituted C₁₋₉ heteroaryl or optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl;

each R⁴ is independently hydrogen, halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, or optionally substituted C₂₋₆ alkynyl;

each R⁵ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, or –SO₂R^{5A}; or both
20 R⁵, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

each R^{5A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;

R^{5B} is hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, –N(R⁵)₂, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or optionally substituted alkoxy;

each R⁶ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or both R⁶, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

30 Q is optionally substituted C₂₋₉ heterocyclylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₁₋₉ heteroarylene, or optionally substituted C₆₋₁₀ arylene; and

X is hydrogen or halogen.

In some embodiments, in the compound of formula (IV), (III), or (III-b):

each Y is independently N or CR⁴;

35 R¹ is H or optionally substituted C₁₋₆ alkyl;

R^2 is optionally substituted C_{1-6} alkyl, optionally substituted C_{3-8} cycloalkyl, optionally substituted C_{2-9} heterocyclyl, optionally substituted C_{6-10} aryl, optionally substituted C_{1-9} heteroaryl, optionally substituted C_{1-9} heteroaryl C_{1-6} alkyl, $-N(R^5)_2$, $-CON(R^6)_2$, $-SO_2N(R^6)_2$, or $-SO_2R^{5A}$;

R^3 is optionally substituted C_{1-9} heteroaryl;

5 each R^4 is independently H or optionally substituted C_{1-6} alkyl;

each R^5 is independently hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted C_{6-10} aryl C_{1-6} alkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{1-9} heteroaryl, or $-SO_2R^{5A}$, where each R^{5A} is independently optionally substituted C_{1-6} alkyl or optionally substituted C_{3-8} cycloalkyl; or both R^5 , together with the atom to which they are attached, combine to form an optionally substituted C_{2-9} heterocyclyl;

10 each R^{5A} is independently optionally substituted C_{1-6} alkyl or optionally substituted C_{3-8} cycloalkyl; and

each R^6 is independently hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted C_{6-10} aryl C_{1-6} alkyl, optionally substituted C_{6-10} aryl, or optionally substituted C_{1-9} heteroaryl; or both R^6 , together with the atom to which they are attached, combine to form an optionally substituted C_{2-9} heterocyclyl.

Methods of making compounds of formula (III) are described, e.g., in International Application No. PCT/US2019/051539, hereby incorporated by reference.

The ATR inhibitor may be, e.g., a compound of formula (III-a):




or a pharmaceutically acceptable salt thereof, where Y, R^1 , R^2 , R^3 , and R^4 are as described for formula (III).

The ATR inhibitor may be, e.g., a compound of formula (III-b):




or a pharmaceutically acceptable salt thereof, where Y, R^1 , R^2 , R^3 , and R^4 are as described for formula (III).

The ATR inhibitor may be, e.g., a compound of formula (IIIA):




or a pharmaceutically acceptable salt thereof, where R^1 , R^2 , R^3 , and R^4 are as described for formula (III).

5 The ATR inhibitor may be, e.g., a compound of formula (IIIA-a):




or a pharmaceutically acceptable salt thereof, where R^1 , R^2 , R^3 , and R^4 are as described for formula (III).

The ATR inhibitor may be, e.g., a compound of Formula (IIIB):




or a pharmaceutically acceptable salt thereof, where R^1 , R^2 , R^3 , and R^4 are as described for formula (III).

The ATR inhibitor may be, e.g., a compound of formula (IIIB-a):



or a pharmaceutically acceptable salt thereof, where R^1 , R^2 , R^3 , and R^4 are as described for formula (III).


The ATR inhibitor may be, e.g., a compound of Formula (IIIC):



(IIIC)

or a pharmaceutically acceptable salt thereof, where R¹, R², R³, and R⁴ are as described for formula (III).


5 The ATR inhibitor may be, e.g., a compound of formula (IIIC-a):



(IIIC-a)

or a pharmaceutically acceptable salt thereof, where R¹, R², R³, and R⁴ are as described for formula (III).


The ATR inhibitor may be, e.g., a compound of formula (IIID):



(IIID)

or a pharmaceutically acceptable salt thereof, where R¹, R², R³, and R⁴ are as described for formula (III).

The ATR inhibitor may be, e.g., a compound of formula (IIID-a):




(IIID-a)

or a pharmaceutically acceptable salt thereof, where R¹, R², R³, and R⁴ are as described for formula (III).

Preferably, R¹ is methyl.

In some embodiments, R² may be, e.g., optionally substituted C₃₋₈ cycloalkyl. For example, R² may be a group of formula (A):



5


where

n is 0, 1, 2, or 3; and

R⁷ is hydrogen, alkylsulfonyl, cyano, -CON(R^A)₂, -SON(R^A)₂, optionally substituted C₁₋₉ heteroaryl, hydroxy, or alkoxy, where each R^A is independently H or alkyl; or both R^A, together with the atom to which they are attached, combine to form C₂₋₉ heterocyclyl.

10

In some embodiments, R² may be, e.g., optionally substituted C₁₋₈ alkyl (e.g., optionally substituted *tertiary* C₃₋₆ alkyl. For example, R² may be a group of formula (B):




15

where R⁷ is hydrogen, alkylsulfonyl, cyano, -CON(R^A)₂, -SON(R^A)₂, optionally substituted C₁₋₉ heteroaryl, hydroxy, or alkoxy, where each R^A is independently H or alkyl; or both R^A, together with the atom to which they are attached, combine to form C₂₋₉ heterocyclyl.


In some embodiments, R² may be, e.g., optionally substituted non-aromatic C₂₋₉ heterocyclyl.


In some embodiments, R² may be, e.g.:

20




25






- 5 In some embodiments, R^3 may be, e.g., optionally substituted, monocyclic C_{1-9} heteroaryl including at least one nitrogen atom (e.g., two nitrogen atoms). For example, R^3 may be a group of formula (C):




- 10 where A is optionally substituted, monocyclic C_{1-9} heteroaryl ring.

In some embodiments, A may be, e.g., a group of formula (C1):




where R^8 is hydrogen, halogen, or optionally substituted C_{1-6} alkyl.

- 15 In some embodiments, R^3 may be, e.g.:



In some embodiments, R³ may be, e.g.:





















In some embodiments, R⁴ may be, e.g., hydrogen.



















The ATR inhibitor may be, e.g., a compound listed in Table 2 or a pharmaceutically acceptable salt thereof.
















Table 2













A 1		A 2		A 3	
A 4		A 5		A 6	
A 7		A 8		A 9	
A 10		A 11		A 12	
A 13		A 14		A 15	
A 16		A 17		A 18	













A 19		A 20		A 21	
A 22		A 23		A 24	
A 25		A 26		A 27	
A 28		A 29		A 30	
A 31		A 32		A 33	
A 34		A 42		A 43	
A 44		A 45		A 47	













A 48 	A 49 	A 50 
A 51 	A 52 	A 53 
A 54 	A 55 	A 56 
A 57 	A 58 	A 59 
A 60 	A 61 	A 62 
A 63 	A 64 	A 65 













A 66 	A 67 	A 68 
A 69 	A 70 	A 71 
A 72 	A 73 	A 74 
A 75 	A 76 	A 77 
A 78 	A 79 	A 80 
A 81 	A 82 	A 83 


A 84 	A 86 	A 87 
A 88 	A 89 	A 90 
A 91 	A 92 	A 93 
A94 		A95 
A96 		A97 
A98 		A99 

A100		A101	
A102		A103	
A104		A105	
A106		A107	
A108		A109	
A110		A111	

A112 	A113 
A114 	A115 
A116 	A117 
A118 	A119 
A120 	A121 
A122 	A123 

A124		A125	
A126		A127	
A128		A129	
A130		A131	
A132		A133	
A134		A135	

A136 	A137 
A138 	A139 
A140 	A141 
A142 	A143 
A144 	A145 
A146 	A147 



An ATR inhibitor may be isotopically enriched (e.g., enriched for deuterium).

AURKA Inhibitors

AURKA inhibitors may be compounds that upon contacting AURKA, whether in vitro, in cell culture, or in an animal, reduce the activity of AURKA, such that the measured AURKA IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain AURKA inhibitors, AURKA IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, AURKA IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of AURKA inhibitors are: MK0547, barasertib (AZD1152), PHA739358, AT9283, AMG900, SNS-314, TAK-901, CYC116, GSK1070916, PF03814735, and pharmaceutically acceptable salts thereof. Exemplary AURKA inhibitors are also disclosed in US 6,977,259; US 6,919,338; US 7,105,669; US 7,214,518; US 7,235,559; US 7,402,585; US 7,709,479; US 8,026,246; US 8,138,338; US 8,377,983; US 9,567,329; US 9,637,474; US 20060178382; US 20090029992; and US 20190352297; the AURKA inhibitors disclosed therein are incorporated herein by reference in their entirety.

AURKB Inhibitors

AURKB inhibitors may be compounds that upon contacting AURKB, whether in vitro, in cell culture, or in an animal, reduce the activity of AURKB, such that the measured AURKB IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain AURKB inhibitors, AURKB IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, AURKB IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of AURKB inhibitors are: MLN8237, MK0547, MLN8054, PHA739358, AT9283, AMG900, MK5108, SNS314, TAK901, CYC116, ENMD2076, and pharmaceutically acceptable salts thereof. Exemplary

AURKB inhibitors are also disclosed in US 7,560,551; US 7,977,477; US 8,110,573; and US 20110293745; the AURKB inhibitors disclosed therein are incorporated herein by reference in their entirety.

5 **BUB1 Inhibitors**

BUB1 inhibitors may be compounds that upon contacting BUB1, whether in vitro, in cell culture, or in an animal, reduce the activity of BUB1, such that the measured BUB1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain BUB1 inhibitors, BUB1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, BUB1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of BUB1 inhibitors are: BAY-320, BAY-419, BAY1816032 and pharmaceutically acceptable salts thereof. Exemplary BUB1 inhibitors are also disclosed in US 9,265,763; US 9,416,125; US 9,745,285; US 10,266,548; US 10,428,044; US 20150141372; US 20160145267; US 20160046604; US 20160046610; US 20170275269; US 20170305882; the BUB1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

CDC7 Inhibitors

CDC7 inhibitors may be compounds that upon contacting CDC7, whether in vitro, in cell culture, or in an animal, reduce the activity of CDC7, such that the measured CDC7 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain CDC7 inhibitors, CDC7 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, CDC7 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of CDC7 inhibitors are: SRA141, TAK931, and pharmaceutically acceptable salts thereof. Exemplary CDC7 inhibitors are also disclosed in US 7,279,575; US 8,314,121; US 8,383,624; US 8,658,662; US 8,691,828; US 9,156,824; US 9,180,105; US 9,974,795; US 10,745,510; US 20050043346; US 20050256121; US 20070293491; US 20190336502; and US 20200093828; the CDC7 inhibitors disclosed therein are incorporated herein by reference in their entirety.

CHEK1 Inhibitors

CHEK1 inhibitors may be compounds that upon contacting CHEK1, whether in vitro, in cell culture, or in an animal, reduce the activity of CHEK1, such that the measured CHEK1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain CHEK1 inhibitors, CHEK1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, CHEK1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of CHEK1 inhibitors are: SRA737 and pharmaceutically acceptable salts thereof. Exemplary CHEK1 inhibitors are also disclosed in US 7,067,506; US 8,093,244; US 8,410,279; US 8,530,468; US 8,618,121; US 8,916,591; US 9,067,920; US 9,440,976; US 10,189,818; US 10,822,327; US 20090182001; US 20090233896; US 20090258852; US20090270416; US 20090275570; US 20150368244; US 20180369202; and US 20200397796; the CHEK1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

CREBBP Inhibitors

CREBBP inhibitors may be compounds that upon contacting CREBBP, whether in vitro, in cell culture, or in an animal, reduce the activity of CREBBP, such that the measured CREBBP IC₅₀ is 10 µM or less (e.g., 5 µM or less or 1 µM or less). For certain CREBBP inhibitors, CREBBP IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, CREBBP IC₅₀ is 0.1 nM to 1 µM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of CREBBP inhibitors are: CPI4, CCS1477, E7386, NEO1132, NEO2734, PRI724, C82, BC001, C646, EML425, CBP30, and pharmaceutically acceptable salts thereof. Exemplary CREBBP inhibitors are also disclosed in US 9,763,922; US 10,206,931; US 10,696,655; US 10,870,648; US 20190270797; US 20190298729; and US 20190308978; the CREBBP inhibitors disclosed therein are incorporated herein by reference in their entirety.

DOT1L Inhibitors

DOT1L inhibitors may be compounds that upon contacting DOT1L, whether in vitro, in cell culture, or in an animal, reduce the activity of DOT1L, such that the measured DOT1L IC₅₀ is 10 µM or less (e.g., 5 µM or less or 1 µM or less). For certain DOT1L inhibitors, DOT1L IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, DOT1L IC₅₀ is 0.1 nM to 1 µM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of DOT1L inhibitors are: pinometostat (EPZ5676) and pharmaceutically acceptable salts thereof. Exemplary DOT1L inhibitors are also disclosed in US 8,722,877; US 9,458,165; US 10,112,968; US 20140100184; US 20150342979; and US 20170335402; the DOT1L inhibitors disclosed therein are incorporated herein by reference in their entirety.

DUT Inhibitors

DUT inhibitors may be compounds that upon contacting DUT, whether in vitro, in cell culture, or in an animal, reduce the activity of DUT, such that the measured DUT IC₅₀ is 10 µM or less (e.g., 5 µM or less or 1 µM or less). For certain DUT inhibitors, DUT IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, DUT IC₅₀ is 0.1 nM to 1 µM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of DUT inhibitors are: TAS114 and pharmaceutically acceptable salts thereof. Exemplary DUT inhibitors are also disclosed in US 7,601,702; US 8,530,490; US 9,790,214; US 9,809,571; US 10,544,105; US 10,562,860; US 10,570,100; US 10,577,321; US 10,829,457; US 10,858,344; US 20110212467; US 20190270756; US 20190330158; US 20190330210; and US 20200039966; the DUT inhibitors disclosed therein are incorporated herein by reference in their entirety.

EZH2 Inhibitors

EZH2 inhibitors may be compounds that upon contacting EZH2, whether in vitro, in cell culture, or in an animal, reduce the activity of EZH2, such that the measured EZH2 IC₅₀ is 10 µM or less (e.g., 5 µM or less or 1 µM or less). For certain EZH2 inhibitors, EZH2 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, EZH2 IC₅₀ is 0.1 nM to 1 µM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of EZH2 inhibitors are: EPZ-6438, GSK126, and pharmaceutically acceptable salts thereof. Exemplary EZH2 inhibitors are also

disclosed in US 8,691,507; US 9,394,283; US 9,889,138; US 10,166,238; US 10,040,782; US 10,457,640; US 10,633,371; US 10,647,700; US 10,786,511; US 20190328743; US 20190345139; and US 20210052595; the EZH2 inhibitors disclosed therein are incorporated herein by reference in their entirety.

5

HASPIN Inhibitors

HASPIN inhibitors may be compounds that upon contacting HASPIN, whether in vitro, in cell culture, or in an animal, reduce the activity of HASPIN, such that the measured HASPIN IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain HASPIN inhibitors, HASPIN IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, HASPIN IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of HASPIN inhibitors are: SEL120 and pharmaceutically acceptable salts thereof. Exemplary HASPIN inhibitors are also disclosed in US 20130102627 and US 20130231360; the HASPIN inhibitors disclosed therein are incorporated herein by reference in their entirety.

15

HDAC3 Inhibitors

HDAC3 inhibitors may be compounds that upon contacting HDAC3, whether in vitro, in cell culture, or in an animal, reduce the activity of HDAC3, such that the measured HDAC3 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain HDAC3 inhibitors, HDAC3 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, HDAC3 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of HDAC3 inhibitors are: RGFP966 and pharmaceutically acceptable salts thereof. Exemplary HDAC3 inhibitors are also disclosed in US 8,716,344; US 9,096,549; US 10,029,988; US 10,059,723; and US 20190216754; the HDAC3 inhibitors disclosed therein are incorporated herein by reference in their entirety.

25

FEN1 Inhibitors

FEN1 inhibitors may be compounds that upon contacting FEN1, whether in vitro, in cell culture, or in an animal, reduce the activity of FEN1, such that the measured FEN1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain FEN1 inhibitors, FEN1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, FEN1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of FEN1 inhibitors are: C8 (PMID: 32719125), SC13, FEN1-IN-3, and pharmaceutically acceptable salts thereof. Exemplary FEN1 inhibitors are also disclosed in US 20200237763 and US 7,927,790; the FEN1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

35

MEN1 Inhibitors

MEN1 inhibitors may be compounds that upon contacting MEN1, whether in vitro, in cell culture, or in an animal, reduce the activity of MEN1, such that the measured MEN1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain MEN1 inhibitors, MEN1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, MEN1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of MEN1 inhibitors are:

40

MI3454, SNDX5613, VTP50469, KO539, and pharmaceutically acceptable salts thereof. Exemplary MEN1 inhibitors are also disclosed in US 8,242,078; US 9,212,180; US 10,077,271; US 10,526,341; US 10,611,778; US 10,745,409; US 10,752,639; US 10,781,218; US 10,899,738; US 20170119769; US 20190010167; US 20190211036; US 20200022953; US 20200216471; and US 20200223853; the MEN1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

METTL3 Inhibitors

METTL3 inhibitors may be compounds that upon contacting METTL3, whether in vitro, in cell culture, or in an animal, reduce the activity of METTL3, such that the measured METTL3 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain METTL3 inhibitors, METTL3 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, METTL3 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of METTL3 inhibitors are: UZH1a, sTC-15, and pharmaceutically acceptable salts thereof. Exemplary METTL3 inhibitors are also disclosed in US 20160264934 and WO 2020201773; the METTL3 inhibitors disclosed therein are incorporated herein by reference in their entirety.

Nucleoside Analogs

Nucleoside analogs may be compounds that can act as antimetabolites by interfering with nucleotide production, or by acting as chain terminators in DNA lengthening by polymerase enzymes, either in cell culture, or in an animal. For certain nucleoside analogs, biological activity make occur at 10 μM or less (e.g., 5 μM or less or 1 μM or less), and could be as low as 100 pM or 10 pM. Preferably, nucleoside analog activity will occur at 1 nM to 1 μM (e.g., 1 nM to 750 nM, 1 nM to 500 nM, or 1 nM to 250 nM). Examples of nucleoside analogs are cytarabine, gemcitabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine or nelarabine.

PLK1 Inhibitors

PLK1 inhibitors may be compounds that upon contacting PLK1, whether in vitro, in cell culture, or in an animal, reduce the activity of PLK1, such that the measured PLK1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain PLK1 inhibitors, PLK1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, PLK1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of PLK1 inhibitors are: BI2536, BI6727, TAK960, NMSP937, GSK461364, and pharmaceutically acceptable salts thereof. Exemplary PLK1 inhibitors are also disclosed in US 7,504,513; US 7,517,873; US 7,851,495; US 7,977,336; US 8,101,628; US 8,129,387; US 8,278,299; US 9,175,038; US 9,175,357; US 20070185133; US 20080015192; US 20100278833; US 20150368209; US 20170283445; and US 20200247796; the PLK1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

PLK4 Inhibitors

PLK4 inhibitors may be compounds that upon contacting PLK4, whether in vitro, in cell culture, or in an animal, reduce the activity of PLK4, such that the measured PLK4 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain PLK4 inhibitors, PLK4 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, PLK4 IC₅₀ is 0.1 nM to 1 μM

(e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of PLK4 inhibitors are: centrinone, CFI-400945, and pharmaceutically acceptable salts thereof. Exemplary PLK4 inhibitors are also disclosed in US 10,752,612; US 20190070190; and US 20200383990; the PLK4 inhibitors disclosed therein are incorporated herein by reference in their entirety.

5

RRM1 and RRM2 Inhibitors

RRM1 inhibitors may be compounds that upon contacting RRM1, whether in vitro, in cell culture, or in an animal, reduces the activity of RRM1, such that the measured RRM1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain RRM1 inhibitors, RRM1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, RRM1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM).

10

RRM2 inhibitors may be compounds that upon contacting RRM2, whether in vitro, in cell culture, or in an animal, reduce the activity of RRM2, such that the measured RRM2 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain RRM2 inhibitors, RRM2 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, RRM2 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of RRM2 inhibitors are: motexafin gadolinium, hydroxyurea, fludarabine, cladribine, tezacitabine, triapine, and pharmaceutically acceptable salts thereof. Exemplary RRM2 inhibitors are also disclosed in US 4,188,378; US 4,357,324; and US 2019/0161461; the RRM2 inhibitors disclosed therein are incorporated herein by reference in their entirety.

15

20

SAE1 Inhibitors

SAE1 inhibitors may be compounds that upon contacting SAE1, whether in vitro, in cell culture, or in an animal, reduce the activity of SAE1, such that the measured SAE1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain SAE1 inhibitors, SAE1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, SAE1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of SAE1 inhibitors are: ML792 and pharmaceutically acceptable salts thereof. Exemplary SAE1 inhibitors are also disclosed in US 7,951,810; US 8,008,307; US 8,207,177; US 9,683,003; and US 9,695,154; the SAE1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

25

30

SOD1 Inhibitors

SOD1 inhibitors may be compounds that upon contacting SOD1, whether in vitro, in cell culture, or in an animal, reduce the activity of SOD1, such that the measured SOD1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain SOD1 inhibitors, SOD1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, SOD1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of SOD1 inhibitors are: LCS1, ATN-224, pyrimethamine, and pharmaceutically acceptable salts thereof.

35

40

SOD2 Inhibitors

SOD2 inhibitors may be compounds that upon contacting SOD2, whether in vitro, in cell culture, or in an animal, reduce the activity of SOD2, such that the measured SOD2 IC₅₀ is 10 μM or less (e.g., 5

μM or less or 1 μM or less). For certain SOD2 inhibitors, SOD2 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, SOD2 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of SOD2 inhibitors are: LCS1, ATN-224, pyrimethamine, and pharmaceutically acceptable salts thereof.

5

TOP1 Inhibitors

TOP1 inhibitors may be compounds that upon contacting TOP1, whether in vitro, in cell culture, or in an animal, reduce the activity of TOP1, such that the measured TOP1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain TOP1 inhibitors, TOP1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, TOP1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of TOP1 inhibitors are: irinotecan, topotecan, camptothecin, lamellarin D, and pharmaceutically acceptable salts thereof. Exemplary TOP1 inhibitors are also disclosed in US 4,604,463; US 4,894,456; and US 5,004,758; the TOP1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

15

TOP2 Inhibitors

TOP2 inhibitors may be compounds that upon contacting TOP2, whether in vitro, in cell culture, or in an animal, reduce the activity of TOP2, such that the measured TOP2 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain TOP2 inhibitors, TOP2 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, TOP2 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of TOP2 inhibitors are: etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticine, and pharmaceutically acceptable salts thereof. Exemplary TOP2 inhibitors are also disclosed in US 3,590,028; US 3,933,827; US 3,989,598; US 4,258,191; US 4,464,529; and US 4,965,348; the TOP2 inhibitors disclosed therein are incorporated herein by reference in their entirety.

25

TTK Inhibitors

TTK inhibitors may be compounds that upon contacting TTK, whether in vitro, in cell culture, or in an animal, reduce the activity of TTK, such that the measured TTK IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain TTK inhibitors, TTK IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, TTK IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of TTK inhibitors are: BAY1217389 and pharmaceutically acceptable salts thereof. Exemplary TTK inhibitors are also disclosed in US 8,551,980; US 8,729,082; US 9,199,999; US 9,212,184; US 9,284,317; US 9,340,528; US 9,388,140; US 9,388,177; US 9,468,642; US 9,512,126; US 9,512,130; US 9,555,022; US 9,586,958; US 9,663,510; US 9,670,202; US 2017/0217946; US 2017/0305912; US 2017/0334899; US 2017/0342064; US 9,676,766; Wengner et al., *Mol. Cancer Ther.*, 15:583-592, 2016; Zaman et al., *Mol. Cancer Ther.*, 16:2609-2617, 2017; Mason et al., *Proc. Nat'l Acad. Sci. U.S.A.*, 21:3127-3132, 2017; and Riggs et al., *J. Med. Chem.*, 62:4401-4410, 2019; the TTK inhibitors disclosed therein are incorporated herein by reference in their entirety.

40

UBA2 Inhibitors

UBA2 inhibitors may be compounds that upon contacting UBA2, whether in vitro, in cell culture, or in an animal, reduce the activity of UBA2, such that the measured UBA2 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain UBA2 inhibitors, UBA2 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, UBA2 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of UBA2 inhibitors are: TAK981 and pharmaceutically acceptable salts thereof. Exemplary UBA2 inhibitors are also disclosed in US 9,045,483; the UBA2 inhibitors disclosed therein are incorporated herein by reference in their entirety.

WEE1 Inhibitors

WEE1 inhibitors may be compounds that upon contacting WEE1, whether in vitro, in cell culture, or in an animal, reduce the activity of WEE1, such that the measured WEE1 IC₅₀ is 10 μM or less (e.g., 5 μM or less or 1 μM or less). For certain WEE1 inhibitors, WEE1 IC₅₀ may be 100 nM or less (e.g., 10 nM or less, or 1 nM or less) and could be as low as 100 pM or 10 pM. Preferably, WEE1 IC₅₀ is 0.1 nM to 1 μM (e.g., 0.1 nM to 750 nM, 0.1 nM to 500 nM, or 0.1 nM to 250 nM). Examples of WEE1 inhibitors are: adavosertib (AZD1775), Debio-0123, ZN-c3 and pharmaceutically acceptable salts thereof. Exemplary WEE1 inhibitors are also disclosed in US 8,791,125; US 9,850,247, WO 2020210320; WO 2019028008; WO 2019173082; and WO 2020210377; the WEE1 inhibitors disclosed therein are incorporated herein by reference in their entirety.

Platinum-Based DNA-Damaging Agent

Platinum-based DNA-damaging agents are coordination compounds of Pt(II) or Pt(IV), typically known in the art as platins. Platinum-based DNA-damaging agents include at least two coordination sites at the platinum center that are occupied by nitrogenous spectator ligand(s). The nitrogenous spectator ligands are monodentate or bidentate ligands, in which the donor atom is an sp³- or sp²-hybridized nitrogen atom within the ligand. Non-limiting examples of nitrogenous spectator ligands are ammonia, 1,2-cyclohexanediamine, a picoline, phenanthrin, or 1,6-hexanediamine. Non-limiting examples of platinum-based DNA-damaging agents include cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, and satraplatin.

Pharmaceutical Compositions

The compounds used in the methods described herein are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo. Pharmaceutical compositions typically include a compound as described herein and a pharmaceutically acceptable excipient. Certain pharmaceutical compositions may include one or more additional pharmaceutically active agents described herein.

The compounds described herein can also be used in the form of the free base, in the form of salts, zwitterions, solvates, or as prodrugs, or pharmaceutical compositions thereof. All forms are within the scope of the invention. The compounds, salts, zwitterions, solvates, prodrugs, or pharmaceutical compositions thereof, may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds used in the

methods described herein may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration, and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.

For human use, a compound of the invention can be administered alone or in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries that facilitate processing of a compound of the invention into preparations which can be used pharmaceutically.

This invention also includes methods of administering pharmaceutical compositions which can contain one or more pharmaceutically acceptable carriers. In making the pharmaceutical compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semisolid, or liquid material (e.g., normal saline), which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, and soft and hard gelatin capsules. As is known in the art, the type of diluent can vary depending upon the intended route of administration. The resulting compositions can include additional agents, e.g., preservatives.

The excipient or carrier is selected on the basis of the mode and route of administration. Suitable pharmaceutical carriers, as well as pharmaceutical necessities for use in pharmaceutical formulations, are described in Remington: The Science and Practice of Pharmacy, 21st Ed., Gennaro, Ed., Lippincott Williams & Wilkins (2005), a well-known reference text in this field, and in the USP/NF (United States Pharmacopeia and the National Formulary). Examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents, e.g., talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents, e.g., methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. Other exemplary excipients are described in Handbook of Pharmaceutical Excipients, 6th Edition, Rowe et al., Eds., Pharmaceutical Press (2009).

These pharmaceutical compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Methods well known in the art for making formulations are found, for example, in Remington: The Science and Practice of Pharmacy, 21st Ed., Gennaro, Ed., Lippincott Williams & Wilkins (2005), and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York. Proper formulation is dependent upon the route of administration chosen. The formulation and preparation of such compositions is well-known to those skilled in the art of pharmaceutical formulation. In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active

compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.

5 **Dosages**

The dosage of the compound used in the methods described herein, or pharmaceutically acceptable salts or prodrugs thereof, or pharmaceutical compositions thereof, can vary depending on many factors, e.g., the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and extent of the symptoms; the frequency of the treatment, and the type of concurrent treatment, if any; and the clearance rate of the compound in the animal to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. The compounds used in the methods described herein may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

A compound of the invention may be administered to the patient in a single dose or in multiple doses. When multiple doses are administered, the doses may be separated from one another by, for example, 1-24 hours, 1-7 days, 1-4 weeks, or 1-12 months. The compound may be administered according to a schedule or the compound may be administered without a predetermined schedule. An active compound may be administered, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per day, every 2nd, 3rd, 4th, 5th, or 6th day, 1, 2, 3, 4, 5, 6, or 7 times per week, 1, 2, 3, 4, 5, or 6 times per month, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per year. It is to be understood that, for any particular subject, specific dosage regimes should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

While the attending physician ultimately will decide the appropriate amount and dosage regimen, an effective amount of a compound of the invention may be, for example, a total daily dosage of, e.g., between 0.05 mg and 3000 mg of any of the compounds described herein. Alternatively, the dosage amount can be calculated using the body weight of the patient. Such dose ranges may include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered.

In the methods of the invention, the time period during which multiple doses of a compound of the invention are administered to a patient can vary. For example, in some embodiments, doses of the compounds of the invention are administered to a patient over a time period that is 1-7 days; 1-12 weeks; or 1-3 months. In some embodiments, the compounds are administered to the patient over a time period that is, for example, 4-11 months or 1-30 years. In some embodiments, the compounds are administered to a patient at the onset of symptoms. In any of these embodiments, the amount of compound that is administered may vary during the time period of administration. When a compound is administered daily, administration may occur, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times per day.

Formulations

A compound identified as capable of treating any of the conditions described herein, using any of the methods described herein, may be administered to patients or animals with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. The chemical compounds for use in such therapies may be produced and isolated by any standard technique known to those in the field of medicinal chemistry. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the identified compound to patients suffering from a disease or condition. Administration may begin before the patient is symptomatic.

Exemplary routes of administration of the compounds (e.g., a compound of the invention), or pharmaceutical compositions thereof, used in the present invention include oral, sublingual, buccal, transdermal, intradermal, intramuscular, parenteral, intravenous, intra-arterial, intracranial, subcutaneous, intraorbital, intraventricular, intraspinal, intraperitoneal, intranasal, inhalation, and topical administration. The compounds desirably are administered with a pharmaceutically acceptable carrier. Pharmaceutical formulations of the compounds described herein formulated for treatment of the disorders described herein are also part of the present invention.

Formulations for Oral Administration

The pharmaceutical compositions contemplated by the invention include those formulated for oral administration ("oral dosage forms"). Oral dosage forms can be, for example, in the form of tablets, capsules, a liquid solution or suspension, a powder, or liquid or solid crystals, which contain the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates, or alginic acid); binding agents (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, carboxymethylcellulose sodium, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol); and lubricating agents, glidants, and antiadhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc). Other pharmaceutically acceptable excipients can be colorants, flavoring agents, plasticizers, humectants, buffering agents, and the like.

Formulations for oral administration may also be presented as chewable tablets, as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. Powders, granulates, and pellets may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g., a mixer, a fluid bed apparatus or a spray drying equipment.

Controlled release compositions for oral use may be constructed to release the active drug by controlling the dissolution and/or the diffusion of the active drug substance. Any of a number of strategies can be pursued in order to obtain controlled release and the targeted plasma concentration versus time

profile. In one example, controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes. In some
5 embodiments, compositions include biodegradable, pH, and/or temperature-sensitive polymer coatings.

Dissolution or diffusion-controlled release can be achieved by appropriate coating of a tablet, capsule, pellet, or granulate formulation of compounds, or by incorporating the compound into an appropriate matrix. A controlled release coating may include one or more of the coating substances mentioned above and/or, e.g., shellac, beeswax, glycowax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glycerol palmitostearate, ethylcellulose, acrylic resins, dl-
10 polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinyl pyrrolidone, polyethylene, polymethacrylate, methylmethacrylate, 2-hydroxymethacrylate, methacrylate hydrogels, 1,3 butylene glycol, ethylene glycol methacrylate, and/or polyethylene glycols. In a controlled release matrix formulation, the matrix material may also include, e.g., hydrated methylcellulose, carnauba wax and
15 stearyl alcohol, carbopol 934, silicone, glyceryl tristearate, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene, and/or halogenated fluorocarbon.

The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils, e.g., cottonseed oil, sesame oil, coconut oil, or
20 peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Formulations for Parenteral Administration

The compounds described herein for use in the methods of the invention can be administered in a pharmaceutically acceptable parenteral (e.g., intravenous or intramuscular) formulation as described
25 herein. The pharmaceutical formulation may also be administered parenterally (intravenous, intramuscular, subcutaneous or the like) in dosage forms or formulations containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants. In particular, formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the
30 intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. For example, to prepare such a composition, the compounds of the invention may be dissolved or suspended in a parenterally acceptable liquid vehicle. Among acceptable vehicles and solvents that may be employed are water, water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's
35 solution and isotonic sodium chloride solution. The aqueous formulation may also contain one or more preservatives, for example, methyl, ethyl, or n-propyl p-hydroxybenzoate. Additional information regarding parenteral formulations can be found, for example, in the United States Pharmacopeia-National Formulary (USP-NF), herein incorporated by reference.

The parenteral formulation can be any of the five general types of preparations identified by the
40 USP-NF as suitable for parenteral administration:

(1) Drug Injection: a liquid preparation that is a drug substance (e.g., a compound of the invention), or a solution thereof;

(2) Drug for Injection: the drug substance (e.g., a compound of the invention) as a dry solid that will be combined with the appropriate sterile vehicle for parenteral administration as a drug injection;

(3) Drug Injectable Emulsion: a liquid preparation of the drug substance (e.g., a compound of the invention) that is dissolved or dispersed in a suitable emulsion medium;

5 (4) Drug Injectable Suspension: a liquid preparation of the drug substance (e.g., a compound of the invention) suspended in a suitable liquid medium; and

(5) Drug for Injectable Suspension: the drug substance (e.g., a compound of the invention) as a dry solid that will be combined with the appropriate sterile vehicle for parenteral administration as a drug injectable suspension.

10 Formulations for parenteral administration include solutions of the compound prepared in water suitably mixed with a surfactant, e.g., hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and
15 preparation of suitable formulations are described, for example, in Remington: The Science and Practice of Pharmacy, 21st Ed., Gennaro, Ed., Lippincott Williams & Wilkins (2005) and in The United States Pharmacopeia: The National Formulary (USP 36 NF31), published in 2013.

Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols, e.g., polyethylene glycol, oils of vegetable origin, or hydrogenated
20 naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for
25 example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

The parenteral formulation can be formulated for prompt release or for sustained/extended release of the compound. Exemplary formulations for parenteral release of the compound include: aqueous solutions, powders for reconstitution, cosolvent solutions, oil/water emulsions, suspensions, oil-
30 based solutions, liposomes, microspheres, and polymeric gels.

EXAMPLES

The following examples were meant to illustrate the invention. They were not meant to limit the invention in any way. Reactions were typically performed at room temperature (rt) under a nitrogen
35 atmosphere using dry solvents (Sure/Seal™) if not described otherwise in the Examples below. Reactions were monitored by TLC or by injection of a small aliquot on a Waters Acquity-H UPLC® Class system using an Acquity® UPLC HSS C18 2.1x30mm column eluting with a gradient (1.86 min) of acetonitrile (15% to 98%) in water (both containing 0.1% formic acid). Purifications by preparative HPLC were performed on a Teledyne Isco Combi *Flash®EZ Prep* system using either Phenomenex Gemini®
40 5µm NX-C18 110Å 150 x 21.2 mm column at a flow of 40 mL/min over 12 min (<100mg or multiple injections of <100mg) or HP C18 *RediSep®Rf* gold column (>100mg) eluting with an appropriate gradient of acetonitrile in water (both containing 0.1% formic acid) unless otherwise specified. The gradient was

selected based on the retention time observed by reaction monitoring on the Waters Acquity-H UPLC® Class system (see above). Fractions containing the desired compounds were combined and finally lyophilized. Purifications by silica gel chromatography were performed on a Teledyne Isco Combi Flash® Rf system using RediSep® Rf silica gel columns of appropriate sizes. Purity of final **Compounds** was assessed by injection of a small aliquot on a Waters Acquity-H UPLC® Class system using an Acquity® UPLC BEH C18 2.1x50mm column eluting with a gradient (7 min) of acetonitrile (2% to 98%) in water (both containing 0.1% formic acid).


Abbreviations

Abbreviations and terms that are commonly used in the fields of organic chemistry, medicinal chemistry, pharmacology, and medicine and are well known to practitioners in these fields are used herein. Representative abbreviations and definitions are provided below:

- Ac is acetyl [$\text{CH}_3\text{C}(\text{O})-$];
ACN is acetonitrile;
- Ac₂O is acetic anhydride;
AcOH is acetic acid;
- Ar is aryl;
BOC is *tert*-butoxycarbonyl;
n-BuLi is n-butyl lithium;
- compd is compound;
conc. is concentrated;
DCM is dichloromethane;
DIPEA is diisopropylethyl amine;
DMAP is 4-(Dimethylamino)pyridine;
- DME is dimethoxyethane;
DMF is N,N-dimethylformamide;
DMSO is dimethyl sulfoxide;
EtOAc is ethyl acetate;
EtOH is ethanol;
- h is hour;
HATU is 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate;
HCl is hydrochloric acid;
Hex is hexanes;
- HPLC is high performance liquid chromatography;
IPA is isopropanol;
LCMS is HPLC with mass spectral detection;
LiHMDS is lithium hexamethyldisilazane;
M is molar; mmol is millimole;
- Me is methyl;
MeCN is acetonitrile;
MeMgBr is methylmagnesium bromide;

- MeMgCl is methylmagnesium chloride;
 MeOH is methanol;
 MOM is methoxymethyl;
 min is minute;
- 5 N is normal;
 NBS is N-bromosuccinimide;
 NCS is N-chlorosuccinimide;
 NIS is N-iodosuccinimide;
 NMP is N-methyl pyrrolidinone;
- 10 NMR is nuclear magnetic resonance spectroscopy;
 PdCl₂(dppf) is [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II);
 PdCl₂(dppf).CH₂Cl₂ is [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane;
 Pd₂(dba)₃ is tris(dibenzylideneacetone)dipalladium(0);
- 15 Pd-PEPPSI™-SiPr is (1,3-Bis(2,6-diisopropylphenyl)imidazolidene) (3-chloropyridyl) palladium(II) dichloride;
 Ph is phenyl;
 PIV-Cl is pivaloyl chloride, Trimethylacetyl chloride;
 Reagent alcohol is a mixture of 90% ethanol, 5% isopropanol and 5% methanol;
- 20 rt is room temperature;
 sat. is saturated;
 tBu is tert-butyl;
 Tf is trifluoromethanesulfonate;
 TFA is trifluoroacetic acid;
- 25 THF is tetrahydrofuran;
 TMS is trimethylsilyl;
 Ts is p-toluenesulfonyl;
 Xantphos is 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene.


30 *Example 1. Preparation of Compounds*



Intermediate B (5-benzyloxy-2-bromo-3-chloro-pyrazine)

- Step 1. Sodium nitrite (40 g, 580 mmol) was added portion wise to a solution of 5-bromo-6-chloro-pyrazin-2-amine (110 g, 528 mmol) in sulfuric acid (770 mL) at 0°C under mechanical stirring. The resulting thick mixture was stirred at 0°C for 1 h and was then slowly poured in 6 L of cold water containing crushed ice maintaining temperature below 30°C. The resulting precipitate was collected by filtration, washed with water then dried by co-evaporation with toluene under vacuum twice to give 5-bromo-6-chloro-pyrazin-2-ol (104.6 g, 95% yield) as a pale beige solid.
- 35


Step 2. Benzyl bromide (48 mL, 404 mmol) was added dropwise to a suspension of 5-bromo-6-chloro-pyrazin-2-ol (80 g, 382 mmol) and silver carbonate (216 g, 778 mmol) in toluene (2 L). After stirring for 3 h, the suspension was filtered on Celite. The filtrate was evaporated to dryness to provide a yellow oil that was dissolved in warm EtOH. After slow addition of water under sonication, the precipitate was collected by filtration to provide 5-benzyloxy-2-bromo-3-chloro-pyrazine (85.2 g, 75% yield) as a beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.27 (s, 1H), 7.51 – 7.46 (m, 2H), 7.44 – 7.33 (m, 3H), 5.36 (s, 2H).



Intermediate C (6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile)

Step 1. To a solution of **Intermediate B** (90 g, 300 mmol) in toluene (1350 mL) were added potassium tert-butoxide (45.0 g, 401 mmol), 3-methoxy-2,6-dimethyl-aniline (48 g, 318 mmol), Pd₂(dba)₃ (14.4 g, 15.7 mmol) and Xantphos (18.0 g, 31 mmol). The mixture was degassed in vacuo and back filled with nitrogen. The resulting mixture was stirred at 80°C for 45 min and then concentrated in vacuo. The residue was dissolved in DCM (500 mL), 200 g of silica gel was added, and the suspension was evaporated to dryness under vacuum. The residue was purified on a pad of silica gel (1 kg of silica gel) eluting with a gradient of 0 to 15% EtOAc in hexanes to provide 5-benzyloxy-3-chloro-N-(3-methoxy-2,6-dimethyl-phenyl)pyrazin-2-amine (108.4 g, 98% yield) as a pale beige solid.

Step 2. To a solution of propanedinitrile (42.1 g, 637 mmol) in DME (1800 mL) was added portion wise NaH (25.0 g, 628 mmol, 60% dispersion in mineral oil). The resulting mixture was stirred for 30 min, then 5-benzyloxy-3-chloro-N-(3-methoxy-2,6-dimethyl-phenyl)pyrazin-2-amine (115 g, 311 mmol) in DME (500 mL) and Pd(PPh₃)₄ (17.7 g, 15.3 mmol) were added. The resulting mixture was stirred at reflux for 2 h, and then concentrated in vacuo to 1 L. Water (1 L) was added slowly and the resulting biphasic mixture was stirred for 18 h with a mechanical stirrer. The resulting solid was recovered by filtration, washed with water, and dried in vacuo. Trituration in DCM provided the first batch of the desired material as a beige solid isolated by filtration. The mother liquor was concentrated in vacuo, and the residue was purified by silica gel chromatography (dry load) eluting with a gradient of 10 to 60% EtOAc in hexanes to provide a second batch of the desired material. The two batches were combined to provide 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (103.1 g, 83% yield) as a beige solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.60 (s, 1H), 7.53 – 7.47 (m, 2H), 7.42 – 7.34 (m, 2H), 7.33 – 7.27 (m, 1H), 7.21 – 7.15 (m, 1H), 6.94 (d, J = 8.5 Hz, 1H), 5.45 (s, 2H), 4.91 (s, 2H), 3.84 (s, 3H), 1.90 (d, J = 0.7 Hz, 3H), 1.83 (s, 3H). MS: [M+1]: 400.4.




Intermediate D ([6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate)

Step 1. A solution of **Intermediate C** (83 g, 208 mmol) in sulfuric acid (550 mL) was stirred with a mechanical stirrer for 18 h. The thick brown mixture was poured slowly in icy water (2 L) in an ice bath maintaining internal temperature below 20 °C while stirred with a mechanical stirrer. A pale-yellow solid precipitated out. The resulting suspension in an ice bath was slowly neutralized to basic pH with aqueous ammonium hydroxide (28% solution; 850 mL) while maintaining the internal temperature below 40°C. The precipitate was collected by filtration, washed with water, and dried in vacuo to provide 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (65.1 g, 96% yield) as a pale beige solid.

Step 2. To a solution of 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (30.5 g, 93.2 mmol) and Cs_2CO_3 (34.9 g, 107 mmol) in DMF (300 mL) was added 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (36.6 g, 103 mmol). The reaction mixture was stirred for 1h, diluted with water (900 mL) and extracted with EtOAc (3x300 mL). The combined organic extracts were washed with water, brine, dried over Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 20 to 100% EtOAc in hexanes to provide [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (28 g, 65% yield) as an off-white solid. ^1H NMR (400 MHz, Chloroform- d) δ 7.75 (s, 1H), 7.22 m, 2H), 6.97 (d, J = 8.5 Hz, 1H), 6.37 (s, 2H), 5.49 (s, 1H), 3.86 (s, 3H), 1.91 (s, 3H), 1.84 (s, 3H). MS: $[\text{M}+1]$: 528.4.

Chiral SFC separation of **Intermediate D** (7.0 g, 15 mmol) (Instrument: Waters Prep 100 SFC-MS; Column: Phenomenex Lux Cellulose-2, 30 x 250 mm, 5 μm ; Conditions: Isocratic at 25% MeOH with 75% CO_2 ; Flow Rate: 70 mL/min) provided **Intermediate D1** and **Intermediate D2**.




25

Intermediate D1 from chiral SFC separation of **Intermediate D**. Peak 1 (retention time 4.95 min, 99.77%): *R*-6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl trifluoromethanesulfonate (1.93 g) as a white fluffy solid. ^1H NMR (400 MHz, DMSO- d_6) δ 7.94 (s, 1H), 7.89 (br s, 2H), 7.50 (br s, 1H), 7.28 (dt, J = 8.4, 0.8 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.80 (br s, 1H),


30

3.85 (s, 3H), 1.82 (d, $J = 0.7$ Hz, 3H), 1.74 (s, 3H). ^{19}F NMR (376 MHz, DMSO- d_6) δ -72.83. MS: $[\text{M}+1]$: 460.0.



Intermediate D2 from chiral SFC separation of **Intermediate D**. Peak 2 (retention time 6.44 min,

99.01%): S-6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl trifluoromethanesulfonate (1.95 g) as a white fluffy solid. ^1H NMR (400 MHz, DMSO- d_6) δ 7.94 (s, 1H), 7.89 (br s, 2H), 7.50 (br s, 1H), 7.28 (dt, $J = 8.5, 0.7$ Hz, 1H), 7.14 (d, $J = 8.5$ Hz, 1H), 6.80 (br s, 1H), 3.85 (s, 3H), 1.82 (d, $J = 0.7$ Hz, 3H), 1.74 (s, 3H). ^{19}F NMR (376 MHz, DMSO- d_6) δ -72.83. MS: $[\text{M}+1]$: 460.0.




Intermediate E (6-amino-3-hydroxy-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile)

Step 1. To a solution of 5-benzyloxy-2-bromo-3-chloro-pyrazine (5.08 g, 17.0 mmol) and 5-(methoxymethoxy)-2-methyl-aniline (5.70 g, 34.1 mmol) in THF (40 mL) at 0 °C was added dropwise potassium tert-butoxide in THF (1 M, 48 mL). After stirring for 90 min at 0 °C, the reaction mixture was quenched with saturated NH_4Cl , diluted with water, and extracted with EtOAc (3x). The combined organic extracts were washed with water, brine, dried over Na_2SO_4 , filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 20% EtOAc in hexanes to provide 6-benzyloxy-3-bromo-N-[5-(methoxymethoxy)-2-methyl-phenyl]pyrazin-2-amine (1.80 g, 25% yield) as a pale yellow solid.

Step 2. To a suspension of NaH (631 mg, 16.5 mmol, 60% dispersion in mineral oil) in THF (28 mL) at 0 °C, was added malononitrile (556 mg, 8.42 mmol) in THF (12 mL) dropwise. After stirring at 0 °C for 30 min, the ice bath was removed and 6-benzyloxy-3-bromo-N-[5-(methoxymethoxy)-2-methyl-phenyl]pyrazin-2-amine (1.80 g, 4.18 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (242 mg, 209 μmol) were added. The resulting mixture was flushed with nitrogen, and stirred at 60 °C for 1 h. The resulting mixture was cooled down to rt, poured slowly in saturated aqueous NH_4Cl and then was extracted with EtOAc (2x). The combined organic extracts were washed with water, brine, dried over Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of 0 to


100% EtOAc in hexanes to provide 6-amino-3-benzyloxy-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (1.63 g, 94% yield) as a light tan solid.

Step 3. A mixture 6-amino-3-benzyloxy-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (1.39 g, 3.35 mmol) and palladium on carbon (350 mg, 0.329 mmol, 10% w/w) was flushed with nitrogen and MeOH (40 mL) was added. The reaction mixture was flushed with hydrogen and stirred under a hydrogen atmosphere (1 atm) for 2 h, then flushed with nitrogen, filtered on a Celite pad using DCM and MeOH. The filtrate was concentrated in vacuo, then dried to afford 6-amino-3-hydroxy-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (1.12 g, 100%) as an ochre solid. MS: [M+1]: 326.1.



Intermediate F ([6-amino-7-cyano-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazin-3-yl] trifluoromethanesulfonate)

Step 1. To a solution of 6-amino-3-hydroxy-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (1.12 g, 3.44 mmol) and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (1.49 g, 4.17 mmol) in THF (45 mL) was added Et₃N (1.23 g, 12.2 mmol, 1.70 mL). The reaction mixture was stirred for 18 h, then concentrated in vacuo. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 100% EtOAc in hexanes to afford [6-amino-7-cyano-5-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[2,3-b]pyrazin-3-yl] trifluoromethanesulfonate (1.72 g, 100%) as a dark yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.38 (s, 1H), 8.13 (br s, 2H), 7.41 (dd, J = 8.5, 0.9 Hz, 1H), 7.19 (dd, J = 8.5, 2.6 Hz, 1H), 7.11 (d, J = 2.6 Hz, 1H), 5.22 (d, J = 6.8 Hz, 1H), 5.17 (d, J = 6.8 Hz, 1H), 3.38 (s, 3H), 1.90 (s, 3H). MS: [M+1]: 458.0.



Intermediate G (2-amino-5-chloro-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridine-3-carboxamide)


Step 1. To a solution of propanedinitrile (11.8 g, 179 mmol) in DME (200 mL) at 0 °C was added portion wise NaH (7.0 g, 175.00 mmol, 60% dispersion in mineral oil). 3-bromo-2,6-dichloro-pyridine (20 g, 88.15 mmol) was then added and the resulting mixture was stirred at 90 °C for 6h. The reaction mixture was cooled to rt, neutralized with 1M HCl, diluted with water and extracted with EtOAc (3x). The combined organic extracts were washed with brine, filtered and concentrated in vacuo. The residue was

purified by preparative HPLC in multiple batches. The desired fractions were combined and concentrated to dryness to provide 2-(3-bromo-6-chloro-2-pyridyl)propanedinitrile (8.0 g, 35% yield) as an off-white solid.

Step 2. To a solution of 2-(3-bromo-6-chloro-2-pyridyl)propanedinitrile (5 g, 19.5 mmol) in DMF (75 mL) were added $\text{Pd}_2(\text{dba})_3$ (1.75g, 1.91 mmol), 5-(methoxymethoxy)-2-methyl-aniline (3.6 g, 21.53 mmol), Cs_2CO_3 (12.7 g) and Xantphos (1.12 g, 1.94 mmol). The mixture was degassed in vacuo and back filled with nitrogen 3 times. The resulting mixture was stirred at 130 °C for 8 h then cooled to rt. The resulting mixture was diluted with water and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 10 to 60% EtOAc in hexanes. The desired fractions were concentrated to dryness, and the residue was triturated with DCM to provide 2-amino-5-chloro-1-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[3,2-b]pyridine-3-carbonitrile (2.2 g, 33% yield) as an off-white solid.

Step 3. To the suspension of 2-amino-5-chloro-1-[5-(methoxymethoxy)-2-methyl-phenyl]pyrrolo[3,2-b]pyridine-3-carbonitrile (2.20 g, 6.42 mmol) in DCM (5 mL) was added hydrogen chloride 4M in dioxane (4 M, 5 mL). The mixture was stirred for 30 min. The volatiles were removed in vacuo to provide 2-amino-5-chloro-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridine-3-carbonitrile HCl salt (2.10 g, 98% yield) as an off-white solid.

Step 4. The solution of 2-amino-5-chloro-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridine-3-carbonitrile (2.3 g, 7.70 mmol) in conc. sulfuric acid (25 mL) was stirred at rt for 1 h. Then it was diluted with crushed ice, basified with conc. aqueous ammonia to pH 8. The suspension was filtered. The precipitate was washed with water, dried in vacuo to provide an off-white mixture mainly containing 2-amino-5-chloro-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridine-3-carboxamide (2 g, 82 % yield) which was used directly in the next step without further purification. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.77 (s, 1H), 7.42 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.16 (m, 3H), 6.98 – 6.91 (m, 2H), 6.87 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 2.6 Hz, 1H), 1.81 (s, 3H). MS: $[\text{M}+1]$: 317.1.



Intermediate H (6-amino-3-bromo-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. Propanedinitrile (26.6 g, 403 mmol) was added dropwise with vigorous stirring to a suspension of NaH 60% dispersion in mineral oil (16 g, 418 mmol) in DME (600 mL). The mixture was stirred for 30 min and then 2,3-dichloropyrazine (30 g, 201 mmol) was added. The reaction mixture was stirred for 3 h and then heated to reflux for 1 h. The DME was evaporated under vacuum and the resulting residue was treated with cold aqueous HCl 1 M to give a yellow product that was recovered by filtration,


washed with water and a minimum of ethanol to afford 2-(3-chloropyrazin-2-yl)propanedinitrile (34.2 g, 95% yield) as a yellow solid.

Step 2. A microwave vial containing 2-(3-chloropyrazin-2-yl)propanedinitrile (1.00 g, 5.60 mmol), 3-methoxy-2,6-dimethyl-aniline (2.54 g, 16.8 mmol) and NMP (10 mL) was capped, stirred at 150 °C for 1 h then at 200 °C for 8 h. The reaction mixture was cooled to rt, poured into saturated aqueous NaHCO₃ and diluted with water and EtOAc. The mixture was filtered through a pad of Celite and the layers were separated. The organic layer was dried over Na₂SO₄, filtered, adsorbed on silica and purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes. The appropriate fractions were combined, concentrated in vacuo. The residue was purified again by silica gel chromatography eluting with a gradient of 0 to 20% MeOH in DCM. The appropriate fractions were combined, concentrated and dried in vacuo to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (346 mg, 21% yield) as a beige solid.

Step 3. To a solution of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (600 mg, 2.05 mmol) in DMF (10 mL) was added NBS (436 mg, 2.45 mmol). The mixture was stirred for 10 min, diluted with water, stirred for 20 min then filtered. The solid was washed with water and dried in vacuo. Purification by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes provided 6-amino-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (350 mg, 46% yield).

Step 4. To a solution of 6-amino-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (350 mg, 940 µmol) in DCM (10 mL) was added H₂SO₄ (1.88 mmol, 1 mL). The mixture was stirred 60 min, quenched with crushed ice and extracted with DCM. The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified on silica gel using a gradient of 0 to 20% MeOH in DCM to provide 6-amino-2-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (300 mg, 82% yield).

Step 5. To a solution of 6-amino-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (300 mg, 769 µmol) in DCM (3 mL) was added BBr₃ solution in DCM (1 M, 2.31 mL). The mixture was stirred for 2 h. The volatiles were removed in vacuo to afford a crude mixture of 6-amino-3-bromo-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (263 mg, 91% yield) that was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.29 (s, 1H), 7.55 (s, 2H), 7.31 (s, 1H), 7.21 (s, 1H), 7.13 – 7.06 (m, 1H), 6.96 (d, J = 8.3 Hz, 1H), 1.78 (s, 3H), 1.70 (s, 3H). MS: [M+1]: 378.3.



Intermediate I (2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide)

Step 1. To a solution of 2,3-dibromo-5-nitro-pyridine (20 g, 63.85 mmol) in NMP (120 mL) were added 2,6-dimethylpyridine (11.08 g, 103.4 mmol, 12 mL), 3-methoxy-2,6-dimethyl-aniline (14 g, 95.23

mmol). The mixture was heated at 130 °C overnight. After it was cooled to rt, it was diluted with water dropwise, stirred at rt for 20 min, filtered. The solid was washed with water, dried in vacuo. The residue was purified using 2 x 330 g silica gel eluting with a gradient of 10 to 30% EtOAc in heptane to provide 3-bromo-N-(3-methoxy-2,6-dimethyl-phenyl)-5-nitro-pyridin-2-amine (12 g, 53% yield) as an off-white solid.

5 Step 2. To a solution of propanedinitrile (4.4 g, 66.6 mmol, 4.19 mL) in DME (120 mL) was added portion wise NaH (2.90 g, 66.9 mmol, 60% dispersion in mineral oil). The resulting mixture was stirred for 5 min, then 3-bromo-N-(3-methoxy-2,6-dimethyl-phenyl)-5-nitro-pyridin-2-amine (11.6 g, 32.9 mmol) and PdCl₂(dppf).CH₂Cl₂ (1.34 g, 1.65 mmol) were added. The mixture was stirred 2h at 110 °C. The mixture was cooled to rt, diluted with water and extracted twice with EtOAc. The combined organic
10 extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 60% EtOAc in hexanes to provide 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-5-nitro-pyrrolo[2,3-b]pyridine-3-carbonitrile (11 g, 99% yield) as a yellow solid.

Step 3. To a solution of 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-5-nitro-pyrrolo[2,3-b]pyridine-3-carbonitrile (1.130 g, 3.35 mmol) in THF (15 mL) were added Et₃N (3.37 mmol, 470 µL), DMAP (45 mg, 368 µmol) and tert-butoxycarbonyl tert-butyl carbonate (1.47 g, 6.73 mmol). The mixture was stirred at 50 °C for 1h then cooled to rt. Ethylenediamine (500 µL) was added and the mixture was stirred for 2h. The resulting mixture was diluted with water, extracted with DCM (2x). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified
15 by silica gel chromatography eluting with a gradient of 20 to 60% EtOAc in to provide tert-butyl N-[3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-5-nitro-pyrrolo[2,3-b]pyridin-2-yl]carbamate (1.27 g, 87% yield).


Step 4. To a solution of tert-butyl N-[3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-5-nitro-pyrrolo[2,3-b]pyridin-2-yl]carbamate (2.94 g, 6.72 mmol) in DCM (30 mL) and MeOH (30 mL) was added palladium on carbon (10% w/w, 400 mg, 376 µmol). The mixture was stirred for 3h under 1 atm of
20 H₂. The suspension was filtered over a pad of Celite and concentrated in vacuo to provide tert-butyl N-[5-amino-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridin-2-yl]carbamate (2.7 g, 99% yield) as an off-white solid.

Step 5. To a solution of tert-butyl N-[5-amino-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridin-2-yl]carbamate (15.1 g, 37.1 mmol) in a mixture of DMF (60 mL) and acetonitrile (80 mL) was added tert-butyl nitrite (5.72 g, 55.5 mmol, 6.6 mL) followed by Copper(II) bromide (10 g, 44.8 mmol). The mixture was stirred at 60 °C for 20 min, then it was diluted with water, treated with ammonia, extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered. The filtrate was concentrated to dryness. The residue was purified using 3 X 330 silica gel column eluting with a gradient of 0 to 5% EtOAc in DCM to provide tert-butyl N-[5-bromo-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridin-2-yl]carbamate (9.67 g, 55% yield) as an
35 off-white solid. MS: 471.2 (M+H)⁺. The following side product was also isolated from the purification: tert-butyl (3-cyano-1-(3-methoxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (350 mg, 2% yield).

Step 6. To a solution of tert-butyl N-[5-bromo-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridin-2-yl]carbamate (1.05 g, 2.23 mmol) in EtOH (15 mL) at 80 °C was added aqueous HCl (6 M, 6 mL). The mixture was stirred for 20 min then concentrated to dryness, coevaporated with MeOH, treated with Et₃N and then concentrated to dryness. The residue was purified
40

by reverse phase flash chromatography on a C18 cartridge eluting with CH₃CN/water/0.1% formic acid to provide 2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile (515 mg, 60% yield) as an off-white solid.

Step 7. To a solution of 2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile (580 mg, 1.56 mmol) in a mixture of EtOH (6 mL) and water (2 mL) were added LiOH.H₂O (500 mg, 11.9 mmol) and H₂O₂ (27% w/w aq. solution, 21.02 mmol, 650 μ L). The mixture was stirred at 60 °C for 20 min, cooled to rt, diluted with water and filtered. The solid was washed with water, dried in vacuo to provide 2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide (600 mg, 99% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.21 (d, J = 2.0 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 7.20 (dt, J = 8.4, 0.7 Hz, 1H), 7.13 (s, 2H), 7.05 (d, J = 8.5 Hz, 1H), 6.83 (s, 2H), 3.73 (s, 3H), 1.75 (d, J = 0.7 Hz, 3H), 1.65 (s, 3H). MS: [M+1]: 469.1.




Compound 2 (6-amino-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(pyrrolidin-2-yl)ethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a solution of **Intermediate D** (0.25 g, 0.55 mmol) in DMF was added *tert*-butyl 2-ethynylpyrrolidine-1-carboxylate (0.213 g, 1.08 mmol) and Et₃N (234 μ L, 1.66 mmol). Nitrogen gas was bubbled in the reaction mixture for 10 min. CuI (10 mg, 0.054 mmol) and PdCl₂(PPh₃)₂ (20 mg, 0.027 mmol) were then added and the reaction mixture was heated at 100 °C for 1.5 h. The reaction mixture was cooled to rt, diluted with cold water and extracted with EtOAc (3x). The combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 60% EtOAc in hexanes to afford of *tert*-butyl 2-((6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)ethynyl)pyrrolidine-1-carboxylate (0.27 g, 83% yield) as a yellow solid.

Step 2. To a solution of *tert*-butyl 2-((6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)ethynyl)pyrrolidine-1-carboxylate (0.13 g, 0.55 mmol) in methanol was added palladium on carbon (10% w/w, 50% moisture). The suspension was stirred under hydrogen atmosphere for 2 h. The reaction mixture was filtered on Celite and washed with methanol. The filtrate was concentrated in vacuo and the residue was purified by silica gel chromatography eluting with 30% EtOAc in hexanes to provide *tert*-butyl 2-(2-(6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)ethyl)pyrrolidine-1-carboxylate (0.105 g, 49% yield) as an off-white solid.

Step 3. For O-Me deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(pyrrolidin-2-yl)ethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (2.7 mg, 3.5% yield) as a white solid.


^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.79 (bs, 1H), 8.40 (s, 1H), 7.65 (s, 1H), 7.47 (s, 1H), 7.35 (s, 2H), 7.27 (s, 1H), 7.07 (d, J = 8 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 3.39 (s, 2H), 3.06 (s, 1H), 2.99 (s, 1H), 2.80 (s, 2H), 2.02 (s, 3H), 1.83 (s, 1H), 1.76 (s, 3H), 1.68 (s, 3H), 1.46 (s, 1H). MS: $[\text{M}+1]$: 395.5.



5

Compound 6 (2-amino-5-(cyclopenten-1-yl)-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridine-3-carboxamide)


To a solution of **Intermediate G** (33 mg, 104 μmol) in dioxane (1.5 mL) were added 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (40 mg, 206 μmol), $\text{PdCl}_2(\text{dppf}) \cdot \text{CH}_2\text{Cl}_2$ (8 mg, 10 μmol) and aqueous Na_2CO_3 (2 M, 200 μL). The mixture was stirred at 100 $^\circ\text{C}$ for 5h. The volatiles were removed in vacuo. The residue was purified by preparative HPLC to provide 2-amino-5-(cyclopenten-1-yl)-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridine-3-carboxamide (5 mg, 14% yield) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.77 (s, 1H), 8.03 (s, 1H), 7.25 (d, J = 8.3 Hz, 1H), 6.99 (d, J = 8.1 Hz, 2H), 6.91 (s, 2H), 6.88 (dd, J = 8.3, 2.6 Hz, 1H), 6.82 (d, J = 8.1 Hz, 1H), 6.66 (d, J = 2.5 Hz, 1H), 6.41 (t, J = 2.1 Hz, 1H), 2.72 (m, 2H), 2.50 (m, 2H), 1.94 (m, 2H), 1.78 (s, 3H). MS: $[\text{M}+1]$: 349.1.



Compound 16 (2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(3-morpholinoprop-1-ynyl)pyrrolo[3,2-b]pyridine-3-carboxamide)

A solution of 4-prop-2-ynylmorpholine (40 mg, 0.32 mmol), **Intermediate G** (50 mg, 0.16 mmol), Copper(I) iodide (3 mg, 16 μmol), Na_2CO_3 (70 mg, 0.66 mmol), tri-tert-butylphosphonium tetrafluoroborate (9 mg, 31 μmol) and PdCl_2 (3 mg, 17 μmol) in DMF (2 mL) was degassed in vacuo and back-filled with nitrogen. The mixture was stirred at 100 $^\circ\text{C}$ for 5 h. The mixture was purified by preparative HPLC eluting with $\text{CH}_3\text{CN}/\text{water}/10$ mM ammonium bicarbonate (pH 10). The desired fractions were combined and lyophilized to provide 2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(3-morpholinoprop-1-ynyl)pyrrolo[3,2-b]pyridine-3-carboxamide (22 mg, 35% yield) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.76

(s, 1H), 7.74 (d, $J = 3.6$ Hz, 1H), 7.38 – 7.16 (m, 1H), 7.06 (s, 3H), 6.98 (d, $J = 8.1$ Hz, 1H), 6.88 (dd, $J = 8.4, 2.6$ Hz, 1H), 6.83 (d, $J = 8.0$ Hz, 1H), 6.66 (d, $J = 2.5$ Hz, 1H), 3.57 (m, 4H), 3.50 (s, 2H), 2.52 – 2.47 (m, 4H), 1.77 (s, 3H). MS: $[M+1]$: 406.2.




5

Compound 18 (2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(3-morpholinopropyl)pyrrolo[3,2-b]pyridine-3-carboxamide)

To a solution of 2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(3-morpholinoprop-1-ynyl)pyrrolo[3,2-b]pyridine-3-carboxamide (20 mg, 49 μ mol) in MeOH (2 mL) was added palladium on carbon (10% w/w, 6 mg). The mixture was stirred under a hydrogen atmosphere for 30 min. The resulting mixture was filtered and concentrated in vacuo to provide 2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(3-morpholinopropyl)pyrrolo[3,2-b]pyridine-3-carboxamide (17.8 mg, 88% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.74 (bs, 1H), 8.01 (d, $J = 4.0$ Hz, 1H), 7.24 (dd, $J = 8.3, 0.8$ Hz, 1H), 6.97 (d, $J = 4.0$ Hz, 1H), 6.90 – 6.81 (m, 3H), 6.76 (d, $J = 8.0$ Hz, 1H), 6.67 (d, $J = 8.1$ Hz, 1H), 6.63 (d, $J = 2.5$ Hz, 1H), 3.51 (m, 4H), 2.77 – 2.58 (m, 2H), 2.28 (m, 6H), 1.91 – 1.78 (m, 2H), 1.77 (s, 3H). MS: $[M+1]$: 410.2.

15




Compound 23 (2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-pyrimidin-2-yl-pyrrolo[3,2-b]pyridine-3-carboxamide)

To a solution of **Intermediate G** (50 mg, 0.158 mmol) in DMF (2 mL) were added tributyl(pyrimidin-2-yl)stannane (73 mg, 0.199 mmol, 60 μ L), CuI (3 mg, 16 μ mol), LiCl (7 mg, 165 μ mol) and $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$ (12 mg, 16 μ mol). The mixture was degassed in vacuo and back filled with nitrogen three times, then stirred at 110 $^\circ\text{C}$ for 18 h. The mixture was then purified by preparative HPLC to provide 2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-pyrimidin-2-yl-pyrrolo[3,2-b]pyridine-3-carboxamide (8 mg, 14% yield) as a yellowish solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.79 (s, 1H), 8.90 (d, $J = 4.8$ Hz, 2H), 8.32 (d, $J = 3.9$ Hz, 1H), 8.02 (d, $J = 8.3$ Hz, 1H), 7.43 (t, $J = 4.8$ Hz, 1H), 7.28 (d, $J = 8.3$ Hz, 1H),

25


7.16 (d, $J = 3.8$ Hz, 1H), 7.05 (s, 2H), 7.02 (d, $J = 8.3$ Hz, 1H), 6.90 (dd, $J = 8.4, 2.5$ Hz, 1H), 6.72 (d, $J = 2.5$ Hz, 1H), 1.82 (s, 3H). MS: $[M+1]$: 361.2.



- 5 **Compound 27** (2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(1,2,3,6-tetrahydropyridin-5-yl)pyrrolo[3,2-b]pyridine-3-carboxamide HCl salt)

To a solution of tert-butyl 5-[2-amino-3-carbamoyl-1-(5-hydroxy-2-methyl-phenyl)pyrrolo[3,2-b]pyridin-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (75 mg, 0.162 mmol, prepared similarly to **Compound 6**) in MeOH (1 mL) was added HCl in dioxane (4 M, 0.5 mL). The mixture was stirred for 2h.

- 10 The volatiles were removed in vacuo. The residue was dissolved in water and CH₃CN then lyophilized to provide 2-amino-1-(5-hydroxy-2-methyl-phenyl)-5-(1,2,3,6-tetrahydropyridin-5-yl)pyrrolo[3,2-b]pyridine-3-carboxamide HCl salt (64 mg, 99% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.76 (s, 1H), 9.20 (s, 2H), 8.01 – 7.41 (m, 1H), 7.26 (d, $J = 8.4$, Hz, 1H), 7.12 (d, $J = 8.3$ Hz, 1H), 7.02 (s, 3H), 6.92 – 6.82 (m, 2H), 6.72 – 6.61 (m, 2H), 4.11 (s, 2H), 3.44 (m 2H), 3.19 (m, 2H), 1.77 (s, 3H). MS: $[M+1]$: 464.2.
- 15




- Compound 28** (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide)

- 20 Step 1. A mixture of tributyl(thiazol-2-yl)stannane (345 mg, 0.922 mmol, 290 μ L), **Intermediate D** (210 mg, 0.457 mmol), CuI (11 mg, 58 μ mol), LiCl (40 mg, 0.943 mmol), PdCl₂(dppf).CH₂Cl₂ (35 mg, 45 μ mol) in DMF (3 mL) was degassed in vacuo, then back filled with nitrogen. The final mixture was stirred at 120 °C for 4 h. The volatiles were removed in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 20 to 100% EtOAc in hexanes to provide a 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (136 mg, 75% yield) as an off-white solid.
- 25

Step 2. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (23 mg, 58 μ mol) to provide a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-

carboxamide (10 mg, 45% yield) as an off-white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.63 (s, 1H), 8.49 (s, 1H), 7.91 (d, J = 3.2 Hz, 1H), 7.78 (d, J = 3.2 Hz, 1H), 7.61 (s, 2H), 7.40 (s, 1H), 7.29 (s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 1.77 (s, 3H), 1.69 (s, 3H). MS: $[\text{M}+1]$: 381.2.



5

Compound 31 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-methyl-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a solution of 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile **Intermediate C** (4 g, 10 mmol) in DMF (40 mL) was added NBS (4 g, 10 mmol). The mixture was stirred for 1 h, diluted with water, and finally stirred for 20 min. The resulting solid was filtered, washed with water and dried in vacuo then purified by silica gel chromatography eluting with a gradient of 20 to 80% EtOAc in hexanes to provide 6-amino-2-benzyloxy-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (3.86 g, 81% yield) as an off-white solid.


Step 2. To a solution of 6-amino-2-benzyloxy-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (650 mg, 1.36 mmol) in dioxane (10 mL) and water (3 mL) were added Pd(PPh₃)₄ (80 mg, 69 μ mol), K₂CO₃ (800 mg, 5.79 mmol). The mixture was degassed in vacuo and then back filled with nitrogen three times. 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (712 mg, 2.84 mmol, 0.8 mL) was then added and the final mixture was stirred at 100 °C for 18 h. The mixture was cooled to rt, diluted with EtOAc, washed with water, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 45% EtOAc in hexanes to provide 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-methyl-pyrrolo[2,3-b]pyrazine-7-carbonitrile (300 mg, 53% yield) as an off-white solid.

Step 3. For nitrile hydrolysis using sulfuric acid, the same procedure used for **Compound 164** was done on the appropriate intermediate (260 mg, 0.629 mmol) to provide 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-methyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (205 mg, 96% yield) as an off-white solid.

Step 4. To a solution of 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-methyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (206 mg, 0.603 mmol) and Cs₂CO₃ (390 mg, 1.20 mmol) in DMF (2 mL) was added 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (235 mg, 0.658 mmol). The mixture was stirred for 1 h, then diluted with water and extracted with EtOAc (4x). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 70% EtOAc in hexanes to provide [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-methyl-pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (160 mg, 56% yield) as an off-white solid.

Step 5. A mixture of tributyl(thiazol-2-yl)stannane (83 mg, 0.223 mmol, 70 μ L), [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-methyl-pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (50 mg, 0.106 mmol), CuI (3 mg, 16 μ mol), LiCl (7 mg, 0.165 mmol), PdCl₂(dppf).CH₂Cl₂ (8 mg, 11 μ mol) in DMF (1.5 mL) was degassed in vacuo, then back filled with nitrogen. The reaction mixture was stirred at 110 °C for 4 h, cooled to rt and concentrated in vacuo. The residue was purified by preparative HPLC to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-3-methyl-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (22 mg, 51% yield) as an off-white solid.


Step 6. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (22 mg, 53 μ mol) to provide a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-methyl-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (5 mg, 24% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.64 (s, 1H), 7.94 (d, *J* = 3.3 Hz, 1H), 7.76 (d, *J* = 3.3 Hz, 1H), 7.47 (s, 2H), 7.35 (s, 1H), 7.22 (s, 1H), 7.06 (d, *J* = 8.3 Hz, 1H), 6.92 (d, *J* = 8.3 Hz, 1H), 2.76 (s, 3H), 1.77 (s, 3H), 1.69 (s, 3H). MS: [M+1]: 395.2.



Compound 33 (6-amino-3-bromo-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a solution of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (**Compound 28**, 60 mg, 0.15 mmol) in DMF (1 mL) was added NBS (30 mg, 0.17 mmol). The mixture was stirred 18 h, diluted with water, treated with 20% aqueous Na₂S₂O₃, extracted with EtOAc (3x). The combined organic extracts were washed with water, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 20 to 100% EtOAc in hexanes to provide 6-amino-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (45 mg, 63% yield) as an off-white solid.


Step 2. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (35 mg, 74 μ mol) to provide a residue which was purified by preparative HPLC to provide 6-amino-3-bromo-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (10 mg, 29% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.71 (s, 1H), 7.97 (d, *J* = 3.3 Hz, 1H), 7.88 (d, *J* = 3.3 Hz, 1H), 7.75 (s, 2H), 7.45 (s, 1H), 7.19 – 7.00 (m, 2H), 6.94 (d, *J* = 8.3 Hz, 1H), 1.79 (s, 3H), 1.71 (s, 3H). MS: [M+1]: 460.2.



Compound 35 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[2-(trifluoromethyl)-4-pyridyl]pyrrolo[2,3-b]pyrazine-7-carboxamide)

5 Step 1. To a solution of **Intermediate D** (50 mg, 0.109 mmol) in dioxane (1 mL) were added PdCl₂(dppf).CH₂Cl₂ (8 mg, 10 μmol). [2-(trifluoromethyl)-4-pyridyl]boronic acid (40 mg, 0.209 mmol) and aqueous Na₂CO₃ (2 M, 200 μL). The mixture was degassed in vacuo and back filled with nitrogen. The reaction mixture was stirred at 100 °C for 4 h, cooled to rt, diluted with water and then filtered. The solid was washed with water, dried in vacuo and finally purified by silica gel chromatography
10 eluting with a gradient of 20 to 100% EtOAc in hexanes to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[2-(trifluoromethyl)-4-pyridyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (36 mg, 72% yield) as an off-white solid.


Step 2. (**General procedure for the OMe deprotection using BBr₃**) To a solution of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[2-(trifluoromethyl)-4-pyridyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (36
15 mg, 79 μmol) in DCM (1 mL) was added BBr₃ (1 M in DCM, 230 μL). The mixture was stirred for 1 h. The volatiles were removed in vacuo. The residue was dissolved in MeOH and concentrated to dryness again. Then it was dissolved in MeOH, Et₃N (100 μL) was added and the mixture was concentrated to dryness again. The residue was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[2-(trifluoromethyl)-4-pyridyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (16 mg, 46% yield) as an
20 off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 8.81 (m, 1H), 8.62 (s, 1H), 8.48 (s, 1H), 8.41 (m, 1H), 7.63 (s, 2H), 7.45 (s, 1H), 7.33 (s, 1H), 7.07 (d, *J* = 8.3 Hz, 1H), 6.93 (d, *J* = 8.3 Hz, 1H), 1.77 (s, 3H), 1.69 (s, 3H). MS: [M+1]: 443.2.



Compound 46 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[4-(methylcarbamoyl)-1-piperidyl]pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a solution of **Intermediate D** (50 mg, 0.109 mmol) in DMSO (1 mL) was added N-methylpiperidine-4-carboxamide (80 mg, 0.563 mmol). The mixture was stirred at 130 °C for 2 h in a sealed vial, then cooled to rt and purified by preparative HPLC to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[4-(methylcarbamoyl)-1-piperidyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (14 mg, 28% yield) as an off-white solid.

Step 2. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (15 mg, 32 μmol) to provide a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[4-(methylcarbamoyl)-1-piperidyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (10 mg, 69% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.51 (s, 1H), 7.72 (d, *J* = 4.8 Hz, 1H), 7.35 (s, 1H), 7.27 (s, 1H), 7.14 – 6.96 (m, 4H), 6.87 (d, *J* = 8.2 Hz, 1H), 4.13 (d, *J* = 12.4 Hz, 2H), 2.85 – 2.68 (m, 2H), 2.53 (d, *J* = 4.6 Hz, 3H), 2.35 – 2.20 (m, 1H), 1.74 (m, 5H), 1.65 (s, 3H), 1.64 – 1.50 (m, 2H). MS: [M+1]: 438.2.



Compound 97 (1-[6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-pyrazin-2-yl-pyrrolo[2,3-b]pyrazin-7-yl]ethanone)

Step 1. To a solution of **Intermediate C** (2.5 g, 6.26 mmol) in THF (20 mL) was added MeMgBr solution in THF (3 M, 6.50 mL) at 0°C. The mixture was warmed and stirred 18 h. An additional amount of MeMgBr solution in THF (3 M, 4.00 mL) was added and the mixture was stirred an extra 5 h. The resulting mixture was quenched with sat. aqueous NH₄Cl, diluted with water, extracted with EtOAc. The organic extract was washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column eluting with a gradient of 0 to 30% EtOAc in hexanes to provide 1-[6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-7-yl]ethanone (120 mg, 5% yield).


Step 2. To a solution of 1-[6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-7-yl]ethanone (100 mg, 0.240 mmol) in DCM (1 mL) was added TFA (500 μL). The mixture was stirred at 50 °C for 10h. The volatiles were removed in vacuo. The residue was purified by preparative HPLC to provide 1-[6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-7-yl]ethanone (43 mg, 55% yield).

Step 3. To a mixture of 1-[6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-7-yl]ethanone (43 mg, 0.132 mmol) and Cs₂CO₃ (50 mg, 0.153 mmol) in DMF (1 mL) was added 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (52 mg, 0.146 mmol). The mixture was stirred for 1 h. The volatiles were removed in vacuo. The residue was purified by silica gel

chromatography eluting with a gradient of 0 to 70% EtOAc in hexanes to provide [7-acetyl-6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (46 mg, 76% yield) as an off-white solid.

Step 4. To a solution of [7-acetyl-6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (46 mg, 0.100 mmol) in DMF (1 mL) were added LiCl (9 mg, 0.212 mmol), tributyl(pyrazin-2-yl)stannane (74 mg, 0.200 mmol), and PdCl₂(dppf).CH₂Cl₂ (7 mg, 9.6 μmol). The mixture was stirred at 120 °C for 10 h. The volatiles were removed in vacuo. The residue was purified by preparative HPLC to provide 1-[6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-pyrazin-2-yl-pyrrolo[2,3-b]pyrazin-7-yl]ethanone (38 mg, 97% yield) as an off-white solid.

Step 5. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (38 mg, 98 μmol) to provide a residue which was purified by preparative HPLC to provide 1-[6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-pyrazin-2-yl-pyrrolo[2,3-b]pyrazin-7-yl]ethanone (18 mg, 49% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.62 (s, 1H), 9.55 (s, 1H), 8.72 (s, 1H), 8.69 – 8.62 (m, 2H), 8.13 (s, 2H), 7.07 (d, *J* = 8.3 Hz, 1H), 6.93 (d, *J* = 8.3 Hz, 1H), 2.76 (s, 3H), 1.77 (s, 3H), 1.69 (s, 3H). MS: [M+1]: 375.



Compound 102 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)-2-vinyl-pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a solution of **Intermediate C** (800 mg, 2.00 mmol) in DMF (10 mL) was added NIS (450 mg, 2.00 mmol). The mixture was stirred for 30 min, diluted with water and stirred for 20 min. The resulting precipitate was collected by filtration and then purified by silica gel chromatography eluting with a gradient of 20 to 60% EtOAc in hexanes to provide 6-amino-2-benzyloxy-3-iodo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (820 mg, 78% yield) as an off-white solid.


Step 2. To a solution of 6-amino-2-benzyloxy-3-iodo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (745 mg, 1.42 mmol) in DMF (10 mL) was added (1,10-phenanthroline)(trifluoromethyl)copper(I) (900 mg, 2.88 mmol). The mixture was stirred at 70 °C for 4 h. The volatiles were removed in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 20 to 60% EtOAc in hexanes to provide 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (300 mg, 45% yield).

Step 3. A solution of 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (300 mg, 0.642 mmol) in sulfuric acid (1 mL) was stirred for 5 h, poured in crushed ice, neutralized with ammonia solution and the resulting precipitate was filtered. The precipitate was washed with water, dried in vacuo to provide 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (232 mg, 91% yield) as a yellow solid.

Step 4. To a solution of 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (232 mg, 0.587 mmol) and Cs_2CO_3 (200 mg, 0.615 mmol) in DMF (2 mL) was added 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (210 mg, 0.588 mmol). The mixture was stirred for 1 h, diluted with water and stirred for 20 min. The resulting precipitate was filtered, washed with water, dried in vacuo. Further purification by silica gel chromatography eluting with a gradient of 20 to 100% EtOAc in hexanes provided [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (190 mg, 61% yield) as an off-white solid.

Step 5. To the solution of [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (90 mg, 0.171 mmol) in dioxane (1 mL) were added $\text{PdCl}_2(\text{dppf}) \cdot \text{CH}_2\text{Cl}_2$ (14 mg, 17 μmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (30 mg, 0.195 mmol) and aqueous Na_2CO_3 (2M, 100 μL). The mixture was stirred at 120 °C for 18 h. The volatiles were removed in vacuo. The residue was purified by preparative HPLC to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)-2-vinyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (10 mg, 14% yield) as an off-white solid.

Step 6. For OMe deprotection using BBr_3 , the same procedure used for **Compound 35** was done on the appropriate intermediate (10 mg, 25 μmol) to provide a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-(trifluoromethyl)-2-vinyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (3 mg, 31% yield) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.67 (s, 1H), 7.85 (s, 2H), 7.41 (m, 2H), 7.10 – 6.89 (m, 3H), 6.50 (m, 1H), 5.60 (m, 1H), 1.76 (s, 3H), 1.68 (s, 3H). MS: $[\text{M}+1]$: 392.2.



Compound 110 (6-amino-2-cyclopropyl-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a suspension of magnesium turnings (140 mg, 5.76 mmol) in THF (10 mL) was added iodine (13 mg, 52 μmol). The mixture was stirred for 10 min, CD_3I (5.14 mmol, 320 μL) was then added and the mixture was stirred for 18 h under nitrogen to generate an off-white suspension. To the mixture was added ZnCl_2 (0.5 M in THF, 10.5 mL) dropwise. After addition, the mixture was stirred for 20 min, then 6-amino-2-benzyloxy-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (500 mg, 1.05 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (120 mg, 0.103 mmol) were added. The final mixture was stirred at 70 °C for 6 h. The reaction was quenched with HCl 1M, diluted with water, and extracted with EtOAc (2x). The combined organic extracts were washed with water, brine, dried over Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 60% EtOAc in hexanes to provide 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (328 mg, 75% yield) as an off-white solid.


Step 2. A mixture of 6-amino-2-benzyloxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (328 mg, 0.788 mmol) in H₂SO₄ (2 mL) was stirred for 4h. The mixture was cooled to 0 °C then neutralized to pH 7 using concentrated aqueous ammonia. The resulting mixture was lyophilized, and the residue was triturated with water and filtered. The solid was dried in vacuo to provide 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (220 mg, 81% yield) as an off-white solid.

Step 3. To a solution of 6-amino-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (232 mg, 0.674 mmol) in DMF (3 mL) were added Cs₂CO₃ (320 mg, 0.982 mmol) and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (360 mg, 1.01 mmol). The mixture was stirred for 1 h. The volatiles were removed in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 20 to 100% EtOAc in hexanes to provide [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (200 mg, 62% yield) as an off-white solid.


Step 4. To the solution of [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (200 mg, 0.420 μmol) in DMF (3 mL) were added lithium chloride (36 mg, 0.849 mmol) and tributyl(cyclopropyl)stannane (275 mg, 0.831 mmol). The mixture was stirred at 120 °C for 10 h. The volatiles were removed in vacuo. The residue was purified by preparative HPLC to provide 6-amino-2-cyclopropyl-5-(3-methoxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (80 mg, 52% yield) as an off-white solid.

Step 5. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (35 mg, 95 μmol) to provide a residue which was purified by preparative HPLC to provide 6-amino-2-cyclopropyl-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (20 mg, 59% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.49 (s, 1H), 7.24 (s, 1H), 7.14 – 6.98 (m, 4H), 6.89 (d, *J* = 8.2 Hz, 1H), 2.11 (m, 1H), 1.84 – 1.68 (s, 3H), 1.64 (s, 3H), 1.04 – 0.81 (m, 4H). MS: [M+1]: 356.2.

Chiral SFC separation of **Compound 110** (20 mg, 0.056 mmol) (Instrument: Waters Prep 15 SFC-MS; Column: Phenomenex Lux Cellulose-2, 10 x 250 mm, 5 μm; Conditions: Isocratic at 55% MeOH with 45% CO₂; Flow Rate: 10 mL/min) provided **Compound 111** and **Compound 112**.




Compound 111 from chiral SFC separation of **110**. Peak 1 (retention time 5.33 min, 99.95%): S-6-amino-2-cyclopropyl-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (7.8 mg) is obtained as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.49 (s, 1H), 7.24 (s, 1H), 7.14 – 6.98 (m, 4H), 6.89 (d, *J* = 8.2 Hz, 1H), 2.11 (m, 1H), 1.84 – 1.68 (s, 3H), 1.64 (s, 3H), 1.04 – 0.81 (m, 4H). MS: [M+1]: 356.2.



Compound 112 from chiral SFC separation of **110**. Peak 2 (retention time 6.00 min, 99.78%): *R*-6-amino-2-cyclopropyl-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-(trideuteriomethyl)pyrrolo[2,3-*b*]pyrazine-7-

- carboxamide (5.3 mg) is obtained as an off-white solid. ^1H NMR (400 MHz, DMSO-*d*₆) δ 9.49 (s, 1H), 7.24 (s, 1H), 7.14 – 6.98 (m, 4H), 6.89 (d, *J* = 8.2 Hz, 1H), 2.11 (m, 1H), 1.84 – 1.68 (s, 3H), 1.64 (s, 3H), 1.04 – 0.81 (m, 4H). MS: [M+1]: 356.2.




- Compound 116** (2-amino-5-cyclopropyl-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carboxamide)

Step 1. To a solution of tert-butyl N-[5-bromo-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridin-2-yl]carbamate (described in the synthesis of **intermediate I**) (110 mg, 0.233 mmol) in water (0.5 mL) and dioxane (2 mL) were added cyclopropylboronic acid (41 mg, 0.477 mmol), Cs₂CO₃ (270 mg, 0.829 mmol), PdCl₂(dppf).CH₂Cl₂ (18 mg, 22 μ mol) in a sealed vial. The mixture was degassed and back filled with nitrogen 3 times. The resulting mixture was heated to 100 °C and stirred 18 h. The volatiles were removed in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 60% EtOAc in hexanes to provide 2-amino-5-cyclopropyl-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carbonitrile (63 mg, 81% yield) as an off-white solid.

Step 2. To a solution of 2-amino-5-cyclopropyl-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carbonitrile (73 mg, 0.220 mmol) in EtOH (1.5 mL) and water (300 μ L) were added LiOH.H₂O (50 mg, 1.19 mmol) and H₂O₂ (700 μ L, 27% w/w aq. soln). The mixture was stirred at 60 °C for 20 min, then the volatiles were removed in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 20 to 60% EtOAc in hexanes to provide 2-amino-5-cyclopropyl-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carboxamide (22 mg, 29% yield) as an off-white solid.

Step 3. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (22 mg, 63 μ mol) to provide a residue which was purified by preparative HPLC to provide 2-amino-5-cyclopropyl-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carboxamide (15 mg, 71% yield) as an off-white solid. ^1H NMR (400 MHz, DMSO-*d*₆) δ 9.43 (s, 1H), 7.58 (s, 1H), 7.50 (s, 1H), 7.00 (d, *J* = 8.3 Hz, 1H), 6.86 (m, 3H), 6.69 (s, 2H), 1.88 m, 1H), 1.69 (s, 3H), 1.61 (s, 3H), 0.86 (m, 2H), 0.81 – 0.68 (m, 2H). MS: [M+1]: 337.2.


Chiral SFC separation of **Compound 116** (410 mg, 1.22 mmol) (Instrument: Waters Prep 100 SFC-MS; Column: Phenomenex Lux Cellulose-2, 30 x 250 mm, 5 μ m; Conditions: Isocratic at 50% ACN/EtOH 1:1 with 50% CO₂; Flow Rate: 70 mL/min) provided **Compound 117** and **Compound 118**.



5


Compound 117 from chiral SFC separation of **116**. Peak 1 (retention time 5.60 min, 99.83%): *S*-2-amino-5-cyclopropyl-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carboxamide (130 mg) is obtained as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.52 (s, 1H), 8.12 (d, *J* = 2.2 Hz, 1H), 8.08 – 7.92 (m, 2H), 7.46 (s, 1H), 7.00 (d, *J* = 8.2 Hz, 2H), 6.86 (d, *J* = 8.3 Hz, 1H), 2.03 (m, 1H), 1.70 (s, 3H), 1.59 (s, 3H), 0.96 (m, 2H), 0.68 (m, 2H). MS: [M+1]: 337.2.

10



15

Compound 118 from chiral SFC separation of **116**. Peak 2 (retention time 7.81 min, 98.81%): *R*-2-amino-5-cyclopropyl-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carboxamide (130 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.52 (s, 1H), 8.12 (d, *J* = 2.2 Hz, 1H), 8.08 – 7.92 (m, 2H), 7.46 (s, 1H), 7.00 (d, *J* = 8.2 Hz, 2H), 6.86 (d, *J* = 8.3 Hz, 1H), 2.03 (m, 1H), 1.70 (s, 3H), 1.59 (s, 3H), 0.96 (m, 2H), 0.68 (m, 2H). MS: [M+1]: 337.2.



20

Compound 132 (2-amino-5-chloro-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyridine-3-carboxamide)

25

Step 1. To a solution of 3-methoxy-2,6-dimethyl-aniline (3.61 g, 23.9 mmol) and 3-bromo-5-chloro-2-fluoro-pyridine (5.02 g, 23.9 mmol) in THF (50 mL) was added LiHMDS solution in THF (1 M, 48 mL) dropwise over 18 min. A 16 °C exotherm was observed. After 30 min, the reaction mixture was diluted with saturated aqueous NH₄Cl and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and concentrated. The crude product was purified by flash chromatography (dry load) eluting with a gradient of 0 to 20% EtOAc in heptane. The fractions were


combined, concentrated and dried in vacuo to provide 3-bromo-5-chloro-N-(3-methoxy-2,6-dimethyl-phenyl)pyridin-2-amine (6.58 g, 81% yield) as a peach solid.

Step 2. To a suspension of NaH (1.08 g, 24.9 mmol, 60% dispersion in mineral oil) in DME (60 mL) is added propanedinitrile (1.62 g, 24.6 mmol) in DME (15 mL) dropwise. After stirring for 30 min, 3-bromo-5-chloro-N-(3-methoxy-2,6-dimethyl-phenyl)pyridin-2-amine (4.00 g, 11.7 mmol) in DME (15 mL) and PdCl₂(dppf).CH₂Cl₂ (1.08 g, 1.32 mmol) were added. The reaction mixture was flushed with nitrogen bubbling through the solution, then stirred at 100 °C for 5 h. The reaction mixture was cooled to rt and icy water (250 mL) was added dropwise. The resulting precipitate was collected by filtration and washed with water. The solid was air-dried then co-evaporated with toluene (2x), dried in vacuo to afford 4.67 g crude product. Purification by silica gel chromatography (dry load) eluting with a gradient of 0 to 100% EtOAc in heptane. The fractions were combined, concentrated and dried in vacuo, to afford 2-amino-5-chloro-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile (3.27 g, 85% yield) as an ivory crystalline solid.


Step 3. To a suspension of 2-amino-5-chloro-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile (7.50 g, 23.0 mmol) in water (60 mL) and reagent alcohol (180 mL) was added LiOH.H₂O, 98% (7.22 g, 172 mmol) and H₂O₂ (27% w/w aq. solution, 9.8 mL). The mixture was stirred at 60 °C for 30 min, then cooled to rt. Water was added dropwise (500 mL) and the solid was collected by filtration, washed with water and air-dried. The filtrate was diluted with water and a second crop of solid was obtained. Finally the filtrate was extracted with EtOAc (3x). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated then dried in vacuo affording a third crop of crude product. The combined crude material was purified by silica gel chromatography using a gradient of 50 to 100% EtOAc in heptane. Pure fractions were combined and concentrated, dried in vacuo to provide 2-amino-5-chloro-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide (3.90 g, 49% yield) as a light yellow solid. Alternatively, nitrile hydrolysis could be performed under H₂SO₄ conditions (using the same procedure used for **Compound 164**) affording 2-amino-5-chloro-1-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide in quantitative yield.

Step 4. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was used on the appropriate intermediate (3.90 g, 11.3 mmol) to provide a residue which was co-evaporated with MeOH (4x), dried in vacuo, triturated with saturated aqueous NaHCO₃ and filtered. The crude product was purified by silica gel chromatography silica using a gradient of 0 to 20% MeOH in CH₂Cl₂ to provide 2-amino-5-chloro-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide (3.54g, 95% yield) as a light beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.54 (s, 1H), 8.14 (d, *J* = 2.2 Hz, 1H), 7.74 (d, *J* = 2.1 Hz, 1H), 7.14 (br s, 2H), 7.06 (d, *J* = 8.3 Hz, 1H), 6.91 (d, *J* = 8.3 Hz, 1H), 6.86 (br s, 2H), 1.74 (s, 3H), 1.65 (s, 3H). MS: [M+1]: 331.1.


Chiral SFC separation of **Compound 132** (3.54 g, 10.7 mmol) (Instrument: Waters Prep 100 SFC-MS; Column: Phenomenex Lux Cellulose-2, 30 x 250 mm, 5 μm; Conditions: Isocratic at 45% ACN/EtOH 1:1 with 55% CO₂; Flow Rate: 70 mL/min) provided **Compound 133** and **Compound 134**.



Compound 133 from chiral SFC separation of **132**. Peak 1 (retention time 5.37 min, 99.70%): *S*-2-amino-5-chloro-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide (1.26 g) is obtained as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.54 (s, 1H), 8.14 (d, *J* = 2.2 Hz, 1H), 7.74 (d, *J* = 2.1 Hz, 1H), 7.14 (br s, 2H), 7.06 (dt, *J* = 8.2, 0.7 Hz, 1H), 6.91 (d, *J* = 8.3 Hz, 1H), 6.86 (br s, 2H), 1.74 (d, *J* = 0.7 Hz, 3H), 1.65 (s, 3H). MS: [M+1]: 331.1.



Compound 134 from chiral SFC separation of **132**. Peak 2 (retention time 7.79 min, 99.19%): *R*-2-amino-5-chloro-1-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyridine-3-carboxamide (1.26 g). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.54 (s, 1H), 8.14 (d, *J* = 2.2 Hz, 1H), 7.74 (d, *J* = 2.1 Hz, 1H), 7.14 (br s, 2H), 7.06 (dt, *J* = 8.2, 0.7 Hz, 1H), 6.91 (d, *J* = 8.3 Hz, 1H), 6.86 (br s, 2H), 1.74 (d, *J* = 0.7 Hz, 3H), 1.65 (s, 3H). MS: [M+1]: 331.1.




Compound 150 (6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-phenyl-pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. **Intermediate F** (101 mg, 0.236 mmol), phenyl boronic acid (29 mg, 0.24 mmol).

Pd(PPh₃)₄ (30 mg, 0.026 mmol) and potassium phosphate tribasic anhydrous (176 mg, 0.829 mmol) were loaded in a microwave vial, which was flushed with nitrogen, then dioxane (2 mL) was added, the vial was capped and placed in a heat block set to 90 °C. After 90 min, the reaction mixture was cooled to rt, diluted with water, extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes to provide 6-amino-5-(5-methoxy-2-methyl-phenyl)-3-phenyl-pyrrolo[2,3-b]pyrazine-7-carbonitrile (30 mg, 36% yield) as an orange solid.

Step 2. For nitrile hydrolysis using sulfuric acid, the same procedure used for **Compound 164** was done on the appropriate intermediate (28 mg, 0.079 mmol) to provide 6-amino-5-(5-methoxy-2-methyl-phenyl)-3-phenyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (20 mg, 68% yield) as a pale yellow solid.

Step 3. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-phenyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (11 mg, 57% yield) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.71 (br s, 1H), 8.73 (s, 1H), 7.92 – 7.76 (m, 2H), 7.49 (br s, 2H), 7.45 – 7.37 (m, 3H), 7.35 – 7.28 (m, 2H), 7.26 (br s, 1H), 6.92 (dd, *J* = 8.3, 2.6 Hz, 1H), 6.77 (d, *J* = 2.5 Hz, 1H), 1.89 (s, 3H). MS: [M+1]: 360.2.



Compound 153 (6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-(3-pyridylmethoxy)pyrrolo[2,3-b]pyrazine-7-carboxamide)


Step 1. To a mixture of **Intermediate E** (51 mg, 0.16 mmol), 3-pyridylmethanol (41 mg, 0.38 mmol) and triphenylphosphine (62 mg, 0.24 mmol) in THF (2mL) was added diisopropyl azodicarboxylate (47 μ L, 0.24 mmol). The resulting mixture was stirred 18 h. Additional triphenylphosphine (62 mg, 0.24 mmol), 3-pyridylmethanol (41 mg, 0.38 mmol) and diisopropyl azodicarboxylate (47 μ L, 0.24 mmol) were added and the mixture was stirred for another 2.5 h and concentrated to dryness. The crude residue was purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes to provide 6-amino-5-[5-(methoxymethoxy)-2-methyl-phenyl]-3-(3-pyridylmethoxy)pyrrolo[2,3-b]pyrazine-7-carbonitrile (115 mg) as an impure amber gum (containing triphenyl phosphine oxide), that was carried to next step without further purification.

Step 2. To a solution of 6-amino-5-[5-(methoxymethoxy)-2-methyl-phenyl]-3-(3-pyridylmethoxy)pyrrolo[2,3-b]pyrazine-7-carbonitrile (65.0 mg, 0.156 mmol) in MeOH (1.5 mL) was added HCl in dioxane (4 M, 1.50 mL). After stirring for 75 min, the reaction mixture was concentrated and dried in vacuo. Crude 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-(3-pyridylmethoxy)pyrrolo[2,3-b]pyrazine-7-carbonitrile assumed bis HCl salt was carried to the next step without further purification.

Step 3. To a solution of crude 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-(3-pyridylmethoxy)pyrrolo[2,3-b]pyrazine-7-carbonitrile (70 mg, 0.156 mmol, assuming bis HCl salt) in MeOH (1.0 mL) was added aqueous NaOH solution (4 M, 1.0 mL). Reaction mixture was transferred to a preheated heat block at 90 °C and stirred for 18 h. After cooling down to rt, the mixture was neutralized with 3N HCl and diluted with water. The precipitate was collected by filtration and washed with water, then air-dried. Purification by preparative HPLC provided 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-(3-pyridylmethoxy)pyrrolo[2,3-b]pyrazine-7-carboxamide (4 mg, 7% yield) as a white fluffy solid. ¹H NMR

(400 MHz, DMSO-*d*₆) δ 9.68 (br s, 1H), 8.48 (d, *J* = 2.2 Hz, 1H), 8.42 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.85 (s, 1H), 7.65 (dt, *J* = 7.8, 2.0 Hz, 1H), 7.26 (ddd, *J* = 7.9, 4.9, 0.9 Hz, 1H), 7.23 (d, *J* = 8.6 Hz, 1H), 7.15 (br s, 1H), 7.04 (br s, 1H), 7.00 (br s, 2H), 6.87 (dd, *J* = 8.3, 2.6 Hz, 1H), 6.66 (d, *J* = 2.5 Hz, 1H), 5.09 (d, *J* = 12.2 Hz, 1H), 5.08 (d, *J* = 12.2 Hz, 1H), 1.72 (s, 3H). MS: [M+1]: 391.2.

5




Compound 160 (6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a microwave vial charged with **Intermediate F** (251 mg, 0.549 mmol), Pd(PPh₃)₄ (65 mg, 0.056 mmol), CuI (43 mg, 0.023 mmol) and flushed with nitrogen was added 3-ethynylpyridine (72 mg, 0.698 mmol) in DMF (2.5 mL) followed by Et₃N (610 μ L, 4.39 mmol). The vial was capped then transferred to a preheated heat block (120°C). After 1 h, the reaction mixture was concentrated under vacuum, then taken in THF and adsorbed on silica. The volatiles were evaporated under vacuum and the residue was purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes then 0 to 20% MeOH in EtOAc, to provide 6-amino-5-[5-(methoxymethoxy)-2-methyl-phenyl]-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (260 mg, 99%) as a tan solid.


Step 2. To a suspension of 6-amino-5-[5-(methoxymethoxy)-2-methyl-phenyl]-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (225 mg, 0.548 mmol) in MeOH (3 mL) was added HCl in dioxane (4 M, 3 mL). After stirring for 30 min, the reaction mixture was concentrated to dryness then dried in vacuo, affording 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile (319 mg, bis HCl salt) as a tan sticky solid which was used in the next step without further purification.

Step 3. 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carbonitrile bis HCl salt (241 mg, 0.548 mmol) was stirred in conc. H₂SO₄ (2 mL). After 3 days, the reaction mixture was quenched with crushed ice, placed in ice bath and made alkaline (pH about 10) with 1:1 NH₄OH/H₂O. The solids were collected by filtration and air-dried overnight, affording crude product as an ochre yellow solid (249 mg). A portion (67 mg) was purified by preparative HPLC to provide 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (26 mg, 46% calculated yield) as a light yellow fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.77 (br s, 1H), 8.75 (dd, *J* = 2.3, 0.9 Hz, 1H), 8.57 (dd, *J* = 4.9, 1.7 Hz, 1H), 8.42 (s, 1H), 7.98 (dt, *J* = 7.9, 1.9 Hz, 1H), 7.73 (br s, 2H), 7.44 (ddd, *J* = 8.0, 4.9, 0.9 Hz, 1H), 7.35 (br d, *J* = 4.4 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 1H), 6.94 (dd, *J* = 8.3, 2.6 Hz, 1H), 6.77 (d, *J* = 2.6 Hz, 1H), 1.85 (s, 3H). MS: [M+1]: 385.3.



Compound 162 (6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethyl]pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethynyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (102 mg, 0.265 mmol) and palladium on carbon (30 mg, 0.028 mmol, 10% w/w) was stirred in MeOH (3 mL) under hydrogen atmosphere overnight, filtered on disk filter using MeOH, concentrated and purified by preparative HPLC to provide 6-amino-5-(5-hydroxy-2-methyl-phenyl)-3-[2-(3-pyridyl)ethyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (7 mg, 7% yield) as an off-white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.34 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.31 (dd, *J* = 2.3, 0.8 Hz, 1H), 7.95 (s, 1H), 7.55 (ddd, *J* = 7.8, 2.4, 1.7 Hz, 1H), 7.34 (br s, 1H), 7.30 (br s, 2H), 7.28 (dd, *J* = 8.4, 0.8 Hz, 1H), 7.23 (ddd, *J* = 7.8, 4.8, 0.9 Hz, 1H), 7.15 (br s, 1H), 6.92 (dd, *J* = 8.3, 2.6 Hz, 1H), 6.72 (d, *J* = 2.6 Hz, 1H), 3.01 – 2.93 (m, 2H), 2.92 – 2.84 (m, 2H), 1.82 (s, 3H). MS: [M+1]: 389.2.



Compound 164 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a suspension of NaH (3.54 g, 92 mmol, 60% dispersion in mineral oil) in THF (100 mL) at 0 °C was added malononitrile (3.99 g, 60.4 mmol) in THF (30 mL) dropwise via an addition funnel. The cold bath was removed at the end of the addition and the resulting mixture was allowed to stir for 45 min at rt. 2,3-dichloro-5,6-dimethyl-pyrazine (5.49 g, 31.0 mmol) and Pd(PPh₃)₄ (1.76 g, 1.52 mmol) were added, the reaction mixture was refluxed for 3.25 h, cooled to rt, poured into 200 mL 1:1 crushed ice and 1N HCl, and extracted with DCM (3x). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated. The crude product was adsorbed on silica using DCM/THF and purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes. Mix fractions were re-purified by a second silica gel chromatography using same conditions. Clean fractions from both columns were combined, concentrated and dried in vacuo to afford 2-(3-chloro-5,6-dimethyl-pyrazin-2-yl)propanedinitrile (5.0 g, 78% yield) as an orange solid.


Step 2. The reaction was split in 3 vials containing 1/3 of the amounts each. The microwave vials were charged with 2-(3-chloro-5,6-dimethyl-pyrazin-2-yl)propanedinitrile (3.04 g, 14.7 mmol), 3-methoxy-2,6-dimethyl-aniline (6.61 g, 43.7 mmol), potassium tert-butoxide (3.30 g, 29.4 mmol) and Pd-PEPPSI™-

SIPr catalyst (513 mg, 0.752 mmol), flushed with nitrogen three times, then dry NMP (30 mL) was added, flushed again with nitrogen, capped and submitted to microwave irradiation (100 °C) for 30 min. The vials were combined and diluted with EtOAc, saturated aqueous NH₄Cl and water. The layers were separated, and the aqueous layer was extracted twice with EtOAc. The combined organic extracts were washed with
 5 brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in heptane. Desired fractions were combined, concentrated and dried in vacuo to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carbonitrile (2.57 g, 54% yield) as a yellow solid.

Step 3. (**General procedure for nitrile hydrolysis using sulfuric acid**) 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carbonitrile (7.11 g, 22.1 mmol) was dissolved
 10 in concentrated sulfuric acid (70 mL), then stirred for 45 min. The reaction mixture was slowly poured into crushed ice (500 cc), then placed in an ice bath and neutralized to pH 8-9 with concentrated NH₄OH (about 190 mL), maintaining internal temperature below 35°C. After stirring for 1 h, the precipitate was filtered, washed with water, air-dried, then further dried by co-evaporation with toluene under vacuum
 15 then dried in vacuo to afford 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (7.5 g, quantitative yield) as a yellow solid.


Step 4. To a suspension of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (7.50 g, 22.1 mmol) in DCM (132 mL) was added BBr₃ (66.3 mmol, 6.4 mL)
 20 slowly. After stirring for 70 min, the reaction mixture was concentrated to dryness, resuspended in DCM, and MeOH was added (exotherm observed). After concentrating, the crude mixture was co-evaporated again with DCM/MeOH then carefully triturated with saturated aqueous NaHCO₃ (100 mL), diluted with water and stirred for 1.5 h. The precipitate was filtered, washed with water and air-dried then purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 20% MeOH in DCM. Mixed fractions
 25 were combined and re-purified by silica gel chromatography using the same conditions. The clean material from both columns was combined, concentrated then dried in vacuo, affording 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (5.3 g, 74% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.57 (s, 1H), 7.45 (br s, 1H), 7.18 – 7.02 (m, 4H), 6.93 (d, J = 8.3 Hz, 1H), 2.48 – 2.45 (m, 3H), 2.35 – 2.24 (m, 3H), 1.81 – 1.73 (m, 3H), 1.68 (s, 3H). MS: [M+1]: 326.4.

Chiral SFC separation of **Compound 164** (5.40 g, 16.6 mmol) (Instrument: Waters Prep 100
 30 SFC-MS; Column: Phenomenex Lux Cellulose-2, 30 x 250 mm, 5 µm; Conditions: Isocratic at 55% ACN/EtOH 1:1 with 45% CO₂; Flow Rate: 70 mL/min) provided **Compound 165** and **Compound 166**.




Compound 165 from chiral SFC separation of **164**. Peak 1 (retention time 4.07 min, 99.99%): S-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (1.31 g) was
 35 obtained as a light beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.57 (s, 1H), 7.45 (br s, 1H), 7.12 (br s,

1H), 7.09 (br s, 2H), 7.06 (d, $J = 8.8$ Hz, 1H), 6.93 (d, $J = 8.3$ Hz, 1H), 2.47 (s, 3H), 2.31 (s, 3H), 1.76 (s, 3H), 1.68 (s, 3H). MS: $[M+1]$: 327.3.



- 5 **Compound 166** from chiral SFC separation of **164**. Peak 2 (retention time 4.81 min, 99.83%): *R*-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (1.43 g) was obtained as a light beige solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.57 (s, 1H), 7.45 (br s, 1H), 7.12 (br s, 1H), 7.09 (br s, 2H), 7.07 (d, $J = 8.4$ Hz, 1H), 6.93 (d, $J = 8.3$ Hz, 1H), 2.47 (s, 3H), 2.31 (s, 3H), 1.76 (s, 3H), 1.68 (s, 3H). MS: $[M+1]$: 327.3.


10



Compound 173 (6-amino-2-cyclobutyl-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

- Step 1. A microwave vial was loaded with [6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (200 mg, 0.435 μmol) and Pd(PPh₃)₄ (56 mg, 49 μmol), flushed with nitrogen, THF (2 mL) was added, bubbled through with nitrogen, cyclobutyl zinc bromide solution (0.5 M, 4.35 mL) added, bubbled through with nitrogen, capped and transferred to a heat block preheated at 70 $^\circ\text{C}$. The reaction mixture was stirred 90 min, cooled to rt, quenched with saturated aqueous NH₄Cl and extracted with EtOAc (2x). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes to provide 6-amino-2-cyclobutyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (110 mg, 69% yield) as a white/beige solid.


- Step 2. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** was done on the appropriate intermediate (110 mg, 0.301 mmol) to provide a residue which was purified by preparative HPLC to provide 6-amino-2-cyclobutyl-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (54 mg, 51% yield) as an off-white fluffy solid. ^1H NMR (400 MHz, DMSO- d_6) δ 9.58 (s, 1H), 7.61 (s, 1H), 7.59 (br s, 1H), 7.32 (br s, 2H), 7.23 (br s, 1H), 7.07 (d, $J = 8.3$ Hz, 1H), 6.93 (d, $J = 8.3$ Hz, 1H), 3.66 (p, $J = 8.6$ Hz, 1H), 2.42 – 2.17 (m, 4H), 2.10 – 1.94 (m, 1H), 1.88 (td, $J = 8.5$, 4.0 Hz, 1H), 1.76 (s, 3H), 1.68 (s, 3H). MS: $[M+1]$: 352.4.




Compound 178 (6-amino-2-(1-fluoro-1-methyl-ethyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a solution of 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-(1-hydroxy-1-methyl-ethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (Compound **190**, 46.0 mg, 0.129 mmol) in DCM (2 mL) at -78 °C was added Deoxo-fluor® solution (315 mg, 0.712 mmol, 50% in THF) dropwise. The mixture was stirred at 0 °C for 45 min, concentrated and purified by preparative HPLC to provide 6-amino-2-(1-fluoro-1-methyl-ethyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (23 mg, 50% yield) as an off-white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 7.92 (d, J = 0.6 Hz, 1H), 7.46 (br s, 2H), 7.37 (br s, 1H), 7.26 (br s, 1H), 7.08 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 1.75 (d, J = 22.4 Hz, 6H), 1.77 (s, 3H), 1.69 (s, 3H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -137.78 (hept, J = 22.1 Hz). MS: [M+1]: 358.2.

Chiral SFC separation of **Compound 178** (19 mg, 0.053 mmol) (Instrument: Mettler Toledo Minigram SFC; Column: Phenomenex Lux Cellulose-2, 10 x 250 mm, 5 μm; Conditions: Isocratic at 45% ACN/EtOH 1:1 with 55% CO₂; Flow Rate: 10 mL/min) provided **Compound 179** and **Compound 180**.




Compound 179 from chiral SFC separation of **178**. Peak 1 (retention time 3.63 min, 99.87%): S-6-amino-2-(1-fluoro-1-methyl-ethyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (5 mg) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 7.92 (s, 1H), 7.46 (br s, 2H), 7.42 – 7.32 (m, 1H), 7.30 – 7.19 (m, 1H), 7.08 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 1.77 (s, 3H), 1.75 (d, J = 22.4 Hz, 6H), 1.69 (s, 3H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -137.75 (hept, J = 22.1 Hz). MS: [M+1]: 358.2.



25

Compound 180 from chiral SFC separation of **178**. Peak 2 (retention time 4.00 min, 99.90%): *R*-6-amino-2-(1-fluoro-1-methyl-ethyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-*b*]pyrazine-7-carboxamide (5 mg) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 7.92 (s, 1H), 7.46 (br s, 2H), 7.37 (br s, 1H), 7.26 (br s, 1H), 7.08 (d, *J* = 8.5 Hz, 1H), 6.94 (d, *J* = 8.3 Hz, 1H), 1.77 (s, 3H), 1.74 (d, *J* = 22.4 Hz, 6H), 1.69 (s, 3H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -137.75 (hept, *J* = 22.1 Hz). MS: [M+1]: 358.2.



Compound 181 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-*b*]pyridine-3-carboxamide (from method D)

Step 1. A pressure vessel was loaded with 3-bromo-2-chloro-6-methyl-5-nitro-pyridine (10.11 g, 40.2 mmol) and 3-methoxy-2,6-dimethylaniline (Aniline A2, 9.20 g, 60.8 mmol). NMP (40 mL) and 2,6-dimethylpyridine (8.58 g, 80.1 mmol, 9.3 mL) were added and the reaction mixture was heated to 130 °C (pellet bath) for 5 days until satisfactory conversion as assessed by UPLCMS was achieved. The reaction mixture was cooled to RT and the resulting paste transferred to a conical flask and 500 mL HCl 0.5 N was added dropwise while stirring, resulting in a sticky gum. The supernatant was filtered on a Buchner funnel. The remaining gum was washed with H₂O, dissolved in DCM, and combined with the solid which had also been dissolved in DCM (200 mL total). The DCM solution was dried over Na₂SO₄, filtered and concentrated. The crude residue was purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 100% DCM in heptanes to provide 3-bromo-N-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyridin-2-amine (10.5 g, 71% yield) as a light yellow solid.

Step 2. To a RBF containing sodium hydride (3.13 g, 72.2 mmol, 60% w/w in mineral oil) in DME (150 mL) was added a solution of propanedinitrile (4.75 g, 71.9 mmol) in DME (50 mL) slowly. After stirring for 1h, 3-bromo-N-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyridin-2-amine (10.5 g, 28.7 mmol) and Pd(dppf)Cl₂•DCM (2.31 g, 2.83 mmol) were added. The resulting mixture was degassed by bubbling N₂ through solution, equipped with a condenser, and heated to 95 °C for 1h. The reaction mixture was cooled to RT, poured into saturated aqueous NH₄Cl and extracted with DCM (3x). The combined organic extracts were washed with H₂O, brine, dried over Na₂SO₄, filtered and adsorbed on silica. The crude residue was purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 100% EtOAc in heptanes. Appropriate fractions were combined, concentrated and the resulting solid was triturated with DCM, filtered, and dried in vacuo, affording 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyrrolo[2,3-*b*]pyridine-3-carbonitrile (7.97 g, 79% yield) as a bright yellow solid. A second crop of material was obtained from the filtrate from the previous trituration by purification by flash chromatography and trituration in the same fashion, providing additional 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyrrolo[2,3-*b*]pyridine-3-carbonitrile (1.04 g, 10% yield) as a dark yellow solid.

Step 3. To a solution of 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyrrolo[2,3-*b*]pyridine-3-carbonitrile (9.0 g, 25.6 mmol) in THF (120 mL) was added triethylamine (7.99 g, 78.9

mmol, 11 mL), DMAP (312 mg, 2.55 mmol) and tert-butoxycarbonyl tert-butyl carbonate (17.0 g, 77.9 mmol). The mixture was stirred at 50 °C for 40 min. The heating was stopped, and ethylenediamine (6.20 g, 103 mmol, 6.90 mL) was added and the mixture was stirred at RT for 45 min, then diluted with H₂O and DCM. The layers were separated and the aqueous layer was extracted with DCM (2x). The combined organic extracts were washed with half-saturated brine, dried over Na₂SO₄, filtered and concentrated. The crude residue was purified by silica gel chromatography eluting with a gradient of 0 to 60% EtOAc in heptanes to provide tert-butyl N-[3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyrrolo[2,3-b]pyridin-2-yl]carbamate (13.94 g, quantitative yield) as an off-white solid, which was contaminated with tert-butyl N-[2-(tert-butoxycarbonylamino)ethyl]carbamate (50 mol% by ¹H NMR).

Step 4. To a RBF containing tert-butyl N-[3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-5-nitro-pyrrolo[2,3-b]pyridin-2-yl]carbamate (13.94 g, 25.6 mmol) (assumed quantitative from the previous step) in DCM (280 mL) and MeOH (280 mL) was added palladium on carbon (2.08 g, 1.95 mmol, 10%w/w) as a slurry in some of the solvent mixture. The reaction mixture was flushed with H₂ and stirred under H₂ atmosphere (balloon) overnight. The reaction mixture was flushed with N₂, filtered on a celite pad, rinsed with DCM and MeOH. The filtrate was concentrated and dried in vacuo, affording a light yellow solid which was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (20 to 100%) in heptanes. Appropriate fractions were combined and concentrated in vacuo to afford tert-butyl N-[5-amino-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridin-2-yl]carbamate (9.34 g, 87% yield) as an off-white solid.

Step 5. To a solution of tert-butyl N-[5-amino-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridin-2-yl]carbamate (10.34 g, 24.5 mmol) in acetonitrile (100 mL) and DMF (60 mL) was added tert-butyl nitrite (5.20 g, 50.5 mmol, 6.0 mL), followed by copper(II) bromide (6.58 g, 29.4 mmol). The mixture was heated to 70 °C for 35 min, cooled to RT, diluted with H₂O (600 mL) and NH₄OH conc (30 mL) and extracted with EtOAc (3x). The combined organic extracts were washed with saturated NH₄Cl (2x), half-saturated brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (0 to 100%) in heptanes. Appropriate fractions were combined and concentrated in vacuo to afford tert-butyl N-[5-bromo-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridin-2-yl]carbamate (6.18 g, 52% yield) as an ivory solid.

Step 6. Tert-butyl N-[5-bromo-3-cyano-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridin-2-yl]carbamate (6.18 g, 12.7 mmol) in EtOH (60 mL) was treated with aqueous HCl (6M, 34 mL) and stirred for 70 min at 80 °C then cooled to RT and concentrated. The residue was dissolved in MeOH, made alkaline with excess Et₃N and concentrated again. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (0 to 100%) in heptanes. Appropriate fractions were combined and concentrated in vacuo to afford 2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridine-3-carbonitrile (3.70 g, 75% yield) as a dark magenta solid.


Step 7. 2-Amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridine-3-carbonitrile (3.70 g, 9.6 mmol) was stirred in concentrated sulfuric acid (18M, 25 mL) for 55 min, then the reaction mixture was quenched with crushed ice, placed in an ice bath and made alkaline to pH 8-9 with saturated NH₄OH added slowly. The resulting solid was collected by filtration on a Buchner funnel and washed with H₂O. The material was air-dried then co-evaporated twice with toluene and dried in vacuo,

then stirred in 10% MeOH/DCM and filtered on a silica plug, eluting with 10% MeOH/DCM to remove residual ammonium salts. The filtrate was concentrated then dried in vacuo, affording 2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridine-3-carboxamide (3.80 g, 98% yield) as a pink solid.


5 Step 8. To a solution of methyl magnesium chloride (3M, 18.8 mL) in THF (160 mL) in a RBF under N₂ was added a solution of zinc dichloride in THF (0.5M, 112 mL) at RT dropwise via an addition funnel. After the addition, the resulting white suspension was stirred at RT for 35 min. To the zincate solution was added 2-amino-5-bromo-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridine-3-carboxamide (4.48 g, 11.1 mmol), the flask was rinsed with 20 mL THF, and palladium (0) tetrakis(triphenylphosphine) (1.14 g, 0.987 mmol) was added. The mixture was bubbled through with N₂ then equipped with a condenser and refluxed (heat block set to 80 °C) for 24h. The reaction mixture was cooled to RT, then diluted with saturated aqueous NH₄Cl and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (0 to 100%) in heptanes then purified again by silica gel chromatography (dry load) eluting with a gradient of MeOH (1 to 15%) in DCM. Appropriate fractions from the two columns were combined and concentrated in vacuo to afford 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (2.22 g, 59% yield, 77% purity) as a light pink solid, which contained some 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-6-methyl-pyrrolo[2,3-b]pyridine-3-carboxamide side product (19% by UPLCMS).

20 Step 9. To a suspension of 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (2.22 g, 6.56 mmol, 77% purity) in DCM (25 mL) was added tribromoborane in DCM (1M, 26 mmol, 26 mL) dropwise. The reaction mixture was stirred at RT for 45 min, then concentrated to dryness. The crude product was taken in DCM and placed in an ice bath and MeOH was added carefully (exotherm). The mixture was concentrated to dryness then co-evaporated twice with MeOH. The residue was triturated with saturated aqueous NaHCO₃. The solids were collected by filtration on a Buchner funnel, washed with H₂O and air-dried. The still wet solid was dissolved in DCM/MeOH, concentrated to dryness and triturated in 20% MeOH/DCM (50 mL). The solid was collected by filtration, washed with 20% MeOH/DCM, air-dried then dried in vacuo to afford 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (1.60g, 75% yield) as a light beige solid. MS: [M+1]: 325.1. A different batch was purified by preparative HPLC to yield 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (63% yield) as an off-white fluffy solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.51 (s, 1H), 7.82 (s, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.71 (br s, 2H), 6.64 (br s, 2H), 2.26 (s, 3H), 2.23 (s, 3H), 1.74 (s, 3H), 1.65 (s, 3H). MS: [M+1]: 325.1.


35 Chiral SFC separation of **Compound 181** (1.60g, 4.93 mmol) (Instrument: Waters Prep 100 SFC-MS; Column: Phenomenex Lux Cellulose-2, 30 x 250 mm, 5 μm; Conditions: isocratic at 55% IPA + 10mM Ammonium Formate with 45% CO₂; Flow Rate: 70 mL/min) provided **Compound 182** and **Compound 183**.



Compound 182 from SFC separation of **181**. Peak 1 (retention time 3.94 min, 99.86%): (*S*)-2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (381 mg) was obtained as an off white fluffy solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.50 (s, 1H), 7.83 (s, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.72 (s, 2H), 6.65 (s, 2H), 2.26 (s, 3H), 2.24 (s, 3H), 1.74 (s, 3H), 1.65 (s, 3H). MS: [M+1]: 325.1.



Compound 183 from SFC separation of **181**. Peak 2 (retention time 4.35 min, 98.09%): (*R*)-2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (495 mg) was obtained as an off white fluffy solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.50 (s, 1H), 7.83 (s, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.72 (s, 2H), 6.66 (s, 2H), 2.26 (s, 3H), 2.24 (s, 3H), 1.74 (s, 3H), 1.65 (s, 3H). MS: [M+1]: 325.1.



Compound 181 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide (From method O)

Step 1. Sulfuric acid (140.1 mL, 2575 mmol) was added slowly to water (1.15 L) and the solution was cooled at 25 °C. 2-Amino-3-bromo-5,6-dimethylpyridine (114.8 g, 571.0 mmol) was added in one portion to get a solution. The solution was cooled to 0 °C – 5 °C with an ice-water bath to give a suspension. Under strong stirring, a solution of sodium nitrite (49.25 g, 713.7 mmol) in water (175.0 mL) was added dropwise over 90 minutes. The ice-water bath was removed, and the suspension was warmed up slowly to 11 °C and stirred for 1 hour. A solution of sodium hydroxide (175 g, 4.37 mol) in 400 mL of water was added dropwise to maintain the temperature under 20 °C. The pH of the solution was adjusted to 7 with K₂HPO₄ (~58 g, 0.33 mol) in 70 mL of water. The suspension was filtered at 10 °C. The filter cake was triturated in water (250 mL) and filtered. The filter cake was washed profusely with ice-cooled water and dried by vacuum suction. The product was oven-dried under vacuum at 60 °C overnight to get 3-bromo-5,6-dimethylpyridin-2-ol as a light yellow crystalline solid (105.69 g, 91.6%) ¹H NMR (400 MHz, DMSO-d₆) δ 11.96 (br s, 1H), 7.73 (s, 1H), 2.11 (s, 3H), 1.96 (s, 3H). MS: [M+1]: 202.0, 204.0


Step 2. To a solution of 3-bromo-5,6-dimethylpyridin-2-ol (105.3 g, 521.2 mmol) in *N,N*-dimethylformamide (316 mL) and toluene (527 mL) at 90 °C under nitrogen was added phosphorus oxybromide (1.3:1, 56.5% (w/w) in xylenes) (278 mL, 781.7 mmol) dropwise over 90 min. After the addition was complete, the mixture was stirred at 90 °C overnight. The mixture was cooled to room temperature and was slowly added to water (2 L). The flask was washed with 500 mL of water. The combined aqueous phases were extracted with MTBE (3 x 1 L). The organic phases were combined and washed with 0.5N NaOH (1 L), water (3 x 1 L) and brine (1 L) then dried with sodium sulfate and concentrated. The solid was partially dissolved in MTBE (400 mL) and heptanes (300 mL) was added. The mixture was concentrated under reduced pressure to ~1.7 volume to provide a precipitate. The mixture was filtered and rinsed with heptanes. The residue was dried to afford 2,3-dibromo-5,6-dimethylpyridine as a beige solid (114.290 g, 82.8 %). The filtrate was further concentrated and filtered to provide a second crop of solid: (8.73 g, 6.32 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.95 (s, 1H), 2.36 (s, 3H), 2.21 (s, 3H). MS: [M+1]: 264.0, 266.0, 268.0.

Step 3. A 2000 mL 4-neck round-bottomed flask was charged with **intermediate A2** (33.0 g, 218.0 mmol), degassed 1,2-dimethoxyethane (750 mL), 2,3-dibromo-5,6-dimethylpyridine (55 g, 207.6 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (10.8 g, 18.68 mmol) and cesium carbonate (169.1 g, 519.0 mmol). The reaction mixture was sonicated for 20 minutes while sparging the suspension with nitrogen. Tris(dibenzylideneacetone)dipalladium(0) (8.55 g, 9.341 mmol) was added and the suspension was heated to reflux. After 13 hours of stirring, the reaction mixture was cooled to room temperature and was filtered over a pad of silica gel. The filter cake was washed with ethyl acetate (1.2L). The filtrate was evaporated to a volume of ~200 mL and heptanes (300 mL) was added. The solvents were evaporated to provide a suspension in ~2 volumes of solvent. The suspension was filtered and washed with heptanes to provide 3-bromo-N-(3-methoxy-2,6-dimethylphenyl)-5,6-dimethylpyridin-2-amine as a light yellow solid. (56.2 g, 80.8 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.57 (s, 1H), 7.26 (s, 1H), 7.02 (d, *J* = 8.6 Hz, 1H), 6.77 (d, *J* = 8.3 Hz, 1H), 3.76 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.94 (s, 3H). MS: [M+1]: 335.2, 337.2.

Step 4. To a degassed solution of malononitrile (33.3 g, 503.5 mmol) in 1,2-dimethoxyethane (1000 mL) was added sodium tert-butoxide (46.3 g, 482.0 mmol) in 4 portions. The reaction mixture was stirred 30 minutes at room temperature to get a solution. 3-bromo-N-(3-methoxy-2,6-dimethylphenyl)-5,6-dimethylpyridin-2-amine (80 g, 238.6 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride, complex with dichloromethane (14.9 g, 18.26 mmol) were added in one portion and the suspension was heated to strong reflux. After 17 hours of stirring, the reaction mixture was transferred into a 5000 mL flask and ethyl acetate (1.5 L) was added. A solution of *N*-acetyl-L-cysteine (12.1 g, 74 mmol, 4x Pd mol content) and Na₂CO₃ (15.7 g, 148 mmol) in water (500 mL) were added. The biphasic solution was stirred for 10 minutes at 60 °C and then cooled slowly to 40 °C over 75 minutes. Inside the 5000 mL flask, the two layers were separated at 40 °C and the organic phase was washed with water (2x 250 mL) and brine (200 mL) and then filtered over a pad of silica gel (3 inches, 185 g). The filter cake was rinsed with DCM/EtOAc. The filtrate was evaporated, and the solvents were switched for EtOAc during rotavap evaporation to provide a suspension. The suspension was filtered at room temperature and the filter cake was triturated in 50 mL of ice-cooled ethyl acetate. The product was filtered and the filter cake was rinsed with 50 mL of ice-cooled ethyl acetate. The product was oven-dried under vacuum at 60 °C overnight to afford 2-amino-1-(3-methoxy-2,6-dimethylphenyl)-5,6-dimethyl-1H-pyrrolo[2,3-*b*]pyridine-3-


carbonitrile as a light yellow solid. (65.38 g, 85.5 %, 8% (w/w) DME). ^1H NMR (400 MHz, DMSO- d_6) δ 7.38 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.76 (br s, 2H), 3.84 (s, 3H), 2.26 (s, 3H), 2.23 (s, 3H), 1.78 (s, 3H), 1.69 (s, 3H). MS: $[\text{M}+1]$: 321.2.

Step 5. To methanesulfonic acid (600 mL, 9239 mmol) was added slowly a solution of sulfuric acid (93 mL) / water (7.0 mL) over 5 minutes at room temperature. 2-amino-1-(3-methoxy-2,6-dimethylphenyl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (80 g, 249.7 mmol) was added portion wise over 15 minutes to keep the reaction temperature below 40 °C. The resulting solution was stirred at room temperature for 90 minutes. DL-Methionine (149.028 g, 998.8 mmol) was added portion wise over 20 minutes below 40°C. The solution was stirred at 40°C. After 37 hours of stirring, the reaction mixture was cooled to room temperature and then added slowly over 1.5h to a solution of K_2HPO_4 (100 g) and NaOH (540 g) in water (5 L). EtOAc (1 L) was added and the biphasic mixture was stirred for 5 min to get a precipitate. The product was filtered. The mother liquors were extracted with EtOAc (3 x 1L). The organic phases were combined, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to ~ 100 mL to get a suspension. The suspension was filtered and rinse with EtOAc (50 mL). The solids were combined and triturated in water (800 mL) two times. The residue was suspended in EtOAc (500 mL), stirred for 10 minutes and filtered. The product was oven-dried under reduced pressure to get 67.8 g of crude product. The compound was suspended in DMSO (350 mL, 5 vol) and the mixture was heated to 65 °C to get a solution. The solution was cooled slowly at 28 °C with a water bath. Water (1.05 L) was added dropwise over 2 hours to get a suspension. After 5 minutes of stirring at room temperature, the product was filtered. The solid was triturated in 100 mL of water and filtered. The filter cake was washed with 2 x 100 mL of water. The product was oven dried at 60 °C under vacuum to get 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5,6-dimethyl-pyrrolo[2,3-b]pyridine-3-carboxamide as a light yellow solid. 61.5 g, (75%, 3% (w/w) EtOAc and 6% (w/w) DMSO). ^1H NMR (400 MHz, DMSO- d_6) δ 9.47 (s, 1H), 7.82 (s, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.71 (br. s, 2H), 6.64 (br. s., 2H), 2.27 (s, 3H), 2.24 (s, 3H), 1.75 (s, 3H), 1.66 (s, 3H). MS: $[\text{M}+1]$: 325.2.



Compound 184

and



Compound 190


Step 1. To a solution of **Intermediate D** (1.07 g, 2.33 mmol) in DCM (9 mL) was added BBr_3 solution in DCM (1 M, 9.3 mL, 9.3 mmol). The mixture was stirred at 0 °C for 2 h, silica was added, the mixture was concentrated, then purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 20% MeOH in DCM to provide [6-amino-7-carbamoyl-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (744 mg, 72% yield) as an off-white solid.

Step 2. A solution of [6-amino-7-carbamoyl-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (744 mg, 1.67 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (117 mg, 0.167 mmol) in a mixture of DMF (8 mL) and MeOH (8 mL) and Et_3N (1.40 mL, 10.0 mmol) was heated at 70 °C under an


atmosphere of carbon monoxide (balloon). The apparatus was previously flushed with carbon monoxide once. After 2 h, more $\text{PdCl}_2(\text{PPh}_3)_2$ (117 mg, 0.167 mmol) was added and the reaction mixture was continued for 18 h. The reaction mixture was cooled to rt, filtered through Celite, rinsing with MeOH and the filtrate was concentrated. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of 0 to 20% of MeOH in DCM to provide a dark green sticky solid. The solid was dissolved in EtOAc, passed through a silica plug using EtOAc / MeOH (5%) that provided upon evaporating the volatiles methyl 6-amino-7-carbamoyl-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2-carboxylate (418 mg, 70% yield) as a light brown sticky solid.

Step 3. A solution of methyl 6-amino-7-carbamoyl-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2-carboxylate (322 mg, 0.906 mmol) in THF (12 mL) was cooled to $-40\text{ }^\circ\text{C}$ and MeMgCl solution in THF (3 M, 4.53 mL, 13.1 mmol) was added dropwise. The mixture was left to warm to rt overnight, quenched with saturated aqueous NH_4Cl (25 mL), the pH was adjusted to 7-8 with 1N HCl and the mixture was extracted with DCM (3x). The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 20% MeOH in DCM to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-(1-hydroxy-1-methyl-ethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide **Compound 190** (103 mg, 32% yield) as a light tan solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.61 (s, 1H), 7.99 (s, 1H), 7.50 (br s, 1H), 7.42 (br s, 2H), 7.23 (br s, 1H), 7.08 (d, $J = 8.5$ Hz, 1H), 6.94 (d, $J = 8.3$ Hz, 1H), 5.95 – 5.81 (m, 1H), 5.30 – 5.17 (m, 1H), 2.19 (s, 3H), 1.78 (s, 3H), 1.70 (s, 3H). MS: $[\text{M}+1]$: 338.1, and 2-acetyl-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide **Compound 184** (31 mg, 10% yield) as a light tan solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.83 (br s, 1H), 8.38 (d, $J = 1.9$ Hz, 1H), 7.68 (br s, 2H), 7.40 (s, 2H), 7.09 (d, $J = 8.2$ Hz, 1H), 6.97 (d, $J = 8.1$ Hz, 1H), 2.68 (s, 3H), 1.77 (s, 3H), 1.69 (s, 3H). MS: $[\text{M}+1]$: 340.1.

Chiral SFC separation of **Compound 190** (39 mg, 0.110 mmol) (Instrument: Mettler Toledo Minigram SFC; Column: Phenomenex Lux Cellulose-2, 10 x 250 mm, 5 μm ; Conditions: Isocratic at 40% IPA + 10mM Ammonium Formate with 60% CO_2 ; Flow Rate: 10 mL/min) provided **Compound 191** and **Compound 192**.




Compound 191 from chiral SFC separation of **190**. Peak 1 (retention time 3.83 min, 100%): S-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-(1-hydroxy-1-methyl-ethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (10 mg) as an off-white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.61 (br s, 1H), 7.99 (s, 1H), 7.52 (br d, $J = 3.0$ Hz, 1H), 7.32 (br s, 2H), 7.18 (br d, $J = 3.1$ Hz, 1H), 7.08 (dt, $J = 8.2, 0.8$ Hz, 1H), 6.93 (d, $J = 8.3$ Hz, 1H), 5.26 (s, 1H), 1.77 (s, 3H), 1.68 (s, 3H), 1.51 (s, 6H). MS: $[\text{M}+1]$: 356.2.




Compound 192 from chiral SFC separation of **190**. Peak 2 (retention time 4.07 min): *R*-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-(1-hydroxy-1-methyl-ethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (10 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.62 (br s, 1H), 7.99 (s, 1H), 7.52 (br d, *J* = 3.2 Hz, 1H), 7.32 (br s, 2H), 7.18 (br d, *J* = 3.1 Hz, 1H), 7.08 (dt, *J* = 8.3, 0.8 Hz, 1H), 6.93 (d, *J* = 8.3 Hz, 1H), 5.26 (s, 1H), 1.77 (s, 3H), 1.68 (s, 3H), 1.51 (s, 6H). MS: [M+1]: 356.2.


Chiral SFC separation of **Compound 184** (103 mg, 0.290 mmol) (Instrument: Mettler Toledo Minigram SFC; Column: Phenomenex Lux Cellulose-2, 10 x 250 mm, 5 μm; Conditions: Isocratic at 40% IPA + 10mM Ammonium Formate with 60% CO₂; Flow Rate: 10 mL/min) provided **Compound 185** and **Compound 186**.



Compound 185 from chiral SFC separation of **184**. Peak 1 (retention time 3.87 min, 100%): *S*-2-acetyl-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (9 mg) as a yellow fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.68 (br s, 1H), 8.38 (s, 1H), 7.69 (br s, 2H), 7.41 (br s, 2H), 7.09 (dt, *J* = 8.3, 0.7 Hz, 1H), 6.95 (d, *J* = 8.3 Hz, 1H), 2.68 (s, 3H), 1.77 (d, *J* = 0.8 Hz, 3H), 1.69 (s, 3H). MS: [M+1]: 340.2.



Compound 186 from chiral SFC separation of **184**. Peak 2 (retention time 4.21 min, 99.80%): *R*-2-acetyl-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (9 mg) as a yellow fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.69 (br s, 1H), 8.38 (s, 1H), 7.69 (br s, 2H), 7.41 (br s, 2H), 7.09 (dt, *J* = 8.2, 0.7 Hz, 1H), 6.95 (d, *J* = 8.3 Hz, 1H), 2.68 (s, 3H), 1.77 (d, *J* = 0.7 Hz, 3H), 1.69 (s, 3H). MS: [M+1]: 340.1.



Compound 198 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)cyclopropyl]pyrrolo[2,3-b]pyrazine-7-carboxamide)

5 Step 1. A microwave vial was loaded with **Intermediate D** (500 mg, 1.09 mmol), 4,4,6-trimethyl-2-[1-(trifluoromethyl)vinyl]-1,3,2-dioxaborinane (502 mg, 2.26 mmol), dioxane (5 mL) and aqueous Na₂CO₃ (2 M, 1.63 mL, 3.26 mmol), flushed with nitrogen (house vac then nitrogen, 3x). PdCl₂(dppf).CH₂Cl₂ (444 mg, 0.544 mmol) added, the vial was flushed again, capped and transferred to a preheated (80 °C) heat block and stirred overnight. After cooling to rt, the reaction mixture was filtered on Celite, washed with
10 water and DCM and diluted with brine. The layers were separated (phase separator). The aqueous layer was extracted with DCM (2x). The combined organic extracts were concentrated and purified by silica gel chromatography eluting with a gradient of 0 to 50% EtOAc in DCM affording 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)vinyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (169 mg, 38% yield) as a dark yellow gum.

15 Step 2. To a solution of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)vinyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (42.0 mg, 0.104 mmol) in DCM (2 mL) at 0 °C was added diazomethane solution in Et₂O (0.5 M, 400 µL) then warmed to rt. Another portion of diazomethane solution (0.5 M, 400 µL) was added. After reaction was deemed complete by UPLCMS, the reaction mixture was quenched with AcOH (200 µL), stirred for a few minutes and concentrated to
20 dryness, then taken in saturated aqueous NaHCO₃ and DCM. The layers were separated (phase separator). The aqueous layer was extracted with DCM (3 x). The combined organic extracts were concentrated then dried in vacuo, affording 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[5-(trifluoromethyl)-3,4-dihydropyrazol-5-yl]pyrrolo[2,3-b]pyrazine-7-carboxamide (48 mg, quantitative yield) as a yellow gum.


25 Step 3. 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[5-(trifluoromethyl)-3,4-dihydropyrazol-5-yl]pyrrolo[2,3-b]pyrazine-7-carboxamide (48.0 mg, 0.107 mmol) was dissolved in xylenes (3 mL) and heated to 130 °C with a reflux condenser open to air for a total of 75 min. The reaction mixture was concentrated then purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in heptane, then a gradient of 0 to 20% MeOH in EtOAc to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)cyclopropyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (35 mg, 81% yield) as a
30 light yellow solid.

Step 4. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)cyclopropyl]pyrrolo[2,3-b]pyrazine-7-carboxamide (17 mg, 50% yield) as a white fluffy
35 solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.62 (s, 1H), 7.88 (s, 1H), 7.49 (br s, 2H), 7.36 (br s, 1H), 7.28 (br s, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 1.76 (s, 3H), 1.69 (s, 3H), 1.46 – 1.29 (m, 4H).

^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) δ -66.85. MS: $[\text{M}+1]$: 406.1.


Chiral SFC separation of **Compound 198** (14.5 mg, 0.358 mmol) (Instrument: Mettler Toledo Minigram SFC; Column: Phenomenex Lux Cellulose-2, 10 x 250 mm, 5 μm ; Conditions: Isocratic at 40% ACN/EtOH 1:1 with 60% CO_2 ; Flow Rate: 10 mL/min) provided **Compound 199** and **Compound 200**.

5




Compound 199 from chiral SFC separation of **198**. Peak 1 (retention time 3.50 min, 99.99%): *S*-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)cyclopropyl]pyrrolo[2,3-*b*]pyrazine-7-carboxamide (5 mg) as a white fluffy solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 9.61 (s, 1H), 7.88 (s, 1H), 7.48 (br s, 2H), 7.36 (br s, 1H), 7.27 (br s, 1H), 7.08 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 1.76 (s, 3H), 1.68 (s, 3H), 1.43 – 1.33 (m, 4H). MS: $[\text{M}+1]$: 406.2.

10



Compound 200 from chiral SFC separation of **198**. Peak 2 ((retention time 3.81 min, 99.95%): *R*-6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-[1-(trifluoromethyl)cyclopropyl]pyrrolo[2,3-*b*]pyrazine-7-carboxamide (5 mg) as a white fluffy solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 9.61 (s, 1H), 7.87 (s, 1H), 7.48 (br s, 2H), 7.36 (br s, 1H), 7.27 (br s, 1H), 7.08 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 1.76 (s, 3H), 1.69 (s, 3H), 1.43 – 1.35 (m, 4H). MS: $[\text{M}+1]$: 406.2.

15



20

Compound 209 (5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-*b*]pyrazine-7-carboxamide)


Step 1. To a solution of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-*b*]pyrazine-7-carbonitrile (298 mg, 0.927 mmol) in THF (7 mL) was added tert-butyl nitrite (550 μL , 4.63 mmol). After stirring 30 min, the mixture was refluxed for 3.5 h then cooled down to rt and concentrated to dryness and purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes. The combined pure fractions were concentrated and dried in vacuo to provide 5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-*b*]pyrazine-7-carbonitrile (150 mg, 53% yield) as a light yellow solid.

25

Step 2. For nitrile hydrolysis using sulfuric acid, the same procedure used for **Compound 164** was done on the appropriate intermediate (150 mg, 0.490 mmol) to provide 5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (144 mg, 91% yield) was obtained as an off-white solid.

5 Step 3. For OMe deprotection using BBr_3 , the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-dimethyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (76 mg, 55% yield) as an off-white fluffy solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.65 (br s, 1H), 8.13 (s, 1H), 7.86 (br s, 1H), 7.60 (br s, 1H), 7.05 (d, $J = 8.2$ Hz, 1H), 6.92 (d, $J = 8.3$ Hz, 1H), 2.64 (s, 3H), 1.75 (s, 3H), 1.64 (s, 3H). 1 Me singlet likely buried under

10 dmso peak. MS: $[\text{M}+1]$: 311.1.



Compound 212 (2-amino-1-(5-hydroxy-2-methyl-phenyl)-6-(trifluoromethyl)pyrrolo[3,2-b]pyridine-3-carboxamide)

15 Step 1. To a suspension of NaH (108 mg, 2.83 mmol, 60% dispersion in mineral oil) in DME (3 mL) was added dropwise 3-bromo-2-chloro-5-(trifluoromethyl)pyridine (300 mg, 1.15 mmol) in DME (3 mL). After the addition, the mixture was stirred for 25 min then propanedinitrile (188 mg, 2.85 mmol) was added. The resulting mixture was refluxed for 18 h, cooled to rt and concentrated under vacuum. The residue was purified by preparative HPLC to provide 2-[3-bromo-5-(trifluoromethyl)-2-

20 pyridyl]propanedinitrile (100 mg, 30% yield).


Step 2. To a solution of 2-[3-bromo-5-(trifluoromethyl)-2-pyridyl]propanedinitrile (50 mg, 172 μmol) in DMF (2 mL) were added Pd_2dba_3 (16 mg, 17 μmol), 5-(methoxymethoxy)-2-methyl-aniline (33.3 mg, 199 μmol), Cs_2CO_3 (84 mg, 259 μmol) and Xantphos (10.0 mg, 17.3 μmol). The mixture was degassed in vacuo and back filled with nitrogen (3 times). The mixture was stirred at 130 $^\circ\text{C}$ for 8 h,

25 cooled to rt, diluted with water and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 5 to 100% EtOAc in hexanes to provide 2-amino-1-[5-(methoxymethoxy)-2-methyl-phenyl]-6-(trifluoromethyl)pyrrolo[3,2-b]pyridine-3-carbonitrile (30 mg, 46% yield).

30 Step 3. 2-amino-1-[5-(methoxymethoxy)-2-methyl-phenyl]-6-(trifluoromethyl)pyrrolo[3,2-b]pyridine-3-carbonitrile (30 mg, 135 μmol) was stirred in H_2SO_4 (1 mL). After 90 min, the reaction mixture was poured into crushed ice, placed in an ice bath and neutralized with 1:1 $\text{NH}_4\text{OH}/\text{H}_2\text{O}$. The precipitate was filtered, washed with water and air-dried overnight. Purification by preparative HPLC provided 2-amino-1-(5-hydroxy-2-methyl-phenyl)-6-(trifluoromethyl)pyrrolo[3,2-b]pyridine-3-carboxamide

35 (3.2 mg, 11% yield) as an orange solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.76 (s, 1H), 8.45 (s, 1H), 7.77

(s, 1H), 7.34 (s, 2H), 7.31 – 7.13 (m, 2H), 6.98 (s, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.71 (s, 1H), 1.78 (s, 3H).
MS: [M+1]: 351.3.



5 **Compound 214** (6-amino-3-(2-cyclopropylethynyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide)


Step 1. A solution of 6-amino-2-benzyloxy-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carbonitrile (400 mg, 836 μ mol, described in the preparation of
10 **compound 31**) in conc. H_2SO_4 (2 mL) and DCM (2 mL) was stirred 10 min. NaOH 0.4 M was added then water and the resulting precipitate was recovered by filtration. The crude product was purified by silica gel chromatography using a gradient of 0 to 20% MeOH in DCM to afford 6-amino-3-bromo-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (300 mg, 88% yield)

Step 2. To a solution of 6-amino-3-bromo-2-hydroxy-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (300 mg, 739 μ mol) and Cs_2CO_3 (440 mg, 1.35 mmol) in
15 DMF (3 mL) was added 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (288 mg, 807 μ mol). The mixture was stirred for 1 h, diluted with water, extracted with EtOAc twice. The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc in hexanes to afford 6-amino-3-bromo-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl
20 trifluoromethanesulfonate (460 mg, 43% yield).

Step 3. A microwave vial charged with [6-amino-3-bromo-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (35 mg, 65 μ mol), ethynylcyclopropane (5.0 mg, 75 μ mol), CuI (1.3 mg, 7 μ mol) and $\text{PdCl}_2(\text{PPh}_3)_2$ (5.0 mg, 7 μ mol) in DMF (1 mL) was flushed with nitrogen, then Et_3N (520 μ mol, 73 μ L) was added and the mixture was stirred for
25 1 h. The mixture was filtered and purified by preparative HPLC to provide [6-amino-7-carbamoyl-3-(2-cyclopropylethynyl)-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl] trifluoromethanesulfonate (10 mg, 29% yield).

Step 4. A mixture of tributyl(thiazol-2-yl)stannane (38.5 μ mol, 12.1 μ L), [6-amino-7-carbamoyl-3-(2-cyclopropylethynyl)-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazin-2-yl]
30 trifluoromethanesulfonate (10.0 mg, 19.1 μ mol), CuI (0.5 mg, 2.5 μ mol), LiCl (1.7 mg, 40 μ mol), $\text{PdCl}_2(\text{dppf}) \cdot \text{CH}_2\text{Cl}_2$ (1.5 mg, 2 μ mol) in DMF (3 mL) was degassed in vacuo, then back filled with nitrogen. The reaction mixture was stirred at 120°C for 3 h. Water was added, and the resulting precipitate was recovered by filtration to afford crude 6-amino-3-(2-cyclopropylethynyl)-5-(3-methoxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (5 mg, 57% yield).



Step 5. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-3-(2-cyclopropylethynyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)-2-thiazol-2-yl-pyrrolo[2,3-b]pyrazine-7-carboxamide (1.1 mg, 23% yield). ¹H NMR (400 MHz, Methanol-d₄) δ 9.16 (d, J = 4.2 Hz, 1H), 8.47 (d, J = 4.2 Hz, 2H), 7.89 (d, J = 1.1 Hz, 1H), 7.15 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 2.55 – 2.47 (m, 1H), 1.88 (d, J = 21.7 Hz, 6H), 1.37 – 1.31 (m, 2H), 1.11 – 1.05 (m, 2H). MS: [M+1]: 445.3.



Compound 215 (2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-3-carboxamide)

Step 1. A microwave vial charged with 4-prop-2-ynylmorpholine (26 mg, 204 μmol), copper (I) iodide (3.5 mg, 19 μmol), and triethylamine (1.49 mmol, 207 μL) was flushed with N₂, then 6-amino-3-bromo-7-carbamoyl-5-(3-methoxy-2,6-dimethylphenyl)-5H-pyrrolo[2,3-b]pyrazine-2-yl trifluoromethanesulfonate (100 mg, 186 μmol) in DMF (1 mL) was added followed by PdCl₂(PPh₃)₂ (14 mg, 19 μmol). The vial was capped heated to 120°C. After 1h, concentrated under vacuum then adsorbed on silica (4g) using THF. Purified by silica gel chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes, then 0 to 20% MeOH in EtOAc to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-bis(3-morpholinoprop-1-ynyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (16mg, 15% yield)


Step 2. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-3-carboxamide (7 mg, 45% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 9.63 (s, 1H), 7.70 (s, 2H), 7.35 – 7.13 (m, 2H), 7.05 (d, J = 8.3 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 3.62 – 3.51 (m, 11H), 3.49 (s, 2H), 2.52 (q, J = 4.3, 3.9 Hz, 4H), 1.74 (s, 3H), 1.66 (s, 3H). MS: [M+1]: 544.5.



Compound 219 and Compound 220

Step 1. A mixture of **Intermediate D** (150 mg, 327 μ mol), $\text{Zn}(\text{CN})_2$ (38.3 mg, 327 μ mol) and Zn powder (4 mg, 65 μ mol) in NMP (3 mL) was degassed. $\text{Pd}(\text{PPh}_3)_4$ (38 mg, 33 μ mol) was added, and the mixture was stirred at 120°C for 24 h, cooled to rt, quenched with saturated aqueous NH_4Cl , and extracted with EtOAc (3x). The combined extracts were washed with brine, dried over Na_2SO_4 , and concentrated. The residue was purified by preparative HPLC to provide 6-amino-2-cyano-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (50 mg, 46% yield).

Step 2. For OMe deprotection using BBr_3 , the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-2-cyano-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide **compound 219** (2.6 mg, 9% yield) ^1H NMR (400 MHz, DMSO-*d*6) δ 9.64 (s, 1H), 8.28 (s, 1H), 7.88 (s, 2H), 7.38 (s, 1H), 7.05 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.3 Hz, 1H), 1.73 (s, 3H), 1.65 (s, 3H), MS: $[\text{M}+1]$: 324.2; and 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2,7-dicarboxamide **compound 220** (10 mg, 33% yield). ^1H NMR (400 MHz, DMSO-*d*6) δ 9.57 (s, 1H), 8.67 (s, 1H), 8.35 (s, 1H), 7.64 (s, 3H), 7.41 (s, 1H), 7.13 (s, 1H), 7.11 – 6.97 (m, 1H), 6.91 (d, J = 8.3 Hz, 1H), 1.73 (s, 3H), 1.65 (s, 3H). MS: $[\text{M}+1]$: 341.4.




Compound 221 (2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-3-carboxamide)

Step 1. To the solution of 3-methoxy-2,6-dimethyl-aniline (2.02 g, 13.4 mmol) in toluene (15 mL) were added potassium tert-butoxide (1.64 g, 14.6 mmol), 3-bromo-2-chloro-5-(trifluoromethyl)pyridine (3.16 g, 12.1 mmol). Pd_2dba_3 (582 mg, 635 μ mol) and Xantphos (723 mg, 1.26 mmol). The mixture was degassed in vacuo and back filled with nitrogen. The resulting mixture was stirred at 120 °C for 2 h. The reaction mixture was cooled to rt, diluted with EtOAc, washed with water, brine, dried over Na_2SO_4 , filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography eluting with a gradient of 0 to 70% EtOAc in hexanes to provide 3-bromo-N-(3-methoxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyridin-2-amine (1.55 g, 34% yield).

Step 2. To a solution of propanedinitrile (556 mg, 8.41 mmol) in DME (20 mL) was added NaH (361 mg, 8.34 mmol, 60% dispersion in mineral oil). The mixture was stirred for 5 min then 3-bromo-N-(3-methoxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyridin-2-amine (1.55 g, 4.13 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (231 mg, 200 μ mol) were added. The resulting mixture was stirred at 120 °C for 17 h in a pressure vial. DME was removed under reduced pressure, then the mixture was diluted with EtOAc, washed with water, brine, dried over Na_2SO_4 , filtered and concentrated to dryness. The residue was purified by flash chromatography eluting with a gradient of 0 to 100% EtOAc in hexanes to provide 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile (44 mg, 3% yield).


Step 3. For nitrile hydrolysis using sulfuric acid, the same procedure used for **Compound 164** was done on the appropriate intermediate (44 mg, 0.121 mmol) to provide 2-amino-1-(3-methoxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-3-carboxamide (40 mg, 87% yield).

Step 4. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 2-amino-1-(3-hydroxy-2,6-dimethyl-phenyl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-3-carboxamide (25 mg, 59% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.66 (s, 1H), 8.47 (dt, *J* = 2.0, 1.0 Hz, 1H), 7.77 (s, 1H), 7.31 (s, 2H), 7.23 (s, 1H), 7.10 (dt, *J* = 8.3, 0.8 Hz, 1H), 7.00 – 6.80 (m, 2H), 1.82 – 1.57 (m, 6H). MS: [M+1]: 365.3.



Compound 242 (6-amino-3-[2-(4,4-difluoro-1-hydroxy-cyclohexyl)ethynyl]-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

To a microwave vial charged with **Intermediate H** (20.0 mg, 53.2 μmol), CuI (1.0 mg, 5.3 μmol), 1-ethynyl-4,4-difluoro-cyclohexanol (43 mg, 266 μmol) in DMF (1 mL) was added PdCl₂(PPh₃)₂ (4 mg, 6 μmol) and Et₃N (425 μmol, 60 uL). The vial was capped and heated to 80 °C for 3 h. After cooling to rt, the mixture was filtered and purified by preparative HPLC to provide 6-amino-3-[2-(4,4-difluoro-1-hydroxy-cyclohexyl)ethynyl]-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (5.1 mg, 21% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 8.21 (s, 1H), 7.57 (d, *J* = 10.6 Hz, 2H), 7.28 (s, 2H), 7.05 (d, *J* = 8.3 Hz, 1H), 6.92 (d, *J* = 8.3 Hz, 1H), 5.77 (s, 1H), 2.11 – 1.74 (m, 8H), 1.73 (s, 3H), 1.65 (s, 3H). MS: [M+1]: 456.4.




Compound 243 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-N2-(3-pyridyl)pyrrolo[2,3-b]pyrazine-2,7-dicarboxamide)

Step 1. A mixture of **Intermediate D** (1.00 g, 2.18 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (319 mg, 435 μmol) in a mixture of DMF (5 mL), MeOH (5 mL) and Et_3N (1.90 mL, 13.6 mmol) was heated at 70°C under an atmosphere of carbon monoxide (balloon) for 18 h. The apparatus was previously flushed with carbon monoxide once. The volatiles were evaporated in vacuo and the residue was purified by preparative HPLC to provide methyl 6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2-carboxylate (689 mg, 86% yield).

Step 2. To methyl 6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2-carboxylate (689 mg, 1.87 mmol) in THF (5 mL) was added NaOH (1 M, 5.60 mL) and the mixture was stirred for 1.5 h. The pH was acidified using conc. HCl, DMSO was added, volatiles were removed under reduced pressure and the residue was purified by preparative HPLC to provide 6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2-carboxylic acid (366 mg, 55% yield).


Step 3. To pyridin-3-amine (7.95 mg, 84.4 μmol), 6-amino-7-carbamoyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-2-carboxylic acid (25 mg, 70 μmol) and HATU (29 mg, 77 μmol) in DCM (5 mL) was added DIPEA (211 μmol , 37 μL). The reaction mixture was stirred for 18 h. Water was added to the mixture, the organic phase was separated, dried over Na_2SO_4 , filtered and concentrated in vacuo to afford crude 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-N2-(3-pyridyl)pyrrolo[2,3-b]pyrazine-2,7-dicarboxamide (21 mg, 34% yield, 49% purity).

Step 4. For OMe deprotection using BBr_3 , the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-N2-(3-pyridyl)pyrrolo[2,3-b]pyrazine-2,7-dicarboxamide (3.5 mg, 12% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.82 (s, 1H), 9.61 (s, 1H), 8.92 (d, $J = 2.5$ Hz, 1H), 8.49 (s, 1H), 8.32 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.20 – 8.10 (m, 1H), 7.75 (d, $J = 9.0$ Hz, 3H), 7.40 (dd, $J = 8.3, 4.7$ Hz, 1H), 7.30 (s, 1H), 7.07 (d, $J = 8.3$ Hz, 1H), 6.93 (d, $J = 8.3$ Hz, 1H), 1.75 (s, 3H), 1.67 (s, 3H). MS: $[\text{M}+1]$: 418.3.



Compound 257 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-vinyl-pyrrolo[2,3-b]pyrazine-7-carboxamide)


Step 1. A mixture of tributyl(vinyl)stannane (37.1 mg, 117 μmol), **Intermediate H** (40.0 mg, 106 μmol), CuI (2.56 mg, 13.4 μmol), LiCl (9.30 mg, 220 μmol), $\text{PdCl}_2(\text{dppf}) \cdot \text{CH}_2\text{Cl}_2$ (8.1 mg, 10 μmol) in DMF (1 mL) was degassed in vacuo, then back filled with nitrogen. The final mixture was stirred at 130 °C for 3 h, cooled to rt, filtered and purified preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-3-vinyl-pyrrolo[2,3-b]pyrazine-7-carboxamide (1.4 mg, 4% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.59 (s, 1H), 8.29 (s, 1H), 8.19 (s, 1H), 7.38 (d, $J = 24.4$ Hz, 2H), 7.20 (s, 1H), 7.05 (d, $J = 8.3$ Hz, 1H), 6.91 (d, $J = 8.3$ Hz, 1H), 6.69 (dd, $J = 17.3, 10.8$ Hz, 1H), 5.80 (dd, $J = 17.3, 1.8$ Hz, 1H), 5.15 (dd, $J = 10.7, 1.8$ Hz, 1H), 1.75 (s, 3H), 1.67 (s, 3H). MS: $[\text{M}+1]$: 324.3.



Compound 260 (6-amino-2-(cyclopropoxy)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. A solution of cyclopropanol (12 mg, 202 μ mol), **Intermediate D** (31 mg, 67 μ mol) and Cs₂CO₃ (66 mg, 202 μ mol) in NMP (1 mL) was stirred at 140 °C for 16 h. The mixture was cooled to rt, filtered and purified by preparative HPLC to provide 6-amino-2-(cyclopropoxy)-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (3 mg, 12% yield)

Step 2. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-2-(cyclopropoxy)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (0.52 mg, 18% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.57 (s, 1H), 8.45 (s, 1H), 7.35 (s, 1H), 7.19 (d, *J* = 19.0 Hz, 3H), 7.02 (d, *J* = 8.3 Hz, 1H), 6.88 (d, *J* = 8.3 Hz, 1H), 4.25 – 4.14 (m, 1H), 1.73 (s, 3H), 1.65 (s, 3H), 0.73 (t, *J* = 5.0 Hz, 2H), 0.68 (s, 2H). MS: [M+1]: 354.4.



Compound 263 (6-amino-2-(difluoromethyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)


Step 1. A microwave flask was charged with PdCl₂(PPh₃)₂ (79.6 mg, 109 μ mol), **Intermediate D** (1.00 g, 2.18 mmol) and sodium formate (222 mg, 3.27 mmol). The flask was flushed with carbon monoxide. DMF (5 mL) was added and a slow stream of carbon monoxide was passed into the suspension. The mixture was vigorously stirred at 100 °C for 2 h under an atmosphere of carbon monoxide. The resulting mixture was cooled to rt, filtered and the supernatant was purified by preparative HPLC to provide a crude mixture of 6-amino-2-formyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (556 mg, 75% yield).

Step 2. To a solution of 6-amino-2-formyl-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (180 mg, 530 μ mol) in DCM (2 mL) at 0 °C was added Deoxo-Fluor® solution (50% in THF, 1.46 M, 2.00 mL) dropwise. The mixture was warmed to rt. After 2 h, extra Deoxo-Fluor® solution (50% in THF, 1.17 g, 2.65 mmol) was added. After 1h more Deoxo-Fluor® solution (50% in THF, 2.35 g, 5.30 mmol) was added and the final mixture was stirred for 4h then diluted with DCM and

saturated aqueous Na₂CO₃ was added. The biphasic mixture was stirred for 1 h. The organic layer was separated, dried over Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to provide 6-amino-2-(difluoromethyl)-5-(3-methoxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (10 mg, 5% yield).

5 Step 3. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-2-(difluoromethyl)-5-(3-hydroxy-2,6-dimethyl-phenyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (3.0 mg, 31% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.66 (s, 1H), 8.29 (s, 1H), 8.00 (s, 1H), 7.65 (s, 2H), 7.30 (d, *J* = 34.1 Hz, 2H), 7.11 – 6.98 (m, 2H), 6.99 – 6.69 (m, 1H), 1.73 (s, 3H), 1.65 (s, 3H). MS: [M+1]: 348.2.

10



Compound 266 (6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-bis(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide)

Step 1. To a suspension of magnesium turnings (380 mg, 15.7 mmol) in Et₂O (20 mL) was added iodine (33 mg, 130 μmol). The mixture was stirred for 10 min and then CD₃I (975 μL, 15.7 mmol) was added. The mixture was stirred 18 h under nitrogen atmosphere to generate an off-white suspension. ZnCl₂ (0.5 M in THF, 1.4 mL) was added dropwise and the mixture was stirred for 20 min. **Intermediate D** (1.2 g, 2.61 mmol) and Pd(PPh₃)₄ (300 mg, 259 μmol) were added. The mixture was stirred at 70 °C for 72 h under nitrogen atmosphere. The reaction was quenched with aqueous HCl 1M, diluted with water, and extracted with EtOAc twice. The combined organic extracts were washed with water, brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 80% EtOAc in hexanes to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (400 mg, 46% yield).

25 Step 2. To a solution of 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (400 mg, 1.22 mmol) in DMF (2 mL) was added NBS (259 mg, 1.46 mmol). The mixture was stirred for 10 min, diluted with water, stirred for 20 min and filtered. The precipitate was purified by preparative HPLC to provide 6-amino-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)-2-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (400 mg, 81% yield).

30 Step 3. To a suspension of magnesium (177 mg, 7.3 mmol) in ether (10 mL) was added iodine (16 mg, 61 μmol). The mixture was stirred for 10 min and then to it was added CD₃I (455 μL, 7.31 mmol). The mixture was stirred for 18 h under nitrogen atmosphere to yield an off-white suspension. ZnCl₂ (0.5 M in THF, 14.6 mL) was added dropwise. After the addition, the mixture was stirred for 20 min. 6-amino-3-bromo-5-(3-methoxy-2,6-dimethyl-phenyl)-2-(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (496 mg, 1.22 mmol), Pd₂dba₃ (111 mg, 122 μmol), and tritert-butylphosphonium tetrafluoroborate (71 mg, 244 μmol) were added and the mixture was stirred at 70 °C for 18 h under nitrogen atmosphere. The reaction was quenched with aqueous HCl 1M, diluted with water and extracted with EtOAc twice. The combined

35

organic extracts were washed with water, brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 60% EtOAc in hexanes to provide 6-amino-5-(3-methoxy-2,6-dimethyl-phenyl)-2,3-bis(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (400 mg, 95% yield).

- 5 Step 4. For OMe deprotection using BBr₃, the same procedure used for **Compound 35** provided a residue which was purified by preparative HPLC to provide 6-amino-5-(3-hydroxy-2,6-dimethyl-phenyl)-2,3-bis(trideuteriomethyl)pyrrolo[2,3-b]pyrazine-7-carboxamide (65 mg, 17% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.55 (s, 1H), 7.41 (s, 1H), 7.22 – 6.98 (m, 4H), 6.89 (d, *J* = 8.3 Hz, 1H), 1.74 – 1.69 (m, 3H), 1.63 (s, 3H). MS: [M+1]: 332.2.

10

Examples of arylamines preparation

A variety of arylamines were used to prepare compounds of the present invention. Some of these arylamines were commercially available and some were prepared. Table 3 list some examples of such arylamines for which the preparation is described herein.

15


Table 3

Arylamine A1 	Arylamine A2 	Arylamine A3 	Arylamine A4
Arylamine A5 	Arylamine A6 	Arylamine A7 	Arylamine A8
Arylamine A9 	Arylamine A10 	Arylamine A11 	

Preparation of arylamine A1

- 20 Compounds of the present invention can be prepared from arylamine **A1** which can be prepared as shown in Scheme A1 and described herein. The commercially available 4-methyl-3-nitrophenol can be O-protected with a suitable protecting group such as O-MOM. The nitro can be reduced to generate arylamine **A1**.

Scheme A1




Step 1. To a suspension of 4-methyl-3-nitro-phenol (25 g, 163 mmol) in DCM (250 mL) was added DIPEA (34 mL, 195 mmol) followed by chloro(methoxy)methane (26.0 g, 323 mmol, 24.5 mL) added dropwise. After stirring 18 h, the reaction mixture was washed with water. The layers were separated. The organic layer was washed with 0.2N HCl (2x), brine, dried over MgSO_4 , filtered and concentrated, then dried in vacuo affording 4-(methoxymethoxy)-1-methyl-2-nitro-benzene (31.4 g, 98% yield) as a dark red oil.

Step 2. To a suspension of 4-(methoxymethoxy)-1-methyl-2-nitro-benzene (31.4 g, 159 mmol) in EtOH (200 mL) and water (75 mL) was added ammonium chloride (43.3 g, 809 mmol) then iron powder (44.5 g, 796 mmol). The reaction mixture was heated to 80 °C for 3.5 h, then temperature was increased to 90 °C, stirring for 4 days. The reaction mixture was cooled to rt, filtered and rinsed with EtOAc. The filtrate was concentrated and diluted with EtOAc and saturated aqueous NaHCO_3 . The layers were separated, and the aqueous layer was back extracted with EtOAc (2x). The combined organic extracts were washed with brine, dried over MgSO_4 , filtered and concentrated, affording 26.3 g crude product as a dark brown oil which was purified on a silica gel pad, eluting with 20-30% EtOAc in hexanes. The pure fractions were combined, concentrated, then dried in vacuo, affording 5-(methoxymethoxy)-2-methylaniline (25.4 g, 95% yield) as a purple oil. ^1H NMR (400 MHz, Chloroform- d) δ 6.94 (dd, J = 8.0, 1.7 Hz, 1H), 6.45 – 6.30 (m, 2H), 5.12 (s, 2H), 3.47 (s, 3H), 2.10 (s, 3H). MS: $[\text{M}+1]$: 168.3.

Preparation of arylamine **A2**

Compounds of the present invention can be prepared from arylamine **A2** which can be prepared as shown in Scheme A2 and described herein (adapted from Can J Chem 2012, 90, 75-84). Commercially available 1,3-dimethyl-2-nitrobenzene can be brominated under suitable bromination conditions. The resulting bromo can be converted to a methoxy upon treatment with sodium methoxide and copper(I) bromide. The nitro can be reduced to generate arylamine **A2**.

Scheme A2



Step 1. A 3 necked 3L round-bottom flask was equipped with a mechanical stirrer, reflux condenser and addition funnel and loaded with 1,3-dimethyl-2-nitro-benzene (300 g, 1.98 mol), DCM (900 mL), iron powder (28.0 g, 501 mmol) and iron(III) bromide (11.9 g, 40.3 mmol). Bromine (112 mL, 2.19 mol) was added dropwise via an addition funnel over 45-60 min. Internal monitoring of the temperature showed an exotherm to 30 °C. 90 min after the addition of bromine was complete, more bromine (5 mL,


97.6 mmol) was added and the reaction mixture was stirred for another 45 min to complete conversion. The reaction mixture was diluted with ice water (1.5 L) and Et₂O (1.5 L). The layers were separated. The aqueous layer was back extracted with Et₂O (0.5 L). The combined organic layers were washed with aqueous 20% Na₂S₂O₃ (1 L), brine (500 mL), dried over Na₂SO₄, filtered over a silica gel pad (300 cc), concentrated then dried in vacuo to provide 1-bromo-2,4-dimethyl-3-nitro-benzene (451.5 g, 99% yield) as an off-white solid.

Step 2. A 5L 4 neck round bottom flask equipped with a mechanical stirrer and a reflux condenser was charged with 1-bromo-2,4-dimethyl-3-nitro-benzene (451.5 g, 1.96 mol) in DMF (1.6 L). CuBr (28.0 g, 195 mmol) was added followed by MeONa (1.31 L, 5.89 mol, 25% in MeOH). The reaction mixture was slowly heated to 95°C, achieving a mild reflux. After 6h, the reaction mixture was left to cool to rt overnight. The reaction mixture was diluted with Et₂O and saturated aqueous NH₄Cl (1.5L each). The layers were separated, and the aqueous layer was back extracted with Et₂O (750 mL). The combined organic extracts were washed with brine (750 mL), dried over Na₂SO₄ and filtered over a silica pad, rinsed with Et₂O and concentrated, dried in vacuo to provide 1-methoxy-2,4-dimethyl-3-nitro-benzene (352 g, 99% yield) as an ochre solid.

Step 3. To a solution of 1-methoxy-2,4-dimethyl-3-nitro-benzene (115 g, 635 mmol) in EtOH (1.5 L) in a 3 neck 3 L flask equipped with a mechanical stirrer was added iron powder (213 g, 3.81 mol), then a solution of ammonium chloride (204 g, 3.81 mol) in water (500 mL) was added portion wise. The mixture was heated to 85 °C for 8h. The mixture was cooled down to rt and filtered on Celite. The volume of the filtrate was reduced (most of the EtOH was evaporated) and the resulting mixture was diluted with Et₂O (800 mL) and water (150 mL). The layers were separated, and the aqueous layer was back extracted with Et₂O (500 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, concentrated and dried in vacuo to provide 3-methoxy-2,6-dimethyl-aniline (89.1 g, 93% yield) as a brown oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.88 (dq, J = 8.3, 0.7 Hz, 1H), 6.31 (d, J = 8.2 Hz, 1H), 3.79 (s, 3H), 3.61 (br s, 2H), 2.14 (d, J = 0.7 Hz, 3H), 2.07 (s, 3H). MS: [M+1]: 152.3.

Preparation of arylamine **A3**

Compounds of the present invention can be prepared from arylamine **A3** which can be prepared as shown in Scheme A3 and described herein. The methoxy of 1-methoxy-2,4-dimethyl-3-nitro-benzene described in the preparation of **Intermediate A2** can be cleaved using BBr₃ and the resulting phenol can be O-protected with a suitable protecting group such as O-MOM. The nitro can be reduced to generate arylamine **A3**.



Step 1. To a solution of 1-methoxy-2,4-dimethyl-3-nitro-benzene (20 g, 110 mmol) in DCM (200 mL), cooled in a dry ice/acetonitrile bath, was added BBr₃ solution in DCM (1 M, 168 mL) dropwise via an addition funnel. The mixture was left to slowly warm to rt overnight. The reaction mixture was then poured

slowly in a stirred mixture of ice, water (1 L) and KH_2PO_4 (75g). The layers were separated, and the aqueous layer was extracted with DCM (2 x 500 mL). The combined organic extracts were washed with brine (500 mL), dried over MgSO_4 , filtered over a silica pad (375g), eluting with DCM, concentrated and dried in vacuo to provide 2,4-dimethyl-3-nitro-phenol (18.0 g, 98% yield) as a yellow solid.


Step 2. To a suspension of 2,4-dimethyl-3-nitro-phenol (18.96 g, 113 mmol) in DCM (200 mL) was added DIPEA (23.7 mL, 136 mmol) then chloro(methoxy)methane (9.5 mL, 125 mmol) dropwise. After stirring for 3.5 h, more chloro(methoxy)methane (2.0 mL, 26 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was quenched with aqueous saturated NH_4Cl (100 mL) and diluted with water (100 mL). The layers were separated, and the aqueous layer was back extracted with DCM (100 mL). The combined organic extracts were washed with 0.2N HCl (2 x 100 mL), 1M NaOH (100 mL), brine (100 mL), dried over MgSO_4 , filtered on silica (ca 100 cc), eluting with DCM, concentrated, and dried in vacuo to provide 1-(methoxymethoxy)-2,4-dimethyl-3-nitro-benzene (22.1 g, 92% yield) as a pale yellow waxy solid.

Step 3. To a flask containing palladium on carbon (5.06 g, 4.76 mmol, 10% w/w) under nitrogen was added MeOH (300 mL) followed by 1-(methoxymethoxy)-2,4-dimethyl-3-nitro-benzene (20.1 g, 95.1 mmol). The flask was flushed with hydrogen and stirred under a hydrogen atmosphere for 2 days. The reaction mixture was flushed with nitrogen for 2 h, and Celite was added. The mixture was filtered on a Celite pad using MeOH and DCM. The filtrate was concentrated and dried in vacuo to provide 3-(methoxymethoxy)-2,6-dimethyl-aniline (17.1 g, 99% yield) as a pale orange turbid oil. ^1H NMR (400 MHz, Chloroform- d) δ 6.86 (d, J = 8.3 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 5.15 (s, 2H), 3.48 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H). MS: $[\text{M}+1]$: 182.2.

Preparation of arylamine **A4**

Compounds of the present invention can be prepared from arylamine **A4** which can be prepared as shown in Scheme A4 and described herein. Commercially available 2-chloro-3-methoxy-benzoic acid can be brominated with a suitable bromination reagent and the carboxylic acid can be converted to a NHBoc under Curtius conditions. The bromo can be converted to a methyl and the NHBoc can be cleaved under acidic conditions to generate arylamine **A4**.

30



Step 1. To a solution of 2-chloro-3-methoxy-benzoic acid (50 g, 268 mmol) in AcOH (250 mL) and water (250 mL) was added bromine (27.5 mL, 537 mmol) dropwise. The mixture was stirred at 60 °C for 18 h, cooled to rt, brine was added, and the mixture was extracted twice with DCM. The combined organic extracts were dried over Na_2SO_4 , filtered and concentrated in vacuo to provide 6-bromo-2-chloro-3-methoxy-benzoic acid (71 g, quantitative yield) as a brown oil which solidified upon standing under vacuum over the weekend.


Step 2. To a solution of 6-bromo-2-chloro-3-methoxy-benzoic acid (23.6 g, 88.9 mmol). Et₃N (38 mL, 271 mmol) and tert-butanol (42.5 mL, 450 mmol) in toluene (500 mL) was added [azido(phenoxy)phosphoryl]oxybenzene (29.5 mL, 136 mmol). The mixture was heated at 100 °C for 16 h, cooled down to rt then the volatiles were removed in vacuo. The residue was diluted with EtOAc (100 mL), and the organic layer was washed with 5% citric acid, water, saturated aqueous NaHCO₃, brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 20% EtOAc in hexanes to provide tert-butyl N-(6-bromo-2-chloro-3-methoxy-phenyl)carbamate (16.2 g, 54% yield) as a yellowish solid.

Step 3. To a solution of tert-butyl N-(6-bromo-2-chloro-3-methoxy-phenyl)carbamate (25 g, 74.3 mmol) in dioxane (500 mL) was added trimethylboroxine (50% w/w in THF, 20.51 g, 81.7 mmol). PdCl₂(dppf).CH₂Cl₂ (5.22 g, 7.43 mmol) and aqueous Na₂CO₃ (2 M, 111 mL, 223 mmol). The mixture was heated at 100 °C for 16 h, cooled down to rt then volatiles were removed in vacuo. EtOAc and water were added. The organic layer was separated and washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 30% EtOAc in heptane to provide tert-butyl N-(2-chloro-3-methoxy-6-methyl-phenyl)carbamate (13.8 g, 68% yield) as a yellowish solid.

Step 4. HCl in dioxane (4 M, 100 mL) was added to a solution of tert-butyl N-(2-chloro-3-methoxy-6-methyl-phenyl)carbamate (13.8 g, 50.8 mmol) in MeOH (100 mL). After 3 h, the volatiles were evaporated to dryness under vacuum to provide a white solid to which was added under vigorous stirring 250 mL of EtOAc and 250 mL of aqueous saturated NaHCO₃. The organic layer was separated. The aqueous layer was back extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 30% EtOAc in heptane to provide 2-chloro-3-methoxy-6-methyl-aniline (7.9 g, 91% yield) as a clear oil which solidified upon standing. ¹H NMR (400 MHz, Chloroform-d) δ 6.95 – 6.79 (m, 1H), 6.27 (dd, J = 8.3, 1.5 Hz, 1H), 4.06 (br s, 2H), 3.83 (d, J = 1.6 Hz, 3H), 2.12 (d, J = 0.8 Hz, 3H). MS: [M+1]: 172.2.

Preparation of arylamine **A5**

Compounds of the present invention can be prepared from arylamine **A5** which can be prepared as shown in Scheme A5 and described herein. Commercially available 3-methoxy-2-methyl-aniline can be chlorinated with a chlorination reagent to generate arylamine **A5**.



Step 1. NCS (98 g, 734 mmol) was added in 4 portions (15 minutes between each addition) to a solution of 3-methoxy-2-methyl-aniline (100 g, 729 mmol) in DCM (500 mL) at 0 °C. 30 min after the last addition, 100 g of silica gel was added, the mixture was evaporated under vacuum and the black residue was purified by silica gel chromatography (dry load) in eluting with a gradient of 0 to 10% EtOAc in


hexanes to provide 6-chloro-3-methoxy-2-methyl-aniline (55.6 g, 44% yield) as an orange solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.08 (d, J = 8.8 Hz, 1H), 6.28 (d, J = 8.8 Hz, 1H), 4.02 (br s, 2H), 3.78 (s, 3H), 2.07 (s, 3H). MS: [M+1]: 172.3.

5 Preparation of arylamine A6

Compounds of the present invention can be prepared from arylamine A6 which can be prepared as shown in Scheme A6 and described herein. Commercially available 3-amino-2,4-dichloro-phenol can be O-protected with a suitable protecting group such as O-PMB to generate arylamine A6.

10

Scheme A6



15

To a suspension of 3-amino-2,4-dichloro-phenol.HCl salt (20 g, 93.3 mmol) in DMF (150 mL) was added 1-(chloromethyl)-4-methoxy-benzene (14.0 mL, 103 mmol), tetrabutylammonium iodide (1 g, 3.00 mmol) and Cs₂CO₃ (64.0 g, 196 mmol). The mixture was stirred at 40 °C overnight, then it was diluted with water, stirred for 20 min, and filtered. The precipitate was washed with water and dried in vacuo. The resulting crude product was purified by silica gel chromatography eluting with a gradient of 0 to 100% DCM in hexanes to provide 2,6-dichloro-3-[(4-methoxyphenyl)methoxy]aniline (20 g, 72% yield) as an off-white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.30 (m, 2H), 7.05 (d, J = 8.9 Hz, 1H), 6.92 – 6.77 (m, 2H), 6.32 (s, 1H), 5.01 (s, 2H), 4.46 (s, 2H), 3.79 (s, 3H). MS: [M+1]: 298.0.

20

Preparation of arylamine A7.


25

Compounds of the present invention can be prepared from key **Intermediate A7, A8 or A9** which can be prepared as shown in Scheme A7 and described herein (adapted from J. AM. CHEM. SOC. 2004, 126, 1150-1160). The commercially available 3-methoxyaniline can be N-protected with a suitable protecting group such as NH-PIV. A directed ortho metalation approach can be used to introduce a suitable R¹ such as CH₃ or CD₃. The NH-PIV protecting group can be cleaved under acidic conditions and the remaining ortho-to-nitrogen can be brominated with a suitable bromination reagent such as NBS. At this point, the bromine can be substituted by a boronate ester under metal-mediated conditions and further derivatized by a suitable R² such as CH₃ or CD₃ to generate key **Intermediate A7, A8 or A9**.

30

Alternatively, the bromoaniline can be N-protected with a suitable protecting group such as NH-Boc prior to the bromo substitution. In this case, the NH-Boc can be cleaved under acidic conditions to generate key **Intermediate A7, A8 or A9**.

Scheme A7



5 Arylamine A7

Step 1. 2,2-dimethylpropanoyl chloride (51 mL, 416 mmol) was slowly added to a solution of 3-methoxyaniline (50 g, 406 mmol, 45.5 mL), pyridine (66 mL, 816 mmol) and DMAP (500 mg, 4.1 mmol) in DCM (500 mL). After 1 h, aqueous 1 N HCl was added and the layers were separated. The aqueous layer was back extracted with CH_2Cl_2 . The organic layers were combined, washed with aqueous 1 N HCl, brine, then dried over Na_2SO_4 , filtered and evaporated to dryness to provide N-(3-methoxyphenyl)-2,2-dimethyl-propanamide (84 g, quantitative yield).

Step 2. To a solution of N-(3-methoxyphenyl)-2,2-dimethyl-propanamide (82 g, 396 mmol) in THF (820 mL) at 0 °C was added nBuLi (2.5 M, 325 mL, 813 mmol) dropwise. After 2 h at 0 °C, the solution was cooled to -78 °C and CD_3I (27 mL, 434 mmol) was added dropwise. The mixture was stirred for 16 h at rt. The mixture was poured into aqueous 1 N HCl and extracted with EtOAc twice. The combined organic layers were dried over Na_2SO_4 , filtered and concentrated to dryness to provide N-[3-methoxy-2-(trideuteriomethyl)phenyl]-2,2-dimethylpropanamide (82 g, 92% yield) as a white solid.

Step 3. N-[3-methoxy-2-(trideuteriomethyl)phenyl]-2,2-dimethyl-propanamide (81.5 g, 363 mmol) in dioxane (300 mL) and HCl conc (12 M, 300 mL) was heated to reflux for 24 h. The dark mixture was cooled to 0 °C in an ice bath, neutralized with aqueous 2N NaOH, extracted with EtOAc twice. The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated to dryness to provide a dark residue that was purified by silica gel chromatography eluting with a gradient of 0 to 50% EtOAc in heptane to provide 3-methoxy-2-(trideuteriomethyl)aniline (36 g, 71% yield) as a clear oil.

Step 4. To a solution of 3-methoxy-2-(trideuteriomethyl)aniline (35 g, 250 mmol) in DCM (500 mL) at 0 °C was added NBS (45 g, 253 mmol). The mixture was stirred at 0 °C for 3 h and concentrated to approximately 75 mL and filtered. The filtrate was evaporated to dryness and the residue

was purified by silica gel chromatography eluting with a gradient of 0% to 50% EtOAc in heptane to provide 6-bromo-3-methoxy-2-(trideuteriomethyl)aniline (35 g, 64% yield).

Step 5. tert-butoxycarbonyl tert-butyl carbonate (87.2 g, 400 mmol) was added to a solution of 6-bromo-3-methoxy-2-(trideuteriomethyl)aniline (35 g, 160 mmol), DMAP (3.90 g, 32 mmol) and DIPEA (415 mmol, 72.3 mL) in THF (500 mL). The mixture was heated to reflux for 18 h. The volatiles were removed under vacuum and the residue was filtered through silica gel eluting with 50% EtOAc in heptane to provide a mixture of tert-butyl N-[6-bromo-3-methoxy-2-(trideuteriomethyl)phenyl]carbamate and tert-butyl N-[6-bromo-3-methoxy-2-(trideuteriomethyl)phenyl]-N-tert-butoxycarbonyl-carbamate (64 g) as a clear oil that was dissolved in methanol (500 mL). K₂CO₃ (110 g, 796 mmol) was added and the mixture was stirred at 60 °C for 48 h. The volatiles were removed under vacuum. EtOAc and water were added to the residue. The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 40% EtOAc to provide tert-butyl N-[6-bromo-3-methoxy-2-trideuteriomethyl]phenyl]carbamate (50 g, quantitative yield) as a clear oil.

Step 6. To a solution of tert-butyl N-[6-bromo-3-methoxy-2-(trideuteriomethyl)phenyl]carbamate (33 g, 103 mmol) in dioxane (700 mL) were added Bis(pinacolato)diboron (51 g, 201 mmol), KOAc (35.5 g, 362 mmol) and PdCl₂(dppf).CH₂Cl₂ (7.6 g, 10.4 mmol). The mixture was degassed in vacuo, back filled with nitrogen and stirred at reflux for 18 h. The mixture was cooled to rt and concentrated to a smaller volume. The black residue was diluted with EtOAc and filtered through a silica gel pad (250 g) eluting with 2L of 50% EtOAc in heptane. The filtrate was evaporated, and the residue was purified by silica gel chromatography eluting with a gradient of 0 to 20% EtOAc in heptane to provide tert-butyl N-[3-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trideuteriomethyl)phenyl]carbamate (22.5 g, 59% yield), which solidified upon standing under vacuum.

Step 7. To a solution of PdCl₂(dppf).CH₂Cl₂ (5.3 g, 7.24 mmol) in DMF (500 mL) was quickly added consecutively CD₃I (60.6 g, 418 mmol, 26 mL), tert-butyl N-[3-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trideuteriomethyl)phenyl]carbamate (52 g, 142 mmol) and aqueous potassium phosphate tribasic (2 M, 350 mL). Nitrogen was bubbled in the solution for 2 min, then the mixture was stirred at 80 °C for 30 min under a nitrogen atmosphere then cooled to rt, and EtOAc was added. The organic layer was washed with water, brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 20% EtOAc in heptane to provide tert-butyl N-[3-methoxy-2,6-bis(trideuteriomethyl)phenyl]carbamate (15 g, 41% yield) as a thick clear oil.

Step 8. HCl in dioxane (4 M, 100 mL) was added to a solution of tert-butyl N-[3-methoxy-2,6-bis(trideuteriomethyl)phenyl]carbamate (22.5 g, 87.4 mmol) in MeOH (100 mL). After 3 h the volatiles were removed under vacuum to provide a white solid. EtOAc and water were added followed by a saturated NaHCO₃ aqueous solution until basic pH. The organic layer was washed with brine, dried over Na₂SO₄, filtered and evaporated to dryness. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 40% EtOAc in heptane to provide 3-methoxy-2,6-bis(trideuteriomethyl)aniline (7.5 g, 55% yield) as a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.96 (dd, J = 8.3, 2.6 Hz, 1H), 6.38 (dd, J = 8.3, 2.5 Hz, 1H), 3.86 (d, J = 2.4 Hz, 3H), 3.64 (s, 2H). MS: [M+1]: 158.3.

Alternative route used for preparation arylamine A8 (without Boc)


Step 1. In a sealed tube, 6-bromo-3-methoxy-2-methylaniline (3.4 g, 15.7 mmol), Bis(pinacolato)diboron (5.58 g, 21.98 mmol) and Cs_2CO_3 (15.4 g, 47.1 mmol) was taken in anhydrous 1,4-dioxane (68 mL) and nitrogen gas was purged into the reaction mixture for 15 min. Then, $\text{PdCl}_2(\text{dppf})$ (1.92 g, 2.36 mmol) was added into the reaction mixture and heated at 100 °C for 2 h. After completion, the reaction mixture was quenched with ice water and extracted using EtOAc (3 x 100 mL). The combined organic layer was dried over Na_2SO_4 , filtered and concentrated to give the crude product which was purified by silica gel chromatography eluting with a gradient of 10 to 12% EtOAc in hexanes) to provide 3-methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.50 g, 60% yield).

Step 2. In a sealed tube, 3-methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.5 g, 9.39 mmol), iodomethane- d_3 (4.08 g, 28.19 mmol) and potassium phosphate tribasic (9.95 g, 46.9 mmol) was taken in anhydrous DMF (50 mL) and nitrogen gas was purged into the reaction mixture for 15 min. Then, $\text{PdCl}_2(\text{dppf})$ (0.766 g, 0.939 mmol) was added and the reaction mixture was heated at 80 °C for 2h. After completion, the reaction mixture was quenched using ice water and extracted using EtOAc (3 x 50 mL). The combined organic layer was dried over Na_2SO_4 , filtered and concentrated to give the crude product which was purified by silica gel chromatography eluting with a gradient of 6 to 8 % EtOAc in hexanes) to get pure 3-methoxy-2-methyl-6-(methyl- d_3) aniline as colorless liquid (0.75 g, 51% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 6.68 (d, J = 7.2 Hz, 1H), 6.31 (d, J = 7.4 Hz, 1H), 4.63 (s, 2H), 3.55 (s, 3H), 1.94 (s, 3H). MS: $[\text{M}+1]$: 155.3.

Preparation of Arylamine A10

Compounds of the present invention can be prepared from key **Intermediate A10** which can be prepared as shown in Scheme A8 and described herein. The commercially available 3-methoxy-2-nitrobenzoic acid can be brominated. The acid can then be esterified, the bromo converted to a methyl and the nitro reduced to the amino. The resulting amino can be converted to a bromo under Sandmeyer conditions and the ester may then be saponified. The resulting acid can then be converted to the NHBoc under Curtius conditions. In this case, the NH-Boc can be cleaved under acidic conditions to generate key **Intermediate A10**.

Scheme A8



Step 1. To 3-methoxy-2-nitro-benzoic acid (10.04 g, 50.93 mmol) and Ag_2SO_4 (8.10 g, 26.0 mmol) in the dark was added conc. sulfuric acid (200 mL) and molecular bromine (9.4 g, 58.6 mmol, 3.0 mL) dropwise. The mixture was stirred in the dark for 3.5h, then quenched by adding crushed ice, cooled in an ice bath and stirred. The solids were collected by filtration, washed with H_2O and air-dried. The resulting solid was taken in acetone (300 mL), filtered, residue (silver salts) washed with acetone. The filtrate was dried over MgSO_4 , filtered and concentrated, affording 6-bromo-3-methoxy-2-nitro-benzoic acid (14.64 g, 100% yield) as a purple solid.

Step 2. To a solution of 6-bromo-3-methoxy-2-nitro-benzoic acid (14.64 g, 53.0 mmol) in DMF (140 mL) was added anhydrous potassium carbonate (14.66 g, 106.1 mmol) followed by methyl iodide (11.4 g, 80.3 mmol, 5.0 mL). After stirring the reaction mixture for 2h, H_2O was added dropwise (420 mL). The solid was collected by filtration and washed with H_2O , air-dried then dried in vacuo, affording methyl 6-bromo-3-methoxy-2-nitro-benzoate (12.89 g, 84% yield) as a light beige solid.

Step 3. In a pressure vessel, a solution of methyl 6-bromo-3-methoxy-2-nitro-benzoate (6.0 g, 20.7 mmol) in dioxane (100 mL) and aqueous Na_2CO_3 solution (2 M, 31 mL, 62.3 mmol) was bubbled through with N_2 then $\text{Pd}(\text{dppf})\text{Cl}_2$ (1.64 g, 2.01 mmol) and trimethylboroxine (6.74 g, 26.8 mmol, 7.5 mL) were added. The solution was bubbled through with N_2 . The vessel was capped stirred at 100 °C overnight. The reaction mixture was cooled to rt, poured in H_2O and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered over a silica plug and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of EtOAc (0 to 100%) in Hep. Appropriate fractions were combined and concentrated in vacuo to afford methyl 3-methoxy-6-methyl-2-nitro-benzoate (3.06 g, 66% yield) as a light beige waxy solid.

Step 4. To a solution of methyl 3-methoxy-6-methyl-2-nitro-benzoate (3.06 g, 13.6 mmol) in MeOH (225 mL) was added palladium on carbon (10% w/w, 1.42 g, 1.33 mmol) slurried in some of the MeOH. The mixture was flushed with H_2 and stirred under a hydrogen atmosphere for 2h. The suspension was filtered through Celite and the filtrate was concentrated then dried in vacuo, affording methyl 2-amino-3-methoxy-6-methyl-benzoate (2.56 g, 97% yield) as a light amber oil.

Step 5. To a solution of methyl 2-amino-3-methoxy-6-methyl-benzoate (2.13 g, 10.9 mmol) in DMF (12 mL) and MeCN (18 mL) was added tert-butyl nitrite (2.0 mL, 17 mmol) followed by copper (II) bromide (2.86 g, 12.8 mmol). The reaction mixture was stirred at 55 °C for 9 min, then cooled to RT, diluted with H₂O and extracted with EtOAc (3x). The combined organic extracts washed with saturated aqueous NH₄Cl, brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography (dry-load) eluting with a gradient of EtOAc (0 to 70%) in Hep. Appropriate fractions were combined and concentrated in vacuo to afford methyl 2-bromo-3-methoxy-6-methyl-benzoate (1.52 g, 54% yield) as a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.15 – 7.05 (m, 1H), 6.84 (d, J = 8.4 Hz, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 2.26 (d, J = 0.7 Hz, 3H).

Step 6. To a solution of methyl 2-bromo-3-methoxy-6-methyl-benzoate (1.52 g, 5.87 mmol) in MeOH (15 mL) and THF (15 mL) was added NaOH aqueous (4 M, 15 mL, 60.0 mmol) and hydrogen peroxide solution 30% (1.5 mL). The reaction mixture was stirred at 70 °C overnight, then at 90 °C for 4 days. The reaction mixture was cooled to RT and the volatiles were removed in vacuo. The residue was diluted with 3N HCl (20 mL) and extracted with CHCl₃/iPrOH (4:1, 4x). The combined organic extracts were concentrated then dried in vacuo and the crude product was purified by silica gel chromatography (dry load) eluting with a gradient of MeOH (0 to 10%) in CH₂Cl₂ with 1% AcOH modifier. Appropriate fractions were combined and concentrated in vacuo to afford 2-bromo-3-methoxy-6-methyl-benzoic acid (896 mg, 62% yield) as a white solid.


Step 7. To a solution of 2-bromo-3-methoxy-6-methyl-benzoic acid (1.15 g, 4.68 mmol), triethylamine (1.42 g, 14.1 mmol, 2.0 mL), and tert-butanol (1.73 g, 23.4 mmol, 2.25 mL) in toluene (8 mL) was added DPPA (1.93 g, 7.01 mmol, 1.52 mL) and the mixture was heated to reflux for 1h and cooled to rt. The volatiles were removed in vacuo. The residue was diluted with aq. citric acid 15% and extracted with EtOAc (3x). The combined organic layers were washed with aqueous 1N NaOH, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude product was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (0 to 30%) in Hep. Appropriate fractions were combined and concentrated in vacuo to afford tert-butyl N-(2-bromo-3-methoxy-6-methyl-phenyl)carbamate (1.34 g, 91% yield) as a colorless oil.

Step 8. To a solution of tert-butyl N-(2-bromo-3-methoxy-6-methyl-phenyl)carbamate (1.34 g, 4.24 mmol) in MeOH (10 mL) was added HCl in dioxane (4 M, 10.5 mL, 42.0 mmol). The reaction mixture was stirred at RT for 75 min. The solution was evaporated to dryness in vacuo then suspended in saturated aqueous NaHCO₃ and extracted with DCM (3 x, phase separator). The combined organic extracts were concentrated and the crude product was purified by silica gel chromatography eluting with a gradient of EtOAc (0 to 50%) in Hep. Appropriate fractions were combined and concentrated in vacuo to afford 2-bromo-3-methoxy-6-methyl-aniline (807 mg, 88% yield) as an off-white waxy solid. MS: [M+1]: 218.0.

Preparation of Arylamine **A11**

Compounds of the present invention can be prepared from key **Intermediate A11** which can be prepared as shown in Scheme A9 and described herein. The commercially available 6-bromo-3-methoxy-2-methylbenzoic acid can be converted to the N-Boc under Curtius rearrangement conditions. The NH-Boc can be cleaved under acidic conditions to generate key **Intermediate A11**.

Scheme A9



Step 1. To a solution of 6-bromo-3-methoxy-2-methylbenzoic acid (1 g, 4.08 mmol), triethylamine (1.23 g, 12.2 mmol, 1.70 mL), and *tert*-butanol (1.55 g, 20.9 mmol) in toluene (7 mL) was added [azido(phenoxy)phosphoryl]oxybenzene (1.72 g, 6.25 mmol, 1.35 mL). The mixture was heated to reflux for 5h and cooled to rt. The volatiles were removed in vacuo. The residue was diluted with aq. citric acid 15% and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (0 to 30%) in Hep. Appropriate fractions were combined and concentrated in vacuo to afford *tert*-butyl N-(6-bromo-3-methoxy-2-methyl-phenyl)carbamate (1.41 g, quantitative yield) as a colorless oil, which was not pure but used as is in the next step.

Step 2. To a solution of *tert*-butyl N-(6-bromo-3-methoxy-2-methyl-phenyl)carbamate (1.41 g, 4.46 mmol) in MeOH (22 mL) was added HCl in dioxane (4 M, 22 mL). The reaction mixture was stirred at RT for 80 min. The solution was evaporated to dryness in vacuo, then suspended in saturated aqueous NaHCO₃ and extracted with DCM (3 x). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography (dry load) eluting with a gradient of EtOAc (0 to 50%) in Hep. Appropriate fractions were combined and concentrated in vacuo to afford 6-bromo-3-methoxy-2-methyl-aniline (586 mg, 61% yield) as a white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.23 (dd, *J* = 8.8, 0.6 Hz, 1H), 6.26 (d, *J* = 8.8 Hz, 1H), 4.06 (br s, 2H), 3.78 (s, 3H), 2.09 (t, *J* = 0.5 Hz, 3H). MS: [*M*+1]: 218.0.

Chiral separation of selected compounds

Racemic mixtures of atropisomers were separated using chiral SFC methods on a Mettler Toledo Minigram SFC (MTM), a Waters Prep 15 SFC-MS (WP15) or a Waters Prep 100 SFC-MS (WP100) (Table 3). An appropriate column was selected to achieve a satisfactory resolution of the peaks. The appropriate fractions for each peak were combined, concentrated and usually taken in a mixture of water and a suitable water miscible organic solvent such as EtOH, IPA, CH₃CN or a mixture thereof and freeze-dried. The separated products were reanalyzed by chiral SFC to assess chiral purity.

C1A is Phenomenex Lux Cellulose-2, 10 x 250 mm, 5 μm; C1B is Phenomenex Lux Cellulose-2, 30 x 250 mm, 5 μm; C2 is Chiral Technologies IA, 10 x 250 mm, 5 μm; C3 is Chiral Technologies IC, 10 x 250 mm, 5 μm; C4 is Chiral Technologies ID, 10 x 250 mm, 5 μm; C5 is Chiral Technologies IG, 10 x 250 mm, 5 μm; C6 is Chiral Technologies AS, 10 x 250 mm, 5 μm; C7 is Phenomenex Lux Cellulose-4, 10 x 250 mm, 5 μm.

Structural assignments of the separated atropisomers were confirmed by biological activity where the biologically active enantiomer was assigned to have the (*S*) configuration, which was confirmed by X-ray crystallography of key compounds.

Table 3

Mixture Cmpd #	Peak 1 Cmpd #	Peak 2 Cmpd #	Instrument	Column	Eluent (% , Flow Rate (mL/min))
28	29	30	WP15	C4	IPA + 10mM Ammonium Formate (40%,10)
38	39	40	MTM	C2	IPA + 10mM Ammonium Formate (40%,10)
43	44	45	MTM	C4	IPA + 10mM Ammonium Formate (40%,10)
46	47	48	MTM	C1A	1:1 ACN/EtOH + 0.1% Formic Acid (55%,10)
49	50	51	MTM	C4	MeOH + 10 mM Ammonium Formate (25%,10)
54	55	56	MTM	C1A	MeOH + 10 mM Ammonium Formate (55%,10)
61	62	63	MTM	C4	IPA + 10mM Ammonium Formate (40%,10)
69	70	71	MTM	C4	MeOH (20%,10)
83	84	82	MTM	C1A	1:1 ACN/EtOH (55%,10)
97	98	99	MTM	C5	IPA (30%,10)
104	105	106	MTM	C1A	MeOH + 10 mM Ammonium Formate (35%,10)
110	111	112	WP15	C1A	MeOH (55%,10)
113	114	115	MTM	C3	MeOH (20%,10)
116	117	118	WP100	C1B	1:1 ACN/EtOH (50%,70)
119	120	121	WP100	C1B	1:1 ACN/EtOH (45%,70)
125	126	127	WP100	C1B	1:1 ACN/EtOH (50%,70)
132	133	134	WP100	C1B	1:1 ACN/EtOH (45%,70)
135	136	137	MTM	C1A	1:1 ACN/EtOH (45%,10)
138	139	140	MTM	C1A	1:1 ACN/EtOH (40%,10)
141	142	nd	WP100	C1B	1:1 ACN/EtOH (50%,70)
143	144	145	MTM	C5	IPA (30%,10)
147	148	149	MTM	C1A	1:1 ACN/EtOH (55%,10)
164	165	166	WP100	C1B	1:1 ACN/EtOH (55%,70)
170	171	172	MTM	C3	MeOH (45%,10)
173	174	175	MTM	C1A	1:1 ACN/EtOH (55%,10)
285	176	177	MTM	C1A	IPA (50%,10)
178	179	180	MTM	C1A	ACN/EtOH (45%,10)
181	182	183	WP-100	C1B	IPA + 10mM Ammonium Formate (55%,70)
184	185	186	MTM	C1A	IPA + 10mM Ammonium Formate (40%,10)
187	188	189	MTM	C1A	IPA + 10mM Ammonium Formate (40%,10)
190	191	192	MTM	C1A	IPA + 10mM Ammonium Formate (40%,10)
193	194	195	MTM	C5	1:1 ACN/EtOH + 0.1% Formic Acid (30%,10)
201	203	205	WP100	C1B	ACN/EtOH (45%, 70)
286	196	197	MTM	C1A	IPA (50%,10)
198	199	200	MTM	C1A	1:1 ACN/EtOH (40%,10)
266	264	265	WP100	C1B	ACN/EtOH (55%,70)
271	272	273	MTM	C1A	IPA + 10mM Ammonium Formate (45%,10)
275	274	276	MTM	C1A	IPA + 10mM Ammonium Formate (50%,10)

Mixture Cmpd #	Peak 1 Cmpd #	Peak 2 Cmpd #	Instrument	Column	Eluent (% , Flow Rate (mL/min))
Int. D	Int. D1	Int. D2	WP100	C1B	MeOH (25%,70)
270	288	269	MTM	C1A	IPA + 10mM Ammonium Formate (55%,10)
267	287	268	MTM	C1A	IPA + 10mM Ammonium Formate (55%,10)
289	290	291	MTM	C3	MeOH + 10mM Ammonium Formate (30%,10)
292	293	294	WP15	C7	MeOH + 10mM Ammonium Formate (55%,10)
295	296	297	MTM	C1A	MeOH (55%, 10)
298	299	300	MTM	C1A	MeOH (55%, 10)
301	302	303	MTM	C1A	MeOH (35%, 10)
304	305	306	MTM	C1A	1:1 ACN/EtOH (55%,10)
308	309	310	WP15	C1A	MeOH (55%, 10)
313	314	315	MTM	C1A	1:1 ACN/EtOH (40%,10)
316	317	318	MTM	C1A	1:1 ACN/EtOH (40%,10)
319	320	321	MTM	C1A	1:1 ACN/EtOH (50%,10)
131	322	323	MTM	C1A	1:1 ACN/EtOH (35%,10)
324	325	326	MTM	C1A	1:1 ACN/EtOH (45%,10)

Example 2. Enzymatic assay

Detection of Myt1 kinase activity utilized a recombinant human Myt1 kinase assay measuring the hydrolysis of ATP using a commercially available ADP-Glo Assay (ADP-Glo™ Kinase Assay from Promega, 10 000 assays, #V9102). Briefly, 5 μ L recombinant human Myt1 (full length PKMYT1 recombinant human protein expressed in insect cells from Thermo Fisher #A33387; ~80% purity) was prepared in reaction buffer (70 mM HEPES, 3 mM MgCl₂, 3 mM MnCl₂, 50 μ g/ml PEG 20000, 3 μ M Na-orthovanadate, 1.2 mM DTT) and added to 384 well white polystyrene, flat bottom well, non-treated, microplate (Corning #3572). After this, 5 μ L of compounds (diluted in reaction buffer to 0.5% DMSO) was added to the microplate and the plate was spun briefly and incubated at 22 °C for 15 minutes. Ultra-Pure Adenosine Triphosphate (ATP) solution (ADP-Glo kit from Promega) was diluted in reaction buffer and 5 μ L was added to the microplate, spun down briefly and incubated for 60 minutes at 30 °C. The final Myt1 enzyme concentration was 18 nM and the final ATP concentration was 10 μ M. After the 60-minute incubation, 15 μ L of ADP-Glo reagent was added and the plate was spun briefly and sealed and incubated in the dark for 40 minutes at 22 °C. Following this, 30 μ L of kinase detection reagent was added per well and the plate was spun briefly, sealed and incubated for 45-60 minutes at 22 °C in the dark. Luminescence was read using the Envision (250 ms integration). The IC₅₀ and the % max inhibition were calculated for each inhibitor compound tested.

Exemplary prepared compounds and their activities were shown in Table 4 below.

Table 4

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
1	A	50	m/z 412.4
2	A	231	m/z 395.5

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
3	A	462	m/z 391.5
4	C	922	m/z 317.2
5	C	277	m/z 349.4
6	C	1240	m/z 349.2
7	C	605	m/z 445.2
8	C	164	m/z 375.4
9	C	363	m/z 403.2
10	C	187	m/z 403.4
11	C	252	m/z 349.2
12	C	988	m/z 363.2
13	C	190	m/z 487.5
14	C	480	m/z 384.2
15	C	1090	m/z 411.9
16	C	9630	m/z 505.6
17	C	9060	m/z 379.2
18	C	1940	m/z 410.4
19	C	527	m/z 383.2
20	C	182	m/z 417.2
21	C	283	m/z 417.2
22	C	79	m/z 375.4
23	C	2470	m/z 361.2
24	C	29	m/z 366.2
25	C	399	m/z 378.2
26	C	2000	m/z 464.4
27	C	604	m/z 365.3
28	A	<10	m/z 381.2
29	A	<10	m/z 381.2
30	A	1830	m/z 381.2
31	J	<10	m/z 395.2
32	A	<10	m/z 409.4
33	L	<10	m/z 460.2
34	A	<10	m/z 375.4
35	A	<10	m/z 443.4
36	A	14	m/z 443.4
37	A	<10	m/z 381.2
38	A	<10	m/z 376.2
39	A	> 5000	m/z 376.2
40	A	<10	m/z 376.2
41	A	<10	m/z 381.2

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
42	A	<10	m/z 401.4
43	A	<10	m/z 411.2
44	A	3020	m/z 411.2
45	A	<10	m/z 411.2
46	A	<10	m/z 437.4
47	A	<10	m/z 437.4
48	A	> 5000	m/z 437.4
49	A	<10	m/z 409.7
50	A	<10	m/z 409.7
51	A	87	m/z 409.7
52	A	10	m/z 411.2
53	A	16	m/z 396.2
54	A	<10	m/z 383.2
55	A	<10	m/z 383.2
56	A	549	m/z 383.2
57	A	<10	m/z 376.2
58	A	<10	m/z 449.2
59	A	12	m/z 397.4
60	A	10	m/z 365.3
61	A	<10	m/z 389.2
62	A	> 5000	m/z 389.2
63	A	<10	m/z 389.2
64	A	<10	m/z 393.2
65	A	<10	m/z 364.2
66	A	10	m/z 396.2
67	A	14	m/z 382.2
68	A	10	m/z 416.2
69	A	<10	m/z 398.4
70	A	2920	m/z 398.4
71	A	<10	m/z 399.3
72	A	11	m/z 378.2
73	A	10	m/z 396.2
74	A	14	m/z 466.5
75	A	11	m/z 431.5
76	A	<10	m/z 378.2
77	A	<10	m/z 363.2
78	A	18	m/z 437.4
79	A	<10	m/z 437.4
80	A	<10	m/z 452.5

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
81	A	<10	m/z 381.2
82	A	> 5000	m/z 380.2
83	A	<10	m/z 380.2
84	A	<10	m/z 380.2
85	A	<10	m/z 367.2
86	A	<10	m/z 378.2
87	A	<10	m/z 424.5
88	A	<10	m/z 369.2
89	A	<10	m/z 369.2
90	A	2800	m/z 369.2
91	A	<10	m/z 369.2
92	A	<10	m/z 409.2
93	A (from int D2)	<10	m/z 409.2
94	A	<10	m/z 338.2
95	A (from int D2)	<10	m/z 338.2
96	A	10	m/z 354.2
97	M	12	m/z 375.2
98	M	> 5000	m/z 375.2
99	M	<10	m/z 375.2
100	J	<10	m/z 352.2
101	J	<10	m/z 367.2
102	J	13	m/z 392.2
104	A	<10	m/z 358.5
105	A	3060	m/z 358.5
106	A	<10	m/z 358.5
107	A	12	m/z 373.8
110	J	Nd	m/z 355.2
111	J	<10	m/z 355.2
112	J	1380	m/z 355.2
113	A	<10	m/z 344.2
114	A	4680	m/z 344.2
115	A	<10	m/z 344.2
116	D	<10	m/z 337.2
117	D	<10	m/z 337.3
118	D	611	m/z 337.3
119	D	<10	m/z 311.2
120	D	<10	m/z 311.2
121	D	1020	m/z 311.2
125	D	16	m/z 325.2

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
126	D	<10	m/z 325.2
127	D	271	m/z 325.2
131	D	<10	m/z 355.2
132	D or K	<10	m/z 331.2
133	D or K	<10	m/z 331.2
134	D or K	653	m/z 331.2
135	D	<10	m/z 314.2
136	D	<10	m/z 314.2
137	D	476	m/z 314.2
138	D	<10	m/z 339.2
139	D	<10	m/z 339.2
140	D	526	m/z 339.2
141	D	<10	m/z 375.2
142	D	<10	m/z 375.2
143	O	<10	m/z 322.2
144	O	<10	m/z 322.2
145	O	> 2000	m/z 322.2
146	E	1420	m/z 284.2
147	E	55	m/z 299.3
148	E	32	m/z 299.3
149	E	> 5000	m/z 299.3
150	B	1350	m/z 360.2
151	B	2750	m/z 390.2
152	E	84	m/z 312.1
153	B	3550	m/z 391.2
154	B	6350	m/z 413.2
155	B	1020	m/z 350.2
156	B	465	m/z 403.3
157	B	1240	m/z 417.2
158	B	953	m/z 385.2
159	B	1720	m/z 389.2
160	B	554	m/z 385.3
161	B	671	m/z 411.3
162	B	596	m/z 389.2
163	B	334	m/z 407.2
164	E	<10	m/z 326.1
165	E	<10	m/z 326.1
166	E	3140	m/z 326.1
167	B	361	m/z 298.2

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
168	E	<10	m/z 346.4
170	E	Nd	m/z 346.3
171	E	6140	m/z 346.3
172	E	<10	m/z 346.3
173	A	<10	m/z 352.4
174	A	<10	m/z 352.4
175	A	> 5000	m/z 352.4
176	A	<10	m/z 312.1
177	A	> 2000	m/z 312.2
178	A	<10	m/z 358.2
179	A	<10	m/z 358.2
180	A	89	m/z 358.2
181	D or O	<10	m/z 325.1
182	D or O	<10	m/z 325.2
183	D or O	1360	m/z 325.2
184	A	10	m/z 340.1
185	A	<10	m/z 340.2
186	A	1750	m/z 340.1
187	D	<10	m/z 391.1
188	D	<10	m/z 391.1
189	D	1010	m/z 391.1
190	A	12	m/z 356.2
191	A	<10	m/z 356.2
192	A	> 2000	m/z 356.2
193	D	<10	m/z 311.1
194	D	> 2000	m/z 311.1
195	D	<10	m/z 311.1
196	F	<10	m/z 312.1
197	F	1700	m/z 312.1
198	A	<10	m/z 406.1
199	A	<10	m/z 406.2
200	A	> 2000	m/z 406.2
201	D	<10	m/z 345.1
202	A	<10	m/z 338.1
203	D	<10	m/z 345.1
204	A (from int D2)	<10	m/z 340.1
205	D	168	m/z 345.1
206	A (from int D2)	<10	m/z 326.1
208	A (from int D2)	<10	m/z 322.1

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
209	N	28	m/z 311.1
212	G	3440	m/z 351.3
213	G	195	m/z 351.3
214	H	136	m/z 445.3
215	H	24	m/z 544.5
216	H	76	m/z 504.5
217	A	168	m/z 421.4
218	F	22	m/z 421.4
219	A	46	m/z 324.2
220	A	<10	m/z 341.4
221	I	81	m/z 365.3
222	F	<10	m/z 420.4
223	F	15	m/z 457.4
224	F	13	m/z 406.4
225	F	34	m/z 406.4
226	F	12	m/z 379.4
227	F	50	m/z 399.3
228	F	21	m/z 362.4
229	F	52	m/z 366.4
230	F	368	m/z 398.4
231	F	<10	m/z 422.4
232	F	11	m/z 392.4
233	F	10	m/z 426.3
234	F	14	m/z 408.3
235	F	13	m/z 406.4
236	F	16	m/z 408.4
237	F	19	m/z 436.4
238	F	10	m/z 394.3
239	F	15	m/z 380.4
240	F	191	m/z 410.4
241	F	24	m/z 366.4
242	F	<10	m/z 456.4
243	A	69	m/z 418.3
244	A	16	m/z 369.4
245	A	11	m/z 431.4
246	A	84	m/z 397.4
247	A	17	m/z 427.4
248	A	<10	m/z 431.3
249	A	20	m/z 415.4

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
250	A	<10	m/z 376.3
251	A	1420	m/z 376.3
252	A	<10	m/z 376.3
253	A	24	m/z 395.4
254	A	10	m/z 428.4
255	A	109	m/z 393.4
256	H	50	m/z 378.4
257	F	43	m/z 324.3
258	A	3130	m/z 475.5
259	A	<10	m/z 324.3
260	A	27	m/z 354.4
261	A	45	m/z 376.3
262	E	<10	m/z 352.4
263	A	16	m/z 348.2
264	L	<10	m/z 332.2
265	L	> 2000	m/z 332.2
266	L	nd	m/z 332.2
267	L	nd	m/z 329.2
268	L	> 2000	m/z 329.2
269	L	> 2000	m/z 329.3
270	L	nd	m/z 329.2
271	L	nd	m/z 395.1
272	L	<10	m/z 395.1
273	L	585	m/z 395.1
274	A	<10	m/z 315.3
275	A	nd	m/z 315.3
276	A	> 2000	m/z 315.3
278	A with 2-(methylsulfonyl)acetonitrile instead of malononitrile	> 5000	m/z 411.3
279	A	250	m/z 391.4
280	A	80	m/z 395.4
281	A	784	m/z 390.5
282	A	625	m/z 389.4
283	A	32	m/z 459.2
284	A	238	m/z 391.5
285	A	11	m/z 312.0
286	F	nd	m/z 312.1
287	L	<10	m/z 329.2
288	L	<10	m/z 329.2

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
289	K	<10	m/z 397.0
290	K	<10	m/z 397.0
291	K	> 2000	m/z 397.0
292	D or O	<10	m/z 331.3
293	D or O	<10	m/z 331.3
294	D or O	> 2000	m/z 331.3
295	D	<10	m/z 374.2
296	D	<10	m/z 374.2
297	D	> 2000	m/z 374.2
298	D	<10	m/z 380.2
299	D	<10	m/z 380.2
300	D	> 2000	m/z 380.2
301	K	13	m/z 397.0
302	K	<10	m/z 397.0
303	K	> 2000	m/z 397.0
304	D	<10	m/z 379.2
305	D	<10	m/z 379.2
306	D	> 2000	m/z 379.2
307	D	<10	m/z 381.2
308	D	<10	m/z 380.2
309	D	<10	m/z 380.2
310	D	> 2000	m/z 380.2
311	D	<10	m/z 401.2
312	D	<10	m/z 322.2
313	K	<10	m/z 345.1
314	K	<10	m/z 345.1
315	K	> 2000	m/z 345.1
316	K	<10	m/z 365.2
317	K	<10	m/z 365.2
318	K	> 2000	m/z 365.2
319	D	<10	m/z 423.2
320	D	<10	m/z 423.2
321	D	> 2000	m/z 423.2
322	D	<10	m/z 355.2
323	D	> 2000	m/z 355.2
324	D	<10	m/z 337.2
325	D	<10	m/z 337.2
326	D	> 2000	m/z 337.2
327	D	<10	m/z 351.1

Compound	Method	Myt1 IC ₅₀ (nM)	MS (+ESI) [M+1]
328	Hydrogenolysis of 142	<10	m/z 297.3

In Table 4, the Method column indicates a preparatory method described above used in the preparation of the compounds.

5 Example 3. Genetic Validation

Two sgRNAs for *PKMYT1* and one sgRNA for LacZ (control) were transduced into the RPE1-hTERT Cas9 TP53^{-/-} parental (WT) and *CCNE1*-overexpressing clones. Infected cells were plated at low density to measure their ability to form colonies of <50 cells. After 10 days of growth, the colonies were stained, imaged, and quantified. Using clonogenic survival assays, we observed a profound cellular fitness defect in *CCNE1*-overexpressing cells compared to parental cells transduced with *PKMYT1* sgRNAs (FIGS. 3A and 3B). This experiment was repeated using FT282-hTERT TP53^{-/-} parental (WT) and *CCNE1*-overexpressing clones and similar results were observed (FIGS. 4A and 4B).

To determine if the kinase activity of *PKMYT1* was responsible for maintaining the viability of *CCNE1*-overexpressing RPE1-hTERT Cas9 TP53^{-/-} cells, the *PKMYT1* open reading frame (ORF) was cloned into an inducible mammalian expression vector. sgRNA-resistant silent mutations in the *PKMYT1* ORF sequence were then created by PCR mutagenesis. A single point mutation was generated that resulted in an asparagine (N) to alanine (A) amino acid change at residue 238. The N238A amino acid change in the kinase domain resulted in a catalytically inactive *PKMYT1* mutant. Stable cell lines in the RPE1-hTERT Cas9 TP53^{-/-} parental and *CCNE1*-overexpressing clones were generated that either expressed the wild type *PKMYT1* ORF or the kinase-dead N238A mutant (FIG. 5A). These stable cell lines were transduced with either a LacZ non-targeting sgRNA or *PKMYT1* sgRNA #4. The cells were then plated at low density to measure their ability to form colonies of >50 cells. After 10 days of growth, the colonies were stained, imaged, and quantified. Expression of an sgRNA-resistant *PKMYT1* ORF but not the catalytic-dead version rescued the fitness defect induced by transduction of sgRNA #4 into both *CCNE1*-overexpressing clones (FIGS. 5B and 5C). This result demonstrated that targeting the kinase activity of *PKMYT1* selectively kills *CCNE1*-overexpressing cells.

Example 4. Pharmacological validation

RPE1-hTERT Cas9 TP53^{-/-} parental (WT) and *CCNE1*-overexpressing clones were treated with compound 133 in a dose titration and cell viability was determined. The *CCNE1*-overexpressing cells were found to be more sensitive to compound 133 than the corresponding WT cells (FIG. 3C). A similar effect was seen in FT282-hTERT TP53^{R175H} WT and *CCNE1*-overexpressing clones (FIG. 4C). For dose-response proliferation assays using RPE1-hTERT and FT282-hTERT cell lines, cells were seeded in 96-well plates and dosed with serially diluted Myt1 inhibitor. Cells were imaged once per day using the IncuCyte S3 microscope and percent well confluency was calculated over time. Once cells reached four population doublings the experiment was ended and IC₅₀ curves were plotted for the final time point. Percentage confluency was calculated relative to the cell confluency in the untreated wells.

A panel of 16 cancer cell lines with either normal (n=8) or elevated levels of *CCNE1* (n=8) was evaluated for their sensitivity to compound 28 in a cell proliferation assay (FIG. 6). Dose-response curves in these cancer cell line proliferation assays were generated as follows. Cells were seeded in 96-well

plates and dosed with serially diluted compound 28. After 7 days, Cell Titer Glo (CTG) was used to assess the proliferation status of these cells and the IC₅₀ values were plotted.

5 A similar experiment was conducted in a panel of 8 cancer cell lines with either wild-type FBXW7 (n=5) or FBXW7-mutations (n=3) in which these cells were evaluated for their sensitivity to compound 95 in a cell proliferation assay (FIG. 7). Dose-response curves in these cancer cell line proliferation assays were generated as follows. Cells were seeded in 96-well plates and dosed with serially diluted Myt1 inhibitor. Cells were imaged once per day using the IncuCyte S3 microscope and percent well confluency was calculated over time. Once cells reached four population doublings the experiment was ended and IC₅₀ curves were plotted for the final time point. Percentage confluency was calculated relative to the cell
10 confluency in the untreated wells.

Combination experiments to establish synergy were performed in a representative CCNE1 high breast cancer cell line, HCC1569. Cells were plated in 96-well plates and were serially dosed with either Myt1 inhibitor (compound 182), gemcitabine, irinotecan, or ATR inhibitor (compound A121) alone or in combination. Cells were imaged once per day using the IncuCyte S3 microscope and percent well
15 confluency was calculated over time. Once cells reached four population doublings the experiment was ended and IC₅₀ curves were calculated for the final time point for each compound alone or in combination. A representative dose combination was then plotted for Myt1 inhibitor, gemcitabine, irinotecan, and ATR inhibitor alone and their certain combinations (FIGS. 8A, 8B, and 8C).

Efficacy of Myt1 inhibitor (compound 182) as monotherapy or in combination with gemcitabine, irinotecan, or compound A121 was assessed in the OVCAR3 ovarian cancer xenograft model (5×10⁶ tumor cells in 0.1 mL, into the right flank of female SCID-beige mice). Myt1 inhibitor was orally (PO) administered as a suspension, twice daily (BID 8:16h, day 0 to 20) in 0.5% methyl cellulose (MC) vehicle. Gemcitabine was administered intraperitoneal (IP) once per week in PBS vehicle. Irinotecan was administered intraperitoneal (IP) twice per week in PBS vehicle. ATR inhibitor was administered PO as a suspension in in 0.5% methyl cellulose (MC), 0.02% sodium lauryl sulphate (SLS) vehicle. Carboplatin
25 was administered intraperitoneal (IP) once per week in PBS vehicle. The results are shown in FIGS. 8D, 8E, 8F and 8G. Tumor volume (TV) was measured using a digital caliper and calculated using the formula $0.52 \times L \times W^2$. Results are expressed as mean ± SEM, N=7/group. Statistical significance relative to vehicle control was established by One-Way ANOVA followed by Bonferroni post hoc test (GraphPad Prism v8); *p<0.05; **p<0.01; *** p<0.001.
30

OTHER EMBODIMENTS


Various modifications and variations of the described invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been
35 described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention.

Other embodiments are in the claims.

1. A method of treating a cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, wherein the cancer has been previously identified as a cancer overexpressing *CCNE1*.
2. A method of treating a cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof,, wherein the cancer is a cancer overexpressing *CCNE1*.
3. A method of inducing cell death in a cancer cell overexpressing *CCNE1*, the method comprising contacting the cell with an effective amount of a Myt1 inhibitor and an effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof.
4. The method of any one of claims 1 to 3, wherein the cancer is uterine cancer, ovarian cancer, bladder cancer, pancreatic cancer, mesothelioma, kidney cancer, bladder cancer, gastric cancer, ovarian cancer, breast cancer, stomach cancer, esophageal cancer, lung cancer, or endometrial cancer.
5. A method of treating a cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, wherein the cancer has been previously identified as a cancer having an inactivating mutation in the *FBXW7* gene.

6. A method of treating a cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a Myt1 inhibitor and a therapeutically effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 Inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof, wherein the cancer has an inactivating mutation in the *FBXW7* gene.
7. A method of inducing cell death in an FBXW7-mutated cancer cell, the method comprising contacting the cell with an effective amount of a Myt1 inhibitor and an effective amount of a WEE1 inhibitor, FEN1 inhibitor, TOP1 inhibitor, RRM1 inhibitor, RRM2 inhibitor, AURKB inhibitor, TOP2A inhibitor, ATR inhibitor, TTK inhibitor, SOD1 inhibitor, SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, AURKA inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analog, platinum-based DNA damaging agent, or a combination thereof.
8. The method of any one of claims 5 to 7, wherein the cancer is uterine cancer, ovarian cancer, bladder cancer, pancreatic cancer, mesothelioma, kidney cancer, bladder cancer, gastric cancer, colorectal cancer, breast cancer, lung cancer, or esophageal cancer.
9. The method of claim 3, 4, 7, or 8, wherein the cell is in a subject.
10. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the WEE1 inhibitor.
11. The method of claim 10, wherein the WEE1 inhibitor is AZD1775, Debio-0123, ZN-c3, or a pharmaceutically acceptable salt thereof.
12. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the FEN1 inhibitor.
13. The method of claim 12, wherein the FEN1 inhibitor is C8 (PMID: 32719125), SC13, FEN1-IN-3, or a pharmaceutically acceptable salt thereof.
14. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the TOP1 inhibitor.
15. The method of claim 14, wherein the TOP1 inhibitor is irinotecan, topotecan, camptothecin, lamellarin D, or a pharmaceutically acceptable salt thereof.

16. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the RRM1 inhibitor.
17. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the RRM2 inhibitor.
18. The method of claim 17, wherein the RRM2 inhibitor is motexafin gadolinium, hydroxyurea, fludarabine, cladribine, tezacitabine, triapine, or a pharmaceutically acceptable salt thereof.
19. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the AURKB inhibitor.
20. The method of claim 19, wherein the AURKB inhibitor is MK0547, AZD1152, PHA739358, AT9283, AMG900, SNS-314, TAK-901, CYC116, GSK1070916, PF03814735, or a pharmaceutically acceptable salt thereof.
21. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the TOP2A inhibitor.
22. The method of claim 21, wherein the TOP2A inhibitor is etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticine, or a pharmaceutically acceptable salt thereof.
23. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the ATR inhibitor.
24. The method of claim 23, wherein the ATR inhibitor is a compound of formula (III):



or a pharmaceutically acceptable salt thereof,
wherein

===== is a double bond, and each Y is independently N or CR⁴; or ===== is a single bond, and each Y is independently NR^Y, carbonyl, or C(R^Y)₂; wherein each R^Y is independently H or optionally substituted C₁₋₆ alkyl;

R¹ is optionally substituted C₁₋₆ alkyl or H;

R² is optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀

aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, –N(R⁵)₂, –OR⁵, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or –Q–R^{5B};

R³ is optionally substituted C₁₋₉ heteroaryl or optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl;

each R⁴ is independently hydrogen, halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, or optionally substituted C₂₋₆ alkynyl;

each R⁵ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, or –SO₂R^{5A}; or both R⁵, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

each R^{5A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;


R^{5B} is hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, –N(R⁵)₂, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or optionally substituted alkoxy;

each R⁶ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₈ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or both R⁶, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

Q is optionally substituted C₂₋₉ heterocyclylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₁₋₉ heteroarylene, or optionally substituted C₆₋₁₀ arylene; and

X is hydrogen or halogen.

25. The method of claim 24, wherein the ATR inhibitor is a compound of formula (IV):



or a pharmaceutically acceptable salt thereof,
wherein

each Y is independently N or CR⁴;

R¹ is optionally substituted C₁₋₆ alkyl or H;

R² is optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, –N(R⁵)₂, –OR⁵, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or –Q–R^{5B};

R³ is optionally substituted C₁₋₉ heteroaryl or optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl;

each R⁴ is independently hydrogen, halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, or optionally substituted C₂₋₆ alkynyl;

each R⁵ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, or –SO₂R^{5A}; or both R⁵, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

each R^{5A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;

R^{5B} is hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, –N(R⁵)₂, –CON(R⁶)₂, –SO₂N(R⁶)₂, –SO₂R^{5A}, or optionally substituted alkoxy;

each R⁶ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or both R⁶, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;

Q is optionally substituted C₂₋₉ heterocyclylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₁₋₉ heteroarylene, or optionally substituted C₆₋₁₀ arylylene; and

X is hydrogen or halogen.



26. The method of claim 24, wherein the ATR inhibitor is selected from the group consisting of compounds A43, A57, A62, A87, A93, A94, A95, A99, A100, A106, A107, A108, A109, A111, A112, A113, A114, A115, A116, A118, A119, A120, A121, A122, A123, A135, A147, A148, and pharmaceutically acceptable salts thereof.

27. The method of claim 26, wherein the ATR inhibitor is compound A43 or a pharmaceutically acceptable salt thereof.

28. The method of claim 26, wherein the ATR inhibitor is compound A121 or a pharmaceutically acceptable salt thereof.

29. The method of claim 26, wherein the ATR inhibitor is compound A122 or a pharmaceutically acceptable salt thereof.

30. The method of claim 23, wherein the ATR inhibitor is




31. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the TTK inhibitor.

32. The method of claim 31, wherein the TTK inhibitor is BAY1217389 or a pharmaceutically acceptable salt thereof.

33. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the SOD1 inhibitor.

34. The method of claim 33, wherein the SOD1 inhibitor is LCS1, ATN-224, Pyrimethamine, a compound of the following structure




or a pharmaceutically acceptable salt thereof.

35. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the SOD2 inhibitor.
36. The method of claim 35, wherein the SOD2 inhibitor is LCS1, ATN-224, pyrimethamine, or a pharmaceutically acceptable salt thereof.
37. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the BUB1 inhibitor.
38. The method of claim 37, wherein the BUB1 inhibitor is BAY-320, BAY-419, BAY1816032, or a pharmaceutically acceptable salt thereof.
39. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the CDC7 inhibitor.
40. The method of claim 39, wherein the CDC7 inhibitor is SRA141, TAK931, or a pharmaceutically acceptable salt thereof.
41. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the SAE1 inhibitor.
42. The method of claim 41, wherein the SAE1 inhibitor is ML792 or a pharmaceutically acceptable salt thereof.
43. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the PLK1 inhibitor.
44. The method of claim 43, wherein the PLK1 inhibitor is BI2536, BI6727, TAK960, NMSP937, GSK461364, or a pharmaceutically acceptable salt thereof.
45. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the UBA2 inhibitor.
46. The method of claim 45, wherein the UBA2 inhibitor is TAK981 or a pharmaceutically acceptable salt thereof.
47. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the DUT inhibitor.
48. The method of claim 47, wherein the DUT inhibitor is TAS114 or a pharmaceutically acceptable salt thereof.

49. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the HDAC3 inhibitor.
50. The method of claim 49, wherein the HDAC3 inhibitor is RGFP966 or a pharmaceutically acceptable salt thereof.
51. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the CHEK1 inhibitor.
52. The method of claim 51, wherein the CHEK1 inhibitor is SRA737 or a pharmaceutically acceptable salt thereof.
53. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the AURKA inhibitor.
54. The method of claim 53, wherein the AURKA inhibitor is MLN8237, MK0547, MLN8054, PHA739358, AT9283, AMG900, MK5108, SNS314, TAK901, CYC116, ENMD2076, or a pharmaceutically acceptable salt thereof.
55. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the MEN1 inhibitor.
56. The method of claim 55, wherein the MEN1 inhibitor is MI3454, SNDX5613, VTP50469, KO539, or a pharmaceutically acceptable salt thereof.
57. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the DOT1L inhibitor.
58. The method of claim 57, wherein the DOT1L inhibitor is EPZ5676 or a pharmaceutically acceptable salt thereof.
59. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the CREBBP inhibitor.
60. The method of claim 59, wherein the CREBBP inhibitor is CPI4, CCS1477, E7386, NEO1132, NEO2734, PRI724, C82, BC001, C646, EML425, CBP30, or a pharmaceutically acceptable salt thereof.
61. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the EZH2 inhibitor.
62. The method of claim 61, wherein the EZH2 inhibitor is EPZ-6438, GSK126, or a pharmaceutically acceptable salt thereof.

63. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the PLK4 inhibitor.
64. The method of claim 63, wherein the PLK4 inhibitor is centrinone, CFI400945, or a pharmaceutically acceptable salt thereof.
65. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the HASPIN inhibitor.
66. The method of claim 65, wherein the HASPIN inhibitor is SEL120 or a pharmaceutically acceptable salt thereof.
67. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the METTL3 inhibitor.
68. The method of claim 67, wherein the METTL3 inhibitor is UZH1a, sTC-15, or a pharmaceutically acceptable salt thereof.
69. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the nucleoside analog.
70. The method of claim 69 wherein the nucleoside analog is cytarabine, gemcitabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nelarabine, or a pharmaceutically acceptable salt thereof or a combination thereof.
71. The method of claim 69, wherein the nucleoside analog is gemcitabine or a pharmaceutically acceptable salt thereof.
72. The method of claim 69, wherein the nucleoside analog is fluorouracil or a pharmaceutically acceptable salt thereof.
73. The method of claim 69, wherein the nucleoside analog is a combination of gemcitabine or a pharmaceutically acceptable salt thereof and fluorouracil or a pharmaceutically acceptable salt thereof.
74. The method of any one of claims 1 to 9, wherein the method comprises the step of administering the platinum-based DNA damaging agent.
75. The method of claim 74, wherein the platinum-based DNA damaging agent is cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin.
76. The method of claim 75, wherein the platinum-based DNA damaging agent is carboplatin.

77. The method of any one of claims 1 to 76, wherein the Myt1 inhibitor is a compound of formula (I):



or a pharmaceutically acceptable salt thereof,
wherein

each of X, Y, and Z is independently N or CR²;

R¹ and each R² are independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, cyano, -N(R⁷)₂, -OR⁷, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or -Q-R^{7B}; or R¹ combines with one R² that is *vicinal* to R¹ to form an optionally substituted C₃₋₆ alkylene;

each of R³ and R⁴ is independently optionally substituted C₁₋₆ alkyl or halogen;

R⁵ is H or -N(R⁷)₂;

R⁶ is -C(O)NH(R⁸), -C(O)R^{7A}, or -SO₂R^{7A};

each R⁷ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, or -SO₂R^{7A}; or two R⁷ groups, together with the atom to which both are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl;


each R^{7A} is independently optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₆₋₁₀ aryl;

each R^{7B} is independently hydroxyl, optionally substituted C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₁₋₉ heteroaryl, -N(R⁷)₂, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or optionally substituted alkoxy;

each R⁸ is independently hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₈ alkoxyalkyl, optionally substituted C₆₋₁₀ aryl C₁₋₆ alkyl, optionally substituted C₆₋₁₀ aryl, optionally substituted C₃₋₈ cycloalkyl, or optionally substituted C₁₋₉ heteroaryl; or two R⁸, together with the atom to which they are attached, combine to form an optionally substituted C₂₋₉ heterocyclyl; and

Q is optionally substituted C₁₋₆ alkylene, optionally substituted C₂₋₆ alkenylene, optionally substituted C₂₋₆ alkynylene, optionally substituted C₃₋₈ cycloalkylene, optionally substituted C₃₋₈ cycloalkenylene optionally substituted C₆₋₁₀ arylene, optionally substituted C₂₋₉ heterocyclylene, or optionally substituted C₁₋₉ heteroarylene.


78. The method of claim 77, or a pharmaceutically acceptable salt thereof, wherein the compound is enriched for the atropisomer of formula (IA):



(IA)


79. The method of claim 77 or 78, or a pharmaceutically acceptable salt thereof, wherein X is CR².

80. The method of claim 77, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (II):




(II)

81. The method of claim 80, or a pharmaceutically acceptable salt thereof, wherein the compound is enriched for the atropisomer of formula (IIA):



(IIA)

82. The method of claim 77, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (III):




(III)

wherein R^{2A} is hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl, optionally substituted C₃₋₈ cycloalkyl, optionally substituted C₃₋₈ cycloalkenyl, optionally substituted C₂₋₉ heterocyclyl, optionally substituted C₂₋₉ heterocyclyl C₁₋₆ alkyl, optionally

substituted C₆₋₁₀ aryl, optionally substituted C₁₋₉ heteroaryl, optionally substituted C₁₋₉ heteroaryl C₁₋₆ alkyl, halogen, -N(R⁷)₂, -OR⁷, -C(O)N(R⁸)₂, -SO₂N(R⁸)₂, -SO₂R^{7A}, or -Q-R^{7B}.

83. The method of claim 82, or a pharmaceutically acceptable salt thereof, wherein the compound is enriched for the atropisomer of formula (IIIA):



84. The method of claim 82 or 83, or a pharmaceutically acceptable salt thereof, wherein R^{2A} is hydrogen, optionally substituted C₁₋₆ alkyl, or halogen.

85. The method of any one of claims 77 to 84, or a pharmaceutically acceptable salt thereof, wherein R³ is optionally substituted C₁₋₆ alkyl.

86. The method of any one of claims 77 to 84, or a pharmaceutically acceptable salt thereof, wherein R³ is halogen.

87. The method of any one of claims 77 to 86, or a pharmaceutically acceptable salt thereof, wherein R⁴ is optionally substituted C₁₋₆ alkyl.

88. The method of any one of claims 77 to 86, or a pharmaceutically acceptable salt thereof, wherein R⁴ is halogen.

89. The method of claim 86 or 88, wherein the halogen is chlorine.

90. The method of any one of claims 77 to 89, or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen.

91. The method of any one of claims 77 to 89, or a pharmaceutically acceptable salt thereof, wherein R² is optionally substituted C₁₋₆ alkyl.

92. The method of claim 91, or a pharmaceutically acceptable salt thereof, wherein R² is optionally substituted methyl or optionally substituted isopropyl.

93. The method of any one of claims 77 to 89, or a pharmaceutically acceptable salt thereof, wherein R² is halogen.

94. The method of any one of claims 77 to 93, or a pharmaceutically acceptable salt thereof, wherein R¹ is hydrogen.
95. The method of any one of claims 77 to 93, or a pharmaceutically acceptable salt thereof, wherein R¹ is halogen.
96. The method of claim 95, or a pharmaceutically acceptable salt thereof, wherein R¹ is chlorine or bromine.
97. The method of any one of claims 77 to 93, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted C₁₋₆ alkyl.
98. The method of claim 97, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted methyl, optionally substituted ethyl, optionally substituted isopropyl, or optionally substituted butyl.
99. The method of any one of claims 77 to 93, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted C₁₋₉ heteroaryl.
100. The method of claim 99, or a pharmaceutically acceptable salt thereof, wherein R¹ is 1,3-thiazolyl, 1,2-thiazolyl, 1,3-oxazolyl, benzo-1,3-thiazolyl, benzo-1,3-oxazolyl, indolyl, benzimidazolyl, pyridyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, or pyrazolyl, wherein R¹ is optionally substituted with substituents as defined for optionally substituted C₁₋₉ heteroaryl.
101. The method of any one of claims 77 to 93, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted C₃₋₈ cycloalkyl.
102. The method of claim 101, or a pharmaceutically acceptable salt thereof, wherein R¹ is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein R¹ is optionally substituted with substituents as defined for optionally substituted C₃₋₈ cycloalkyl.
103. The method of any one of claims 77 to 95, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted C₂₋₉ heterocyclyl.
104. The method of claim 103, or a pharmaceutically acceptable salt thereof, wherein R¹ is 1,2,3,6-tetrahydropyridinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, oxa-aza-spiro[3,3]heptane, or oxa-aza-bicyclo[3.2.1]octane, wherein R¹ is optionally substituted with substituents as defined for optionally substituted C₂₋₉ heterocyclyl.
105. The method of any one of claims 77 to 95, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted C₃₋₈ cycloalkyl.

106. The method of claim 105, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted cyclohexenyl or optionally substituted cyclopentenyl.
107. The method of any one of claims 77 to 95, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted C₆₋₁₀ aryl.
108. The method of claim 107, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted phenyl.
109. The method of any one of claims 77 to 95, or a pharmaceutically acceptable salt thereof, wherein R¹ is -Q-R^{7B}.
110. The method of claim 109, or a pharmaceutically acceptable salt thereof, wherein Q is optionally substituted C₂₋₆ alkynylene.
111. The method of claim 109, or a pharmaceutically acceptable salt thereof, wherein Q is optionally substituted C₁₋₆ alkylene.
112. The method of claim 109, or a pharmaceutically acceptable salt thereof, wherein Q is optionally substituted C₆₋₁₀ arylene.
113. The method of any one of claims 109 to 112, or a pharmaceutically acceptable salt thereof, wherein R^{7B} is optionally substituted C₂₋₉ heterocyclyl.
114. The method of any one of claims 109 to 112, or a pharmaceutically acceptable salt thereof, wherein R^{7B} is optionally substituted C₆₋₁₀ aryl.
115. The method of any one of claims 77 to 114, or a pharmaceutically acceptable salt thereof, wherein R¹ is optionally substituted with one, two, or three groups independently selected from the group consisting of methyl, difluoromethyl, trifluoromethyl, fluorine, chlorine, bromine, amino, hydroxyl, cyano, oxo, -C(O)NH₂, -C(O)NH(Me), -C(O)N(Me)₂, -(CH₂)_n-C(O)OH, and -(CH₂)_n-C(O)Ot-Bu, wherein n is 0 or 1.
116. The method of any one of claims 77 to 93, or a pharmaceutically acceptable salt thereof, wherein R¹ is -N(R⁷)₂.
117. The method of claim 116, or a pharmaceutically acceptable salt thereof, wherein R¹ is diethylamino.
118. The method of any one of claims 77 to 117, or a pharmaceutically acceptable salt thereof, wherein R⁵ is hydrogen.

119. The method of any one of claims 77 to 117, or a pharmaceutically acceptable salt thereof, wherein R^5 is $-N(R^7)_2$.
120. The method of claim 119, or a pharmaceutically acceptable salt thereof, wherein R^5 is $-NH_2$.
121. The method of any one of claims 77 to 120, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-C(O)NH(R^8)$.
122. The method of any one of claims 77 to 122, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-C(O)NH_2$.
123. The method of any one of claims 77 to 122, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-C(O)NH(Me)$.
124. The method of any one of claims 77 to 122, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-SO_2R^{7A}$.
125. The method of claim 124, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-SO_2Me$.
126. The method of any one of claims 1 to 76, wherein the compound is selected from the group consisting of compounds 1-328 and pharmaceutically acceptable salts thereof.
127. The method of any one of claims 1 to 126, wherein the Myt1 inhibitor is administered as a pharmaceutical composition.
128. The method of claim 127, wherein the pharmaceutical composition is isotopically enriched in deuterium.

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D


Compound 182/Gemcitabine combination

FIG. 8E


Compound 182/Irinotecan combination

FIG. 8F

Myt1 inhibitor + ATR inhibitor combination

In OVCAR3 xenograft model






FIG. 8G

Myt1 inhibitor + carboplatin combination in OVCAR3 xenograft model





(I)